hmg-coa	Itraconazole	4	6	false	none	Hence when simvastatin is used with an inhibitor of CYP3A4 (e.g., as listed below), elevated plasma levels of HMG-CoA reductase inhibitory activity can increase the risk of myopathy and rhabdomyolysis, particularly with higher doses of simvastatin.  [See Warnings and Precautions (5.1) and Clinical Pharmacology (12.3).]  Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  		none	28031	none	D017964
hmg-coa	Itraconazole	4	6	false	none	Hence when simvastatin is used with an inhibitor of CYP3A4 (e.g., as listed below), elevated plasma levels of HMG-CoA reductase inhibitory activity can increase the risk of myopathy and rhabdomyolysis, particularly with higher doses of simvastatin.  [See Warnings and Precautions (5.1) and Clinical Pharmacology (12.3).]  Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  		none	28031	none	D017964
hmg-coa	Simvastatin	1	1	false	none	7 DRUG INTERACTIONS    7.1 CYP3A4 Interactions    Simvastatin, like several other inhibitors of HMG-CoA reductase, is a substrate of CYP3A4.  		none	36567	none	36567
hmg-coa	Simvastatin	1	1	false	none	7 DRUG INTERACTIONS    7.1 CYP3A4 Interactions    Simvastatin, like several other inhibitors of HMG-CoA reductase, is a substrate of CYP3A4.  		none	36567	none	36567
hmg-coa	Simvastatin	1	2	false	none	7 DRUG INTERACTIONS    7.1 CYP3A4 Interactions    Simvastatin, like several other inhibitors of HMG-CoA reductase, is a substrate of CYP3A4.  Simvastatin is metabolized by CYP3A4 but has no CYP3A4 inhibitory activity; therefore it is not expected to affect the plasma concentrations of other drugs metabolized by CYP3A4.  		none	36567	none	36567
hmg-coa	Simvastatin	1	2	false	none	7 DRUG INTERACTIONS    7.1 CYP3A4 Interactions    Simvastatin, like several other inhibitors of HMG-CoA reductase, is a substrate of CYP3A4.  Simvastatin is metabolized by CYP3A4 but has no CYP3A4 inhibitory activity; therefore it is not expected to affect the plasma concentrations of other drugs metabolized by CYP3A4.  		none	36567	none	36567
hmg-coa	Simvastatin	1	3	false	none	7 DRUG INTERACTIONS    7.1 CYP3A4 Interactions    Simvastatin, like several other inhibitors of HMG-CoA reductase, is a substrate of CYP3A4.  Simvastatin is metabolized by CYP3A4 but has no CYP3A4 inhibitory activity; therefore it is not expected to affect the plasma concentrations of other drugs metabolized by CYP3A4.  The risk of myopathy is increased by reducing the elimination of simvastatin.  		none	36567	none	36567
hmg-coa	Simvastatin	1	3	false	none	7 DRUG INTERACTIONS    7.1 CYP3A4 Interactions    Simvastatin, like several other inhibitors of HMG-CoA reductase, is a substrate of CYP3A4.  Simvastatin is metabolized by CYP3A4 but has no CYP3A4 inhibitory activity; therefore it is not expected to affect the plasma concentrations of other drugs metabolized by CYP3A4.  The risk of myopathy is increased by reducing the elimination of simvastatin.  		none	36567	none	36567
hmg-coa	Simvastatin	4	2	false	none	Simvastatin is metabolized by CYP3A4 but has no CYP3A4 inhibitory activity; therefore it is not expected to affect the plasma concentrations of other drugs metabolized by CYP3A4.  The risk of myopathy is increased by reducing the elimination of simvastatin.  Hence when simvastatin is used with an inhibitor of CYP3A4 (e.g., as listed below), elevated plasma levels of HMG-CoA reductase inhibitory activity can increase the risk of myopathy and rhabdomyolysis, particularly with higher doses of simvastatin.  		none	36567	none	36567
hmg-coa	Simvastatin	4	2	false	none	Simvastatin is metabolized by CYP3A4 but has no CYP3A4 inhibitory activity; therefore it is not expected to affect the plasma concentrations of other drugs metabolized by CYP3A4.  The risk of myopathy is increased by reducing the elimination of simvastatin.  Hence when simvastatin is used with an inhibitor of CYP3A4 (e.g., as listed below), elevated plasma levels of HMG-CoA reductase inhibitory activity can increase the risk of myopathy and rhabdomyolysis, particularly with higher doses of simvastatin.  		none	36567	none	36567
hmg-coa	Simvastatin	4	3	false	none	The risk of myopathy is increased by reducing the elimination of simvastatin.  Hence when simvastatin is used with an inhibitor of CYP3A4 (e.g., as listed below), elevated plasma levels of HMG-CoA reductase inhibitory activity can increase the risk of myopathy and rhabdomyolysis, particularly with higher doses of simvastatin.  		none	36567	none	36567
hmg-coa	Simvastatin	4	3	false	none	The risk of myopathy is increased by reducing the elimination of simvastatin.  Hence when simvastatin is used with an inhibitor of CYP3A4 (e.g., as listed below), elevated plasma levels of HMG-CoA reductase inhibitory activity can increase the risk of myopathy and rhabdomyolysis, particularly with higher doses of simvastatin.  		none	36567	none	36567
hmg-coa	Simvastatin	4	4	false	none	Hence when simvastatin is used with an inhibitor of CYP3A4 (e.g., as listed below), elevated plasma levels of HMG-CoA reductase inhibitory activity can increase the risk of myopathy and rhabdomyolysis, particularly with higher doses of simvastatin.  		none	36567	none	36567
hmg-coa	Simvastatin	4	4	false	none	Hence when simvastatin is used with an inhibitor of CYP3A4 (e.g., as listed below), elevated plasma levels of HMG-CoA reductase inhibitory activity can increase the risk of myopathy and rhabdomyolysis, particularly with higher doses of simvastatin.  		none	36567	none	36567
hmg-coa	grapefruit	4	6	false	none	Hence when simvastatin is used with an inhibitor of CYP3A4 (e.g., as listed below), elevated plasma levels of HMG-CoA reductase inhibitory activity can increase the risk of myopathy and rhabdomyolysis, particularly with higher doses of simvastatin.  [See Warnings and Precautions (5.1) and Clinical Pharmacology (12.3).]  Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  		none	none	none	none
hmg-coa	ketoconazole	4	6	false	none	Hence when simvastatin is used with an inhibitor of CYP3A4 (e.g., as listed below), elevated plasma levels of HMG-CoA reductase inhibitory activity can increase the risk of myopathy and rhabdomyolysis, particularly with higher doses of simvastatin.  [See Warnings and Precautions (5.1) and Clinical Pharmacology (12.3).]  Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  		none	6135	none	D007654
hmg-coa	ketoconazole	4	6	false	none	Hence when simvastatin is used with an inhibitor of CYP3A4 (e.g., as listed below), elevated plasma levels of HMG-CoA reductase inhibitory activity can increase the risk of myopathy and rhabdomyolysis, particularly with higher doses of simvastatin.  [See Warnings and Precautions (5.1) and Clinical Pharmacology (12.3).]  Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  		none	6135	none	D007654
hmg-coa	itraconazole	4	6	false	none	Hence when simvastatin is used with an inhibitor of CYP3A4 (e.g., as listed below), elevated plasma levels of HMG-CoA reductase inhibitory activity can increase the risk of myopathy and rhabdomyolysis, particularly with higher doses of simvastatin.  [See Warnings and Precautions (5.1) and Clinical Pharmacology (12.3).]  Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  		none	28031	none	D017964
hmg-coa	itraconazole	4	6	false	none	Hence when simvastatin is used with an inhibitor of CYP3A4 (e.g., as listed below), elevated plasma levels of HMG-CoA reductase inhibitory activity can increase the risk of myopathy and rhabdomyolysis, particularly with higher doses of simvastatin.  [See Warnings and Precautions (5.1) and Clinical Pharmacology (12.3).]  Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  		none	28031	none	D017964
hmg-coa	simvastatin	1	1	false	none	7 DRUG INTERACTIONS    7.1 CYP3A4 Interactions    Simvastatin, like several other inhibitors of HMG-CoA reductase, is a substrate of CYP3A4.  		none	36567	none	36567
hmg-coa	simvastatin	1	1	false	none	7 DRUG INTERACTIONS    7.1 CYP3A4 Interactions    Simvastatin, like several other inhibitors of HMG-CoA reductase, is a substrate of CYP3A4.  		none	36567	none	36567
hmg-coa	simvastatin	1	2	false	none	7 DRUG INTERACTIONS    7.1 CYP3A4 Interactions    Simvastatin, like several other inhibitors of HMG-CoA reductase, is a substrate of CYP3A4.  Simvastatin is metabolized by CYP3A4 but has no CYP3A4 inhibitory activity; therefore it is not expected to affect the plasma concentrations of other drugs metabolized by CYP3A4.  		none	36567	none	36567
hmg-coa	simvastatin	1	2	false	none	7 DRUG INTERACTIONS    7.1 CYP3A4 Interactions    Simvastatin, like several other inhibitors of HMG-CoA reductase, is a substrate of CYP3A4.  Simvastatin is metabolized by CYP3A4 but has no CYP3A4 inhibitory activity; therefore it is not expected to affect the plasma concentrations of other drugs metabolized by CYP3A4.  		none	36567	none	36567
hmg-coa	simvastatin	1	3	false	none	7 DRUG INTERACTIONS    7.1 CYP3A4 Interactions    Simvastatin, like several other inhibitors of HMG-CoA reductase, is a substrate of CYP3A4.  Simvastatin is metabolized by CYP3A4 but has no CYP3A4 inhibitory activity; therefore it is not expected to affect the plasma concentrations of other drugs metabolized by CYP3A4.  The risk of myopathy is increased by reducing the elimination of simvastatin.  		none	36567	none	36567
hmg-coa	simvastatin	1	3	false	none	7 DRUG INTERACTIONS    7.1 CYP3A4 Interactions    Simvastatin, like several other inhibitors of HMG-CoA reductase, is a substrate of CYP3A4.  Simvastatin is metabolized by CYP3A4 but has no CYP3A4 inhibitory activity; therefore it is not expected to affect the plasma concentrations of other drugs metabolized by CYP3A4.  The risk of myopathy is increased by reducing the elimination of simvastatin.  		none	36567	none	36567
hmg-coa	simvastatin	4	2	false	none	Simvastatin is metabolized by CYP3A4 but has no CYP3A4 inhibitory activity; therefore it is not expected to affect the plasma concentrations of other drugs metabolized by CYP3A4.  The risk of myopathy is increased by reducing the elimination of simvastatin.  Hence when simvastatin is used with an inhibitor of CYP3A4 (e.g., as listed below), elevated plasma levels of HMG-CoA reductase inhibitory activity can increase the risk of myopathy and rhabdomyolysis, particularly with higher doses of simvastatin.  		none	36567	none	36567
hmg-coa	simvastatin	4	2	false	none	Simvastatin is metabolized by CYP3A4 but has no CYP3A4 inhibitory activity; therefore it is not expected to affect the plasma concentrations of other drugs metabolized by CYP3A4.  The risk of myopathy is increased by reducing the elimination of simvastatin.  Hence when simvastatin is used with an inhibitor of CYP3A4 (e.g., as listed below), elevated plasma levels of HMG-CoA reductase inhibitory activity can increase the risk of myopathy and rhabdomyolysis, particularly with higher doses of simvastatin.  		none	36567	none	36567
hmg-coa	simvastatin	4	3	false	none	The risk of myopathy is increased by reducing the elimination of simvastatin.  Hence when simvastatin is used with an inhibitor of CYP3A4 (e.g., as listed below), elevated plasma levels of HMG-CoA reductase inhibitory activity can increase the risk of myopathy and rhabdomyolysis, particularly with higher doses of simvastatin.  		none	36567	none	36567
hmg-coa	simvastatin	4	3	false	none	The risk of myopathy is increased by reducing the elimination of simvastatin.  Hence when simvastatin is used with an inhibitor of CYP3A4 (e.g., as listed below), elevated plasma levels of HMG-CoA reductase inhibitory activity can increase the risk of myopathy and rhabdomyolysis, particularly with higher doses of simvastatin.  		none	36567	none	36567
hmg-coa	simvastatin	4	4	false	none	Hence when simvastatin is used with an inhibitor of CYP3A4 (e.g., as listed below), elevated plasma levels of HMG-CoA reductase inhibitory activity can increase the risk of myopathy and rhabdomyolysis, particularly with higher doses of simvastatin.  		none	36567	none	36567
hmg-coa	simvastatin	4	4	false	none	Hence when simvastatin is used with an inhibitor of CYP3A4 (e.g., as listed below), elevated plasma levels of HMG-CoA reductase inhibitory activity can increase the risk of myopathy and rhabdomyolysis, particularly with higher doses of simvastatin.  		none	36567	none	36567
hmg-coa	clarithromycin	4	6	false	none	Hence when simvastatin is used with an inhibitor of CYP3A4 (e.g., as listed below), elevated plasma levels of HMG-CoA reductase inhibitory activity can increase the risk of myopathy and rhabdomyolysis, particularly with higher doses of simvastatin.  [See Warnings and Precautions (5.1) and Clinical Pharmacology (12.3).]  Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  		none	21212	none	21212
hmg-coa	clarithromycin	4	6	false	none	Hence when simvastatin is used with an inhibitor of CYP3A4 (e.g., as listed below), elevated plasma levels of HMG-CoA reductase inhibitory activity can increase the risk of myopathy and rhabdomyolysis, particularly with higher doses of simvastatin.  [See Warnings and Precautions (5.1) and Clinical Pharmacology (12.3).]  Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  		none	21212	none	21212
hmg-coa	telithromycin	4	6	false	none	Hence when simvastatin is used with an inhibitor of CYP3A4 (e.g., as listed below), elevated plasma levels of HMG-CoA reductase inhibitory activity can increase the risk of myopathy and rhabdomyolysis, particularly with higher doses of simvastatin.  [See Warnings and Precautions (5.1) and Clinical Pharmacology (12.3).]  Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  		none	274786	none	274786
hmg-coa	telithromycin	4	6	false	none	Hence when simvastatin is used with an inhibitor of CYP3A4 (e.g., as listed below), elevated plasma levels of HMG-CoA reductase inhibitory activity can increase the risk of myopathy and rhabdomyolysis, particularly with higher doses of simvastatin.  [See Warnings and Precautions (5.1) and Clinical Pharmacology (12.3).]  Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  		none	274786	none	274786
hmg-coa	nefazodone	4	6	false	none	Hence when simvastatin is used with an inhibitor of CYP3A4 (e.g., as listed below), elevated plasma levels of HMG-CoA reductase inhibitory activity can increase the risk of myopathy and rhabdomyolysis, particularly with higher doses of simvastatin.  [See Warnings and Precautions (5.1) and Clinical Pharmacology (12.3).]  Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  		none	31565	none	C051752
hmg-coa	nefazodone	4	6	false	none	Hence when simvastatin is used with an inhibitor of CYP3A4 (e.g., as listed below), elevated plasma levels of HMG-CoA reductase inhibitory activity can increase the risk of myopathy and rhabdomyolysis, particularly with higher doses of simvastatin.  [See Warnings and Precautions (5.1) and Clinical Pharmacology (12.3).]  Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  		none	31565	none	C051752
hmg-coa	erythromycin	4	6	false	none	Hence when simvastatin is used with an inhibitor of CYP3A4 (e.g., as listed below), elevated plasma levels of HMG-CoA reductase inhibitory activity can increase the risk of myopathy and rhabdomyolysis, particularly with higher doses of simvastatin.  [See Warnings and Precautions (5.1) and Clinical Pharmacology (12.3).]  Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  		none	4053	none	D004917
hmg-coa	erythromycin	4	6	false	none	Hence when simvastatin is used with an inhibitor of CYP3A4 (e.g., as listed below), elevated plasma levels of HMG-CoA reductase inhibitory activity can increase the risk of myopathy and rhabdomyolysis, particularly with higher doses of simvastatin.  [See Warnings and Precautions (5.1) and Clinical Pharmacology (12.3).]  Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  		none	4053	none	D004917
Coumarin	Digoxin	14	12	false	none	7.5 Digoxin    In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma.  Patients taking digoxin should be monitored appropriately when simvastatin is initiated [see Clinical Pharmacology (12.3)].  7.6 Coumarin Anticoagulants    In two clinical studies, one in normal volunteers and the other in hypercholesterolemic patients, simvastatin 20-40 mg/day modestly potentiated the effect of coumarin anticoagulants: the prothrombin time, reported as International Normalized Ratio (INR), increased from a baseline of 1.7 to 1.8 and from 2.6 to 3.4 in the volunteer and patient studies, respectively.  		none	none	none	none
Coumarin	Digoxin	14	13	false	none	Patients taking digoxin should be monitored appropriately when simvastatin is initiated [see Clinical Pharmacology (12.3)].  7.6 Coumarin Anticoagulants    In two clinical studies, one in normal volunteers and the other in hypercholesterolemic patients, simvastatin 20-40 mg/day modestly potentiated the effect of coumarin anticoagulants: the prothrombin time, reported as International Normalized Ratio (INR), increased from a baseline of 1.7 to 1.8 and from 2.6 to 3.4 in the volunteer and patient studies, respectively.  		none	none	none	none
Coumarin	Digoxin	15	13	false	none	Patients taking digoxin should be monitored appropriately when simvastatin is initiated [see Clinical Pharmacology (12.3)].  7.6 Coumarin Anticoagulants    In two clinical studies, one in normal volunteers and the other in hypercholesterolemic patients, simvastatin 20-40 mg/day modestly potentiated the effect of coumarin anticoagulants: the prothrombin time, reported as International Normalized Ratio (INR), increased from a baseline of 1.7 to 1.8 and from 2.6 to 3.4 in the volunteer and patient studies, respectively.  With other statins, clinically evident bleeding and/or increased prothrombin time has been reported in a few patients taking coumarin anticoagulants concomitantly.  		none	none	none	none
Coumarin	Simvastatin	17	16	false	none	In such patients, prothrombin time should be determined before starting simvastatin and frequently enough during early therapy to ensure that no significant alteration of prothrombin time occurs.  Once a stable prothrombin time has been documented, prothrombin times can be monitored at the intervals usually recommended for patients on coumarin anticoagulants.  		none	36567	none	36567
Coumarin	Simvastatin	17	16	false	none	In such patients, prothrombin time should be determined before starting simvastatin and frequently enough during early therapy to ensure that no significant alteration of prothrombin time occurs.  Once a stable prothrombin time has been documented, prothrombin times can be monitored at the intervals usually recommended for patients on coumarin anticoagulants.  		none	36567	none	36567
Coumarin	Simvastatin	17	19	false	none	Once a stable prothrombin time has been documented, prothrombin times can be monitored at the intervals usually recommended for patients on coumarin anticoagulants.  If the dose of simvastatin is changed or discontinued, the same procedure should be repeated.  Simvastatin therapy has not been associated with bleeding or with changes in prothrombin time in patients not taking anticoagulants.  		none	36567	none	36567
Coumarin	Simvastatin	17	19	false	none	Once a stable prothrombin time has been documented, prothrombin times can be monitored at the intervals usually recommended for patients on coumarin anticoagulants.  If the dose of simvastatin is changed or discontinued, the same procedure should be repeated.  Simvastatin therapy has not been associated with bleeding or with changes in prothrombin time in patients not taking anticoagulants.  		none	36567	none	36567
Coumarin	Simvastatin	17	18	false	none	Once a stable prothrombin time has been documented, prothrombin times can be monitored at the intervals usually recommended for patients on coumarin anticoagulants.  If the dose of simvastatin is changed or discontinued, the same procedure should be repeated.  		none	36567	none	36567
Coumarin	Simvastatin	17	18	false	none	Once a stable prothrombin time has been documented, prothrombin times can be monitored at the intervals usually recommended for patients on coumarin anticoagulants.  If the dose of simvastatin is changed or discontinued, the same procedure should be repeated.  		none	36567	none	36567
Coumarin	Simvastatin	14	12	false	none	7.5 Digoxin    In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma.  Patients taking digoxin should be monitored appropriately when simvastatin is initiated [see Clinical Pharmacology (12.3)].  7.6 Coumarin Anticoagulants    In two clinical studies, one in normal volunteers and the other in hypercholesterolemic patients, simvastatin 20-40 mg/day modestly potentiated the effect of coumarin anticoagulants: the prothrombin time, reported as International Normalized Ratio (INR), increased from a baseline of 1.7 to 1.8 and from 2.6 to 3.4 in the volunteer and patient studies, respectively.  		none	36567	none	36567
Coumarin	Simvastatin	14	12	false	none	7.5 Digoxin    In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma.  Patients taking digoxin should be monitored appropriately when simvastatin is initiated [see Clinical Pharmacology (12.3)].  7.6 Coumarin Anticoagulants    In two clinical studies, one in normal volunteers and the other in hypercholesterolemic patients, simvastatin 20-40 mg/day modestly potentiated the effect of coumarin anticoagulants: the prothrombin time, reported as International Normalized Ratio (INR), increased from a baseline of 1.7 to 1.8 and from 2.6 to 3.4 in the volunteer and patient studies, respectively.  		none	36567	none	36567
Coumarin	Simvastatin	14	13	false	none	Patients taking digoxin should be monitored appropriately when simvastatin is initiated [see Clinical Pharmacology (12.3)].  7.6 Coumarin Anticoagulants    In two clinical studies, one in normal volunteers and the other in hypercholesterolemic patients, simvastatin 20-40 mg/day modestly potentiated the effect of coumarin anticoagulants: the prothrombin time, reported as International Normalized Ratio (INR), increased from a baseline of 1.7 to 1.8 and from 2.6 to 3.4 in the volunteer and patient studies, respectively.  		none	36567	none	36567
Coumarin	Simvastatin	14	13	false	none	Patients taking digoxin should be monitored appropriately when simvastatin is initiated [see Clinical Pharmacology (12.3)].  7.6 Coumarin Anticoagulants    In two clinical studies, one in normal volunteers and the other in hypercholesterolemic patients, simvastatin 20-40 mg/day modestly potentiated the effect of coumarin anticoagulants: the prothrombin time, reported as International Normalized Ratio (INR), increased from a baseline of 1.7 to 1.8 and from 2.6 to 3.4 in the volunteer and patient studies, respectively.  		none	36567	none	36567
Coumarin	Simvastatin	14	14	false	none	7.6 Coumarin Anticoagulants    In two clinical studies, one in normal volunteers and the other in hypercholesterolemic patients, simvastatin 20-40 mg/day modestly potentiated the effect of coumarin anticoagulants: the prothrombin time, reported as International Normalized Ratio (INR), increased from a baseline of 1.7 to 1.8 and from 2.6 to 3.4 in the volunteer and patient studies, respectively.  		none	36567	none	36567
Coumarin	Simvastatin	14	14	false	none	7.6 Coumarin Anticoagulants    In two clinical studies, one in normal volunteers and the other in hypercholesterolemic patients, simvastatin 20-40 mg/day modestly potentiated the effect of coumarin anticoagulants: the prothrombin time, reported as International Normalized Ratio (INR), increased from a baseline of 1.7 to 1.8 and from 2.6 to 3.4 in the volunteer and patient studies, respectively.  		none	36567	none	36567
Coumarin	Simvastatin	14	16	false	none	7.6 Coumarin Anticoagulants    In two clinical studies, one in normal volunteers and the other in hypercholesterolemic patients, simvastatin 20-40 mg/day modestly potentiated the effect of coumarin anticoagulants: the prothrombin time, reported as International Normalized Ratio (INR), increased from a baseline of 1.7 to 1.8 and from 2.6 to 3.4 in the volunteer and patient studies, respectively.  With other statins, clinically evident bleeding and/or increased prothrombin time has been reported in a few patients taking coumarin anticoagulants concomitantly.  In such patients, prothrombin time should be determined before starting simvastatin and frequently enough during early therapy to ensure that no significant alteration of prothrombin time occurs.  		none	36567	none	36567
Coumarin	Simvastatin	14	16	false	none	7.6 Coumarin Anticoagulants    In two clinical studies, one in normal volunteers and the other in hypercholesterolemic patients, simvastatin 20-40 mg/day modestly potentiated the effect of coumarin anticoagulants: the prothrombin time, reported as International Normalized Ratio (INR), increased from a baseline of 1.7 to 1.8 and from 2.6 to 3.4 in the volunteer and patient studies, respectively.  With other statins, clinically evident bleeding and/or increased prothrombin time has been reported in a few patients taking coumarin anticoagulants concomitantly.  In such patients, prothrombin time should be determined before starting simvastatin and frequently enough during early therapy to ensure that no significant alteration of prothrombin time occurs.  		none	36567	none	36567
Coumarin	Simvastatin	15	13	false	none	Patients taking digoxin should be monitored appropriately when simvastatin is initiated [see Clinical Pharmacology (12.3)].  7.6 Coumarin Anticoagulants    In two clinical studies, one in normal volunteers and the other in hypercholesterolemic patients, simvastatin 20-40 mg/day modestly potentiated the effect of coumarin anticoagulants: the prothrombin time, reported as International Normalized Ratio (INR), increased from a baseline of 1.7 to 1.8 and from 2.6 to 3.4 in the volunteer and patient studies, respectively.  With other statins, clinically evident bleeding and/or increased prothrombin time has been reported in a few patients taking coumarin anticoagulants concomitantly.  		none	36567	none	36567
Coumarin	Simvastatin	15	13	false	none	Patients taking digoxin should be monitored appropriately when simvastatin is initiated [see Clinical Pharmacology (12.3)].  7.6 Coumarin Anticoagulants    In two clinical studies, one in normal volunteers and the other in hypercholesterolemic patients, simvastatin 20-40 mg/day modestly potentiated the effect of coumarin anticoagulants: the prothrombin time, reported as International Normalized Ratio (INR), increased from a baseline of 1.7 to 1.8 and from 2.6 to 3.4 in the volunteer and patient studies, respectively.  With other statins, clinically evident bleeding and/or increased prothrombin time has been reported in a few patients taking coumarin anticoagulants concomitantly.  		none	36567	none	36567
Coumarin	Simvastatin	15	14	false	none	7.6 Coumarin Anticoagulants    In two clinical studies, one in normal volunteers and the other in hypercholesterolemic patients, simvastatin 20-40 mg/day modestly potentiated the effect of coumarin anticoagulants: the prothrombin time, reported as International Normalized Ratio (INR), increased from a baseline of 1.7 to 1.8 and from 2.6 to 3.4 in the volunteer and patient studies, respectively.  With other statins, clinically evident bleeding and/or increased prothrombin time has been reported in a few patients taking coumarin anticoagulants concomitantly.  		none	36567	none	36567
Coumarin	Simvastatin	15	14	false	none	7.6 Coumarin Anticoagulants    In two clinical studies, one in normal volunteers and the other in hypercholesterolemic patients, simvastatin 20-40 mg/day modestly potentiated the effect of coumarin anticoagulants: the prothrombin time, reported as International Normalized Ratio (INR), increased from a baseline of 1.7 to 1.8 and from 2.6 to 3.4 in the volunteer and patient studies, respectively.  With other statins, clinically evident bleeding and/or increased prothrombin time has been reported in a few patients taking coumarin anticoagulants concomitantly.  		none	36567	none	36567
Coumarin	Simvastatin	15	16	false	none	With other statins, clinically evident bleeding and/or increased prothrombin time has been reported in a few patients taking coumarin anticoagulants concomitantly.  In such patients, prothrombin time should be determined before starting simvastatin and frequently enough during early therapy to ensure that no significant alteration of prothrombin time occurs.  		none	36567	none	36567
Coumarin	Simvastatin	15	16	false	none	With other statins, clinically evident bleeding and/or increased prothrombin time has been reported in a few patients taking coumarin anticoagulants concomitantly.  In such patients, prothrombin time should be determined before starting simvastatin and frequently enough during early therapy to ensure that no significant alteration of prothrombin time occurs.  		none	36567	none	36567
Coumarin	prothrombin	17	17	false	none	Once a stable prothrombin time has been documented, prothrombin times can be monitored at the intervals usually recommended for patients on coumarin anticoagulants.  		none	none	none	none
Coumarin	prothrombin	17	16	false	none	In such patients, prothrombin time should be determined before starting simvastatin and frequently enough during early therapy to ensure that no significant alteration of prothrombin time occurs.  Once a stable prothrombin time has been documented, prothrombin times can be monitored at the intervals usually recommended for patients on coumarin anticoagulants.  		none	none	none	none
Coumarin	prothrombin	17	19	false	none	Once a stable prothrombin time has been documented, prothrombin times can be monitored at the intervals usually recommended for patients on coumarin anticoagulants.  If the dose of simvastatin is changed or discontinued, the same procedure should be repeated.  Simvastatin therapy has not been associated with bleeding or with changes in prothrombin time in patients not taking anticoagulants.  		none	none	none	none
Coumarin	prothrombin	17	15	false	none	With other statins, clinically evident bleeding and/or increased prothrombin time has been reported in a few patients taking coumarin anticoagulants concomitantly.  In such patients, prothrombin time should be determined before starting simvastatin and frequently enough during early therapy to ensure that no significant alteration of prothrombin time occurs.  Once a stable prothrombin time has been documented, prothrombin times can be monitored at the intervals usually recommended for patients on coumarin anticoagulants.  		none	none	none	none
Coumarin	prothrombin	14	16	false	none	7.6 Coumarin Anticoagulants    In two clinical studies, one in normal volunteers and the other in hypercholesterolemic patients, simvastatin 20-40 mg/day modestly potentiated the effect of coumarin anticoagulants: the prothrombin time, reported as International Normalized Ratio (INR), increased from a baseline of 1.7 to 1.8 and from 2.6 to 3.4 in the volunteer and patient studies, respectively.  With other statins, clinically evident bleeding and/or increased prothrombin time has been reported in a few patients taking coumarin anticoagulants concomitantly.  In such patients, prothrombin time should be determined before starting simvastatin and frequently enough during early therapy to ensure that no significant alteration of prothrombin time occurs.  		none	none	none	none
Coumarin	prothrombin	14	14	false	none	7.6 Coumarin Anticoagulants    In two clinical studies, one in normal volunteers and the other in hypercholesterolemic patients, simvastatin 20-40 mg/day modestly potentiated the effect of coumarin anticoagulants: the prothrombin time, reported as International Normalized Ratio (INR), increased from a baseline of 1.7 to 1.8 and from 2.6 to 3.4 in the volunteer and patient studies, respectively.  		none	none	none	none
Coumarin	prothrombin	14	15	false	none	7.6 Coumarin Anticoagulants    In two clinical studies, one in normal volunteers and the other in hypercholesterolemic patients, simvastatin 20-40 mg/day modestly potentiated the effect of coumarin anticoagulants: the prothrombin time, reported as International Normalized Ratio (INR), increased from a baseline of 1.7 to 1.8 and from 2.6 to 3.4 in the volunteer and patient studies, respectively.  With other statins, clinically evident bleeding and/or increased prothrombin time has been reported in a few patients taking coumarin anticoagulants concomitantly.  		none	none	none	none
Coumarin	prothrombin	15	17	false	none	With other statins, clinically evident bleeding and/or increased prothrombin time has been reported in a few patients taking coumarin anticoagulants concomitantly.  In such patients, prothrombin time should be determined before starting simvastatin and frequently enough during early therapy to ensure that no significant alteration of prothrombin time occurs.  Once a stable prothrombin time has been documented, prothrombin times can be monitored at the intervals usually recommended for patients on coumarin anticoagulants.  		none	none	none	none
Coumarin	prothrombin	15	16	false	none	With other statins, clinically evident bleeding and/or increased prothrombin time has been reported in a few patients taking coumarin anticoagulants concomitantly.  In such patients, prothrombin time should be determined before starting simvastatin and frequently enough during early therapy to ensure that no significant alteration of prothrombin time occurs.  		none	none	none	none
Coumarin	prothrombin	15	14	false	none	7.6 Coumarin Anticoagulants    In two clinical studies, one in normal volunteers and the other in hypercholesterolemic patients, simvastatin 20-40 mg/day modestly potentiated the effect of coumarin anticoagulants: the prothrombin time, reported as International Normalized Ratio (INR), increased from a baseline of 1.7 to 1.8 and from 2.6 to 3.4 in the volunteer and patient studies, respectively.  With other statins, clinically evident bleeding and/or increased prothrombin time has been reported in a few patients taking coumarin anticoagulants concomitantly.  		none	none	none	none
Coumarin	prothrombin	15	15	false	none	With other statins, clinically evident bleeding and/or increased prothrombin time has been reported in a few patients taking coumarin anticoagulants concomitantly.  		none	none	none	none
Coumarin	coumarin	17	17	false	none	Once a stable prothrombin time has been documented, prothrombin times can be monitored at the intervals usually recommended for patients on coumarin anticoagulants.  		none	none	none	none
Coumarin	coumarin	17	15	false	none	With other statins, clinically evident bleeding and/or increased prothrombin time has been reported in a few patients taking coumarin anticoagulants concomitantly.  In such patients, prothrombin time should be determined before starting simvastatin and frequently enough during early therapy to ensure that no significant alteration of prothrombin time occurs.  Once a stable prothrombin time has been documented, prothrombin times can be monitored at the intervals usually recommended for patients on coumarin anticoagulants.  		none	none	none	none
Coumarin	coumarin	14	14	false	none	7.6 Coumarin Anticoagulants    In two clinical studies, one in normal volunteers and the other in hypercholesterolemic patients, simvastatin 20-40 mg/day modestly potentiated the effect of coumarin anticoagulants: the prothrombin time, reported as International Normalized Ratio (INR), increased from a baseline of 1.7 to 1.8 and from 2.6 to 3.4 in the volunteer and patient studies, respectively.  		none	none	none	none
Coumarin	coumarin	14	15	false	none	7.6 Coumarin Anticoagulants    In two clinical studies, one in normal volunteers and the other in hypercholesterolemic patients, simvastatin 20-40 mg/day modestly potentiated the effect of coumarin anticoagulants: the prothrombin time, reported as International Normalized Ratio (INR), increased from a baseline of 1.7 to 1.8 and from 2.6 to 3.4 in the volunteer and patient studies, respectively.  With other statins, clinically evident bleeding and/or increased prothrombin time has been reported in a few patients taking coumarin anticoagulants concomitantly.  		none	none	none	none
Coumarin	coumarin	15	17	false	none	With other statins, clinically evident bleeding and/or increased prothrombin time has been reported in a few patients taking coumarin anticoagulants concomitantly.  In such patients, prothrombin time should be determined before starting simvastatin and frequently enough during early therapy to ensure that no significant alteration of prothrombin time occurs.  Once a stable prothrombin time has been documented, prothrombin times can be monitored at the intervals usually recommended for patients on coumarin anticoagulants.  		none	none	none	none
Coumarin	coumarin	15	14	false	none	7.6 Coumarin Anticoagulants    In two clinical studies, one in normal volunteers and the other in hypercholesterolemic patients, simvastatin 20-40 mg/day modestly potentiated the effect of coumarin anticoagulants: the prothrombin time, reported as International Normalized Ratio (INR), increased from a baseline of 1.7 to 1.8 and from 2.6 to 3.4 in the volunteer and patient studies, respectively.  With other statins, clinically evident bleeding and/or increased prothrombin time has been reported in a few patients taking coumarin anticoagulants concomitantly.  		none	none	none	none
Coumarin	coumarin	15	15	false	none	With other statins, clinically evident bleeding and/or increased prothrombin time has been reported in a few patients taking coumarin anticoagulants concomitantly.  		none	none	none	none
Coumarin	digoxin	14	12	false	none	7.5 Digoxin    In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma.  Patients taking digoxin should be monitored appropriately when simvastatin is initiated [see Clinical Pharmacology (12.3)].  7.6 Coumarin Anticoagulants    In two clinical studies, one in normal volunteers and the other in hypercholesterolemic patients, simvastatin 20-40 mg/day modestly potentiated the effect of coumarin anticoagulants: the prothrombin time, reported as International Normalized Ratio (INR), increased from a baseline of 1.7 to 1.8 and from 2.6 to 3.4 in the volunteer and patient studies, respectively.  		none	none	none	none
Coumarin	digoxin	14	13	false	none	Patients taking digoxin should be monitored appropriately when simvastatin is initiated [see Clinical Pharmacology (12.3)].  7.6 Coumarin Anticoagulants    In two clinical studies, one in normal volunteers and the other in hypercholesterolemic patients, simvastatin 20-40 mg/day modestly potentiated the effect of coumarin anticoagulants: the prothrombin time, reported as International Normalized Ratio (INR), increased from a baseline of 1.7 to 1.8 and from 2.6 to 3.4 in the volunteer and patient studies, respectively.  		none	none	none	none
Coumarin	digoxin	15	13	false	none	Patients taking digoxin should be monitored appropriately when simvastatin is initiated [see Clinical Pharmacology (12.3)].  7.6 Coumarin Anticoagulants    In two clinical studies, one in normal volunteers and the other in hypercholesterolemic patients, simvastatin 20-40 mg/day modestly potentiated the effect of coumarin anticoagulants: the prothrombin time, reported as International Normalized Ratio (INR), increased from a baseline of 1.7 to 1.8 and from 2.6 to 3.4 in the volunteer and patient studies, respectively.  With other statins, clinically evident bleeding and/or increased prothrombin time has been reported in a few patients taking coumarin anticoagulants concomitantly.  		none	none	none	none
Coumarin	simvastatin	17	16	false	none	In such patients, prothrombin time should be determined before starting simvastatin and frequently enough during early therapy to ensure that no significant alteration of prothrombin time occurs.  Once a stable prothrombin time has been documented, prothrombin times can be monitored at the intervals usually recommended for patients on coumarin anticoagulants.  		none	36567	none	36567
Coumarin	simvastatin	17	16	false	none	In such patients, prothrombin time should be determined before starting simvastatin and frequently enough during early therapy to ensure that no significant alteration of prothrombin time occurs.  Once a stable prothrombin time has been documented, prothrombin times can be monitored at the intervals usually recommended for patients on coumarin anticoagulants.  		none	36567	none	36567
Coumarin	simvastatin	17	19	false	none	Once a stable prothrombin time has been documented, prothrombin times can be monitored at the intervals usually recommended for patients on coumarin anticoagulants.  If the dose of simvastatin is changed or discontinued, the same procedure should be repeated.  Simvastatin therapy has not been associated with bleeding or with changes in prothrombin time in patients not taking anticoagulants.  		none	36567	none	36567
Coumarin	simvastatin	17	19	false	none	Once a stable prothrombin time has been documented, prothrombin times can be monitored at the intervals usually recommended for patients on coumarin anticoagulants.  If the dose of simvastatin is changed or discontinued, the same procedure should be repeated.  Simvastatin therapy has not been associated with bleeding or with changes in prothrombin time in patients not taking anticoagulants.  		none	36567	none	36567
Coumarin	simvastatin	17	18	false	none	Once a stable prothrombin time has been documented, prothrombin times can be monitored at the intervals usually recommended for patients on coumarin anticoagulants.  If the dose of simvastatin is changed or discontinued, the same procedure should be repeated.  		none	36567	none	36567
Coumarin	simvastatin	17	18	false	none	Once a stable prothrombin time has been documented, prothrombin times can be monitored at the intervals usually recommended for patients on coumarin anticoagulants.  If the dose of simvastatin is changed or discontinued, the same procedure should be repeated.  		none	36567	none	36567
Coumarin	simvastatin	14	12	false	none	7.5 Digoxin    In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma.  Patients taking digoxin should be monitored appropriately when simvastatin is initiated [see Clinical Pharmacology (12.3)].  7.6 Coumarin Anticoagulants    In two clinical studies, one in normal volunteers and the other in hypercholesterolemic patients, simvastatin 20-40 mg/day modestly potentiated the effect of coumarin anticoagulants: the prothrombin time, reported as International Normalized Ratio (INR), increased from a baseline of 1.7 to 1.8 and from 2.6 to 3.4 in the volunteer and patient studies, respectively.  		none	36567	none	36567
Coumarin	simvastatin	14	12	false	none	7.5 Digoxin    In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma.  Patients taking digoxin should be monitored appropriately when simvastatin is initiated [see Clinical Pharmacology (12.3)].  7.6 Coumarin Anticoagulants    In two clinical studies, one in normal volunteers and the other in hypercholesterolemic patients, simvastatin 20-40 mg/day modestly potentiated the effect of coumarin anticoagulants: the prothrombin time, reported as International Normalized Ratio (INR), increased from a baseline of 1.7 to 1.8 and from 2.6 to 3.4 in the volunteer and patient studies, respectively.  		none	36567	none	36567
Coumarin	simvastatin	14	13	false	none	Patients taking digoxin should be monitored appropriately when simvastatin is initiated [see Clinical Pharmacology (12.3)].  7.6 Coumarin Anticoagulants    In two clinical studies, one in normal volunteers and the other in hypercholesterolemic patients, simvastatin 20-40 mg/day modestly potentiated the effect of coumarin anticoagulants: the prothrombin time, reported as International Normalized Ratio (INR), increased from a baseline of 1.7 to 1.8 and from 2.6 to 3.4 in the volunteer and patient studies, respectively.  		none	36567	none	36567
Coumarin	simvastatin	14	13	false	none	Patients taking digoxin should be monitored appropriately when simvastatin is initiated [see Clinical Pharmacology (12.3)].  7.6 Coumarin Anticoagulants    In two clinical studies, one in normal volunteers and the other in hypercholesterolemic patients, simvastatin 20-40 mg/day modestly potentiated the effect of coumarin anticoagulants: the prothrombin time, reported as International Normalized Ratio (INR), increased from a baseline of 1.7 to 1.8 and from 2.6 to 3.4 in the volunteer and patient studies, respectively.  		none	36567	none	36567
Coumarin	simvastatin	14	14	false	none	7.6 Coumarin Anticoagulants    In two clinical studies, one in normal volunteers and the other in hypercholesterolemic patients, simvastatin 20-40 mg/day modestly potentiated the effect of coumarin anticoagulants: the prothrombin time, reported as International Normalized Ratio (INR), increased from a baseline of 1.7 to 1.8 and from 2.6 to 3.4 in the volunteer and patient studies, respectively.  		none	36567	none	36567
Coumarin	simvastatin	14	14	false	none	7.6 Coumarin Anticoagulants    In two clinical studies, one in normal volunteers and the other in hypercholesterolemic patients, simvastatin 20-40 mg/day modestly potentiated the effect of coumarin anticoagulants: the prothrombin time, reported as International Normalized Ratio (INR), increased from a baseline of 1.7 to 1.8 and from 2.6 to 3.4 in the volunteer and patient studies, respectively.  		none	36567	none	36567
Coumarin	simvastatin	14	16	false	none	7.6 Coumarin Anticoagulants    In two clinical studies, one in normal volunteers and the other in hypercholesterolemic patients, simvastatin 20-40 mg/day modestly potentiated the effect of coumarin anticoagulants: the prothrombin time, reported as International Normalized Ratio (INR), increased from a baseline of 1.7 to 1.8 and from 2.6 to 3.4 in the volunteer and patient studies, respectively.  With other statins, clinically evident bleeding and/or increased prothrombin time has been reported in a few patients taking coumarin anticoagulants concomitantly.  In such patients, prothrombin time should be determined before starting simvastatin and frequently enough during early therapy to ensure that no significant alteration of prothrombin time occurs.  		none	36567	none	36567
Coumarin	simvastatin	14	16	false	none	7.6 Coumarin Anticoagulants    In two clinical studies, one in normal volunteers and the other in hypercholesterolemic patients, simvastatin 20-40 mg/day modestly potentiated the effect of coumarin anticoagulants: the prothrombin time, reported as International Normalized Ratio (INR), increased from a baseline of 1.7 to 1.8 and from 2.6 to 3.4 in the volunteer and patient studies, respectively.  With other statins, clinically evident bleeding and/or increased prothrombin time has been reported in a few patients taking coumarin anticoagulants concomitantly.  In such patients, prothrombin time should be determined before starting simvastatin and frequently enough during early therapy to ensure that no significant alteration of prothrombin time occurs.  		none	36567	none	36567
Coumarin	simvastatin	15	13	false	none	Patients taking digoxin should be monitored appropriately when simvastatin is initiated [see Clinical Pharmacology (12.3)].  7.6 Coumarin Anticoagulants    In two clinical studies, one in normal volunteers and the other in hypercholesterolemic patients, simvastatin 20-40 mg/day modestly potentiated the effect of coumarin anticoagulants: the prothrombin time, reported as International Normalized Ratio (INR), increased from a baseline of 1.7 to 1.8 and from 2.6 to 3.4 in the volunteer and patient studies, respectively.  With other statins, clinically evident bleeding and/or increased prothrombin time has been reported in a few patients taking coumarin anticoagulants concomitantly.  		none	36567	none	36567
Coumarin	simvastatin	15	13	false	none	Patients taking digoxin should be monitored appropriately when simvastatin is initiated [see Clinical Pharmacology (12.3)].  7.6 Coumarin Anticoagulants    In two clinical studies, one in normal volunteers and the other in hypercholesterolemic patients, simvastatin 20-40 mg/day modestly potentiated the effect of coumarin anticoagulants: the prothrombin time, reported as International Normalized Ratio (INR), increased from a baseline of 1.7 to 1.8 and from 2.6 to 3.4 in the volunteer and patient studies, respectively.  With other statins, clinically evident bleeding and/or increased prothrombin time has been reported in a few patients taking coumarin anticoagulants concomitantly.  		none	36567	none	36567
Coumarin	simvastatin	15	14	false	none	7.6 Coumarin Anticoagulants    In two clinical studies, one in normal volunteers and the other in hypercholesterolemic patients, simvastatin 20-40 mg/day modestly potentiated the effect of coumarin anticoagulants: the prothrombin time, reported as International Normalized Ratio (INR), increased from a baseline of 1.7 to 1.8 and from 2.6 to 3.4 in the volunteer and patient studies, respectively.  With other statins, clinically evident bleeding and/or increased prothrombin time has been reported in a few patients taking coumarin anticoagulants concomitantly.  		none	36567	none	36567
Coumarin	simvastatin	15	14	false	none	7.6 Coumarin Anticoagulants    In two clinical studies, one in normal volunteers and the other in hypercholesterolemic patients, simvastatin 20-40 mg/day modestly potentiated the effect of coumarin anticoagulants: the prothrombin time, reported as International Normalized Ratio (INR), increased from a baseline of 1.7 to 1.8 and from 2.6 to 3.4 in the volunteer and patient studies, respectively.  With other statins, clinically evident bleeding and/or increased prothrombin time has been reported in a few patients taking coumarin anticoagulants concomitantly.  		none	36567	none	36567
Coumarin	simvastatin	15	16	false	none	With other statins, clinically evident bleeding and/or increased prothrombin time has been reported in a few patients taking coumarin anticoagulants concomitantly.  In such patients, prothrombin time should be determined before starting simvastatin and frequently enough during early therapy to ensure that no significant alteration of prothrombin time occurs.  		none	36567	none	36567
Coumarin	simvastatin	15	16	false	none	With other statins, clinically evident bleeding and/or increased prothrombin time has been reported in a few patients taking coumarin anticoagulants concomitantly.  In such patients, prothrombin time should be determined before starting simvastatin and frequently enough during early therapy to ensure that no significant alteration of prothrombin time occurs.  		none	36567	none	36567
Digoxin	Simvastatin	12	10	false	none	7.3 Cyclosporine or Danazol    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of cyclosporine or danazol particularly with higher doses of simvastatin [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].  7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  7.5 Digoxin    In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma.  		none	36567	none	36567
Digoxin	Simvastatin	12	10	false	none	7.3 Cyclosporine or Danazol    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of cyclosporine or danazol particularly with higher doses of simvastatin [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].  7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  7.5 Digoxin    In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma.  		none	36567	none	36567
Digoxin	Simvastatin	12	11	false	none	7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  7.5 Digoxin    In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma.  		none	36567	none	36567
Digoxin	Simvastatin	12	11	false	none	7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  7.5 Digoxin    In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma.  		none	36567	none	36567
Digoxin	Simvastatin	12	12	false	none	7.5 Digoxin    In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma.  		none	36567	none	36567
Digoxin	Simvastatin	12	12	false	none	7.5 Digoxin    In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma.  		none	36567	none	36567
Digoxin	Simvastatin	12	13	false	none	7.5 Digoxin    In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma.  Patients taking digoxin should be monitored appropriately when simvastatin is initiated [see Clinical Pharmacology (12.3)].  		none	36567	none	36567
Digoxin	Simvastatin	12	13	false	none	7.5 Digoxin    In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma.  Patients taking digoxin should be monitored appropriately when simvastatin is initiated [see Clinical Pharmacology (12.3)].  		none	36567	none	36567
Digoxin	Simvastatin	12	14	false	none	7.5 Digoxin    In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma.  Patients taking digoxin should be monitored appropriately when simvastatin is initiated [see Clinical Pharmacology (12.3)].  7.6 Coumarin Anticoagulants    In two clinical studies, one in normal volunteers and the other in hypercholesterolemic patients, simvastatin 20-40 mg/day modestly potentiated the effect of coumarin anticoagulants: the prothrombin time, reported as International Normalized Ratio (INR), increased from a baseline of 1.7 to 1.8 and from 2.6 to 3.4 in the volunteer and patient studies, respectively.  		none	36567	none	36567
Digoxin	Simvastatin	12	14	false	none	7.5 Digoxin    In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma.  Patients taking digoxin should be monitored appropriately when simvastatin is initiated [see Clinical Pharmacology (12.3)].  7.6 Coumarin Anticoagulants    In two clinical studies, one in normal volunteers and the other in hypercholesterolemic patients, simvastatin 20-40 mg/day modestly potentiated the effect of coumarin anticoagulants: the prothrombin time, reported as International Normalized Ratio (INR), increased from a baseline of 1.7 to 1.8 and from 2.6 to 3.4 in the volunteer and patient studies, respectively.  		none	36567	none	36567
Digoxin	Simvastatin	13	11	false	none	7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  7.5 Digoxin    In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma.  Patients taking digoxin should be monitored appropriately when simvastatin is initiated [see Clinical Pharmacology (12.3)].  		none	36567	none	36567
Digoxin	Simvastatin	13	11	false	none	7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  7.5 Digoxin    In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma.  Patients taking digoxin should be monitored appropriately when simvastatin is initiated [see Clinical Pharmacology (12.3)].  		none	36567	none	36567
Digoxin	Simvastatin	13	12	false	none	7.5 Digoxin    In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma.  Patients taking digoxin should be monitored appropriately when simvastatin is initiated [see Clinical Pharmacology (12.3)].  		none	36567	none	36567
Digoxin	Simvastatin	13	12	false	none	7.5 Digoxin    In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma.  Patients taking digoxin should be monitored appropriately when simvastatin is initiated [see Clinical Pharmacology (12.3)].  		none	36567	none	36567
Digoxin	Simvastatin	13	13	false	none	Patients taking digoxin should be monitored appropriately when simvastatin is initiated [see Clinical Pharmacology (12.3)].  		none	36567	none	36567
Digoxin	Simvastatin	13	13	false	none	Patients taking digoxin should be monitored appropriately when simvastatin is initiated [see Clinical Pharmacology (12.3)].  		none	36567	none	36567
Digoxin	Simvastatin	13	14	false	none	Patients taking digoxin should be monitored appropriately when simvastatin is initiated [see Clinical Pharmacology (12.3)].  7.6 Coumarin Anticoagulants    In two clinical studies, one in normal volunteers and the other in hypercholesterolemic patients, simvastatin 20-40 mg/day modestly potentiated the effect of coumarin anticoagulants: the prothrombin time, reported as International Normalized Ratio (INR), increased from a baseline of 1.7 to 1.8 and from 2.6 to 3.4 in the volunteer and patient studies, respectively.  		none	36567	none	36567
Digoxin	Simvastatin	13	14	false	none	Patients taking digoxin should be monitored appropriately when simvastatin is initiated [see Clinical Pharmacology (12.3)].  7.6 Coumarin Anticoagulants    In two clinical studies, one in normal volunteers and the other in hypercholesterolemic patients, simvastatin 20-40 mg/day modestly potentiated the effect of coumarin anticoagulants: the prothrombin time, reported as International Normalized Ratio (INR), increased from a baseline of 1.7 to 1.8 and from 2.6 to 3.4 in the volunteer and patient studies, respectively.  		none	36567	none	36567
Digoxin	Amiodarone	12	11	false	none	7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  7.5 Digoxin    In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma.  		none	none	none	none
Digoxin	Amiodarone	13	11	false	none	7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  7.5 Digoxin    In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma.  Patients taking digoxin should be monitored appropriately when simvastatin is initiated [see Clinical Pharmacology (12.3)].  		none	none	none	none
Digoxin	Verapamil	12	11	false	none	7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  7.5 Digoxin    In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma.  		none	none	none	none
Digoxin	Verapamil	13	11	false	none	7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  7.5 Digoxin    In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma.  Patients taking digoxin should be monitored appropriately when simvastatin is initiated [see Clinical Pharmacology (12.3)].  		none	none	none	none
Digoxin	prothrombin	12	14	false	none	7.5 Digoxin    In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma.  Patients taking digoxin should be monitored appropriately when simvastatin is initiated [see Clinical Pharmacology (12.3)].  7.6 Coumarin Anticoagulants    In two clinical studies, one in normal volunteers and the other in hypercholesterolemic patients, simvastatin 20-40 mg/day modestly potentiated the effect of coumarin anticoagulants: the prothrombin time, reported as International Normalized Ratio (INR), increased from a baseline of 1.7 to 1.8 and from 2.6 to 3.4 in the volunteer and patient studies, respectively.  		none	none	none	none
Digoxin	prothrombin	13	14	false	none	Patients taking digoxin should be monitored appropriately when simvastatin is initiated [see Clinical Pharmacology (12.3)].  7.6 Coumarin Anticoagulants    In two clinical studies, one in normal volunteers and the other in hypercholesterolemic patients, simvastatin 20-40 mg/day modestly potentiated the effect of coumarin anticoagulants: the prothrombin time, reported as International Normalized Ratio (INR), increased from a baseline of 1.7 to 1.8 and from 2.6 to 3.4 in the volunteer and patient studies, respectively.  		none	none	none	none
Digoxin	prothrombin	13	15	false	none	Patients taking digoxin should be monitored appropriately when simvastatin is initiated [see Clinical Pharmacology (12.3)].  7.6 Coumarin Anticoagulants    In two clinical studies, one in normal volunteers and the other in hypercholesterolemic patients, simvastatin 20-40 mg/day modestly potentiated the effect of coumarin anticoagulants: the prothrombin time, reported as International Normalized Ratio (INR), increased from a baseline of 1.7 to 1.8 and from 2.6 to 3.4 in the volunteer and patient studies, respectively.  With other statins, clinically evident bleeding and/or increased prothrombin time has been reported in a few patients taking coumarin anticoagulants concomitantly.  		none	none	none	none
Digoxin	coumarin	12	14	false	none	7.5 Digoxin    In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma.  Patients taking digoxin should be monitored appropriately when simvastatin is initiated [see Clinical Pharmacology (12.3)].  7.6 Coumarin Anticoagulants    In two clinical studies, one in normal volunteers and the other in hypercholesterolemic patients, simvastatin 20-40 mg/day modestly potentiated the effect of coumarin anticoagulants: the prothrombin time, reported as International Normalized Ratio (INR), increased from a baseline of 1.7 to 1.8 and from 2.6 to 3.4 in the volunteer and patient studies, respectively.  		none	none	none	none
Digoxin	coumarin	13	14	false	none	Patients taking digoxin should be monitored appropriately when simvastatin is initiated [see Clinical Pharmacology (12.3)].  7.6 Coumarin Anticoagulants    In two clinical studies, one in normal volunteers and the other in hypercholesterolemic patients, simvastatin 20-40 mg/day modestly potentiated the effect of coumarin anticoagulants: the prothrombin time, reported as International Normalized Ratio (INR), increased from a baseline of 1.7 to 1.8 and from 2.6 to 3.4 in the volunteer and patient studies, respectively.  		none	none	none	none
Digoxin	coumarin	13	15	false	none	Patients taking digoxin should be monitored appropriately when simvastatin is initiated [see Clinical Pharmacology (12.3)].  7.6 Coumarin Anticoagulants    In two clinical studies, one in normal volunteers and the other in hypercholesterolemic patients, simvastatin 20-40 mg/day modestly potentiated the effect of coumarin anticoagulants: the prothrombin time, reported as International Normalized Ratio (INR), increased from a baseline of 1.7 to 1.8 and from 2.6 to 3.4 in the volunteer and patient studies, respectively.  With other statins, clinically evident bleeding and/or increased prothrombin time has been reported in a few patients taking coumarin anticoagulants concomitantly.  		none	none	none	none
Digoxin	Danazol	12	10	false	none	7.3 Cyclosporine or Danazol    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of cyclosporine or danazol particularly with higher doses of simvastatin [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].  7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  7.5 Digoxin    In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma.  		none	none	none	none
Digoxin	digoxin	12	12	false	none	7.5 Digoxin    In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma.  		none	none	none	none
Digoxin	digoxin	12	13	false	none	7.5 Digoxin    In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma.  Patients taking digoxin should be monitored appropriately when simvastatin is initiated [see Clinical Pharmacology (12.3)].  		none	none	none	none
Digoxin	digoxin	13	12	false	none	7.5 Digoxin    In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma.  Patients taking digoxin should be monitored appropriately when simvastatin is initiated [see Clinical Pharmacology (12.3)].  		none	none	none	none
Digoxin	digoxin	13	13	false	none	Patients taking digoxin should be monitored appropriately when simvastatin is initiated [see Clinical Pharmacology (12.3)].  		none	none	none	none
Digoxin	simvastatin	12	10	false	none	7.3 Cyclosporine or Danazol    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of cyclosporine or danazol particularly with higher doses of simvastatin [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].  7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  7.5 Digoxin    In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma.  		none	36567	none	36567
Digoxin	simvastatin	12	10	false	none	7.3 Cyclosporine or Danazol    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of cyclosporine or danazol particularly with higher doses of simvastatin [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].  7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  7.5 Digoxin    In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma.  		none	36567	none	36567
Digoxin	simvastatin	12	11	false	none	7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  7.5 Digoxin    In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma.  		none	36567	none	36567
Digoxin	simvastatin	12	11	false	none	7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  7.5 Digoxin    In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma.  		none	36567	none	36567
Digoxin	simvastatin	12	12	false	none	7.5 Digoxin    In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma.  		none	36567	none	36567
Digoxin	simvastatin	12	12	false	none	7.5 Digoxin    In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma.  		none	36567	none	36567
Digoxin	simvastatin	12	13	false	none	7.5 Digoxin    In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma.  Patients taking digoxin should be monitored appropriately when simvastatin is initiated [see Clinical Pharmacology (12.3)].  		none	36567	none	36567
Digoxin	simvastatin	12	13	false	none	7.5 Digoxin    In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma.  Patients taking digoxin should be monitored appropriately when simvastatin is initiated [see Clinical Pharmacology (12.3)].  		none	36567	none	36567
Digoxin	simvastatin	12	14	false	none	7.5 Digoxin    In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma.  Patients taking digoxin should be monitored appropriately when simvastatin is initiated [see Clinical Pharmacology (12.3)].  7.6 Coumarin Anticoagulants    In two clinical studies, one in normal volunteers and the other in hypercholesterolemic patients, simvastatin 20-40 mg/day modestly potentiated the effect of coumarin anticoagulants: the prothrombin time, reported as International Normalized Ratio (INR), increased from a baseline of 1.7 to 1.8 and from 2.6 to 3.4 in the volunteer and patient studies, respectively.  		none	36567	none	36567
Digoxin	simvastatin	12	14	false	none	7.5 Digoxin    In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma.  Patients taking digoxin should be monitored appropriately when simvastatin is initiated [see Clinical Pharmacology (12.3)].  7.6 Coumarin Anticoagulants    In two clinical studies, one in normal volunteers and the other in hypercholesterolemic patients, simvastatin 20-40 mg/day modestly potentiated the effect of coumarin anticoagulants: the prothrombin time, reported as International Normalized Ratio (INR), increased from a baseline of 1.7 to 1.8 and from 2.6 to 3.4 in the volunteer and patient studies, respectively.  		none	36567	none	36567
Digoxin	simvastatin	13	11	false	none	7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  7.5 Digoxin    In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma.  Patients taking digoxin should be monitored appropriately when simvastatin is initiated [see Clinical Pharmacology (12.3)].  		none	36567	none	36567
Digoxin	simvastatin	13	11	false	none	7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  7.5 Digoxin    In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma.  Patients taking digoxin should be monitored appropriately when simvastatin is initiated [see Clinical Pharmacology (12.3)].  		none	36567	none	36567
Digoxin	simvastatin	13	12	false	none	7.5 Digoxin    In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma.  Patients taking digoxin should be monitored appropriately when simvastatin is initiated [see Clinical Pharmacology (12.3)].  		none	36567	none	36567
Digoxin	simvastatin	13	12	false	none	7.5 Digoxin    In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma.  Patients taking digoxin should be monitored appropriately when simvastatin is initiated [see Clinical Pharmacology (12.3)].  		none	36567	none	36567
Digoxin	simvastatin	13	13	false	none	Patients taking digoxin should be monitored appropriately when simvastatin is initiated [see Clinical Pharmacology (12.3)].  		none	36567	none	36567
Digoxin	simvastatin	13	13	false	none	Patients taking digoxin should be monitored appropriately when simvastatin is initiated [see Clinical Pharmacology (12.3)].  		none	36567	none	36567
Digoxin	simvastatin	13	14	false	none	Patients taking digoxin should be monitored appropriately when simvastatin is initiated [see Clinical Pharmacology (12.3)].  7.6 Coumarin Anticoagulants    In two clinical studies, one in normal volunteers and the other in hypercholesterolemic patients, simvastatin 20-40 mg/day modestly potentiated the effect of coumarin anticoagulants: the prothrombin time, reported as International Normalized Ratio (INR), increased from a baseline of 1.7 to 1.8 and from 2.6 to 3.4 in the volunteer and patient studies, respectively.  		none	36567	none	36567
Digoxin	simvastatin	13	14	false	none	Patients taking digoxin should be monitored appropriately when simvastatin is initiated [see Clinical Pharmacology (12.3)].  7.6 Coumarin Anticoagulants    In two clinical studies, one in normal volunteers and the other in hypercholesterolemic patients, simvastatin 20-40 mg/day modestly potentiated the effect of coumarin anticoagulants: the prothrombin time, reported as International Normalized Ratio (INR), increased from a baseline of 1.7 to 1.8 and from 2.6 to 3.4 in the volunteer and patient studies, respectively.  		none	36567	none	36567
Digoxin	verapamil	12	11	false	none	7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  7.5 Digoxin    In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma.  		none	none	none	none
Digoxin	verapamil	13	11	false	none	7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  7.5 Digoxin    In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma.  Patients taking digoxin should be monitored appropriately when simvastatin is initiated [see Clinical Pharmacology (12.3)].  		none	none	none	none
Digoxin	Cyclosporine	12	10	false	none	7.3 Cyclosporine or Danazol    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of cyclosporine or danazol particularly with higher doses of simvastatin [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].  7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  7.5 Digoxin    In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma.  		none	none	none	none
Digoxin	danazol	12	10	false	none	7.3 Cyclosporine or Danazol    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of cyclosporine or danazol particularly with higher doses of simvastatin [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].  7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  7.5 Digoxin    In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma.  		none	none	none	none
Digoxin	amiodarone	12	11	false	none	7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  7.5 Digoxin    In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma.  		none	none	none	none
Digoxin	amiodarone	13	11	false	none	7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  7.5 Digoxin    In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma.  Patients taking digoxin should be monitored appropriately when simvastatin is initiated [see Clinical Pharmacology (12.3)].  		none	none	none	none
Digoxin	cyclosporine	12	10	false	none	7.3 Cyclosporine or Danazol    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of cyclosporine or danazol particularly with higher doses of simvastatin [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].  7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  7.5 Digoxin    In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma.  		none	none	none	none
Itraconazole	Simvastatin	6	4	false	none	Hence when simvastatin is used with an inhibitor of CYP3A4 (e.g., as listed below), elevated plasma levels of HMG-CoA reductase inhibitory activity can increase the risk of myopathy and rhabdomyolysis, particularly with higher doses of simvastatin.  [See Warnings and Precautions (5.1) and Clinical Pharmacology (12.3).]  Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  		28031	36567	D017964	36567
Itraconazole	Simvastatin	6	4	false	none	Hence when simvastatin is used with an inhibitor of CYP3A4 (e.g., as listed below), elevated plasma levels of HMG-CoA reductase inhibitory activity can increase the risk of myopathy and rhabdomyolysis, particularly with higher doses of simvastatin.  [See Warnings and Precautions (5.1) and Clinical Pharmacology (12.3).]  Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  		28031	36567	D017964	36567
Itraconazole	Simvastatin	6	7	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		28031	36567	D017964	36567
Itraconazole	Simvastatin	6	7	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		28031	36567	D017964	36567
Itraconazole	Simvastatin	7	7	false	none	If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		28031	36567	D017964	36567
Itraconazole	Simvastatin	7	7	false	none	If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		28031	36567	D017964	36567
Itraconazole	niacin	6	8	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  		28031	7393	D017964	D009525
Itraconazole	niacin	6	8	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  		28031	7393	D017964	D009525
Itraconazole	niacin	7	8	false	none	If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  		28031	7393	D017964	D009525
Itraconazole	niacin	7	8	false	none	If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  		28031	7393	D017964	D009525
Itraconazole	nicotinic acid	6	8	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  		28031	7393	D017964	D009525
Itraconazole	nicotinic acid	6	8	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  		28031	7393	D017964	D009525
Itraconazole	nicotinic acid	7	8	false	none	If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  		28031	7393	D017964	D009525
Itraconazole	nicotinic acid	7	8	false	none	If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  		28031	7393	D017964	D009525
Itraconazole	grapefruit	6	6	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  		28031	none	D017964	none
Itraconazole	grapefruit	6	6	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  		28031	none	D017964	none
Itraconazole	grapefruit	7	6	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		28031	none	D017964	none
Itraconazole	grapefruit	7	6	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		28031	none	D017964	none
Itraconazole	ketoconazole	6	6	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  		28031	6135	D017964	D007654
Itraconazole	ketoconazole	6	6	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  		28031	6135	D017964	D007654
Itraconazole	ketoconazole	6	7	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		28031	6135	D017964	D007654
Itraconazole	ketoconazole	6	7	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		28031	6135	D017964	D007654
Itraconazole	ketoconazole	7	6	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		28031	6135	D017964	D007654
Itraconazole	ketoconazole	7	6	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		28031	6135	D017964	D007654
Itraconazole	ketoconazole	7	7	false	none	If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		28031	6135	D017964	D007654
Itraconazole	ketoconazole	7	7	false	none	If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		28031	6135	D017964	D007654
Itraconazole	itraconazole	6	6	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  		D017964	D017964
Itraconazole	itraconazole	6	7	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		D017964	D017964
Itraconazole	itraconazole	7	6	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		D017964	D017964
Itraconazole	itraconazole	7	7	false	none	If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		D017964	D017964
Itraconazole	simvastatin	6	4	false	none	Hence when simvastatin is used with an inhibitor of CYP3A4 (e.g., as listed below), elevated plasma levels of HMG-CoA reductase inhibitory activity can increase the risk of myopathy and rhabdomyolysis, particularly with higher doses of simvastatin.  [See Warnings and Precautions (5.1) and Clinical Pharmacology (12.3).]  Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  		28031	36567	D017964	36567
Itraconazole	simvastatin	6	4	false	none	Hence when simvastatin is used with an inhibitor of CYP3A4 (e.g., as listed below), elevated plasma levels of HMG-CoA reductase inhibitory activity can increase the risk of myopathy and rhabdomyolysis, particularly with higher doses of simvastatin.  [See Warnings and Precautions (5.1) and Clinical Pharmacology (12.3).]  Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  		28031	36567	D017964	36567
Itraconazole	simvastatin	6	7	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		28031	36567	D017964	36567
Itraconazole	simvastatin	6	7	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		28031	36567	D017964	36567
Itraconazole	simvastatin	7	7	false	none	If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		28031	36567	D017964	36567
Itraconazole	simvastatin	7	7	false	none	If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		28031	36567	D017964	36567
Itraconazole	gemfibrozil	6	8	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  		28031	4719	D017964	D015248
Itraconazole	gemfibrozil	6	8	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  		28031	4719	D017964	D015248
Itraconazole	gemfibrozil	7	8	false	none	If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  		28031	4719	D017964	D015248
Itraconazole	gemfibrozil	7	8	false	none	If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  		28031	4719	D017964	D015248
Itraconazole	clarithromycin	6	6	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  		28031	21212	D017964	21212
Itraconazole	clarithromycin	6	6	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  		28031	21212	D017964	21212
Itraconazole	clarithromycin	6	7	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		28031	21212	D017964	21212
Itraconazole	clarithromycin	6	7	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		28031	21212	D017964	21212
Itraconazole	clarithromycin	7	6	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		28031	21212	D017964	21212
Itraconazole	clarithromycin	7	6	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		28031	21212	D017964	21212
Itraconazole	clarithromycin	7	7	false	none	If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		28031	21212	D017964	21212
Itraconazole	clarithromycin	7	7	false	none	If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		28031	21212	D017964	21212
Itraconazole	telithromycin	6	6	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  		28031	274786	D017964	274786
Itraconazole	telithromycin	6	6	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  		28031	274786	D017964	274786
Itraconazole	telithromycin	6	7	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		28031	274786	D017964	274786
Itraconazole	telithromycin	6	7	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		28031	274786	D017964	274786
Itraconazole	telithromycin	7	6	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		28031	274786	D017964	274786
Itraconazole	telithromycin	7	6	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		28031	274786	D017964	274786
Itraconazole	telithromycin	7	7	false	none	If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		28031	274786	D017964	274786
Itraconazole	telithromycin	7	7	false	none	If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		28031	274786	D017964	274786
Itraconazole	fibrates	6	8	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  		28031	none	D017964	none
Itraconazole	fibrates	6	8	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  		28031	none	D017964	none
Itraconazole	fibrates	7	8	false	none	If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  		28031	none	D017964	none
Itraconazole	fibrates	7	8	false	none	If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  		28031	none	D017964	none
Itraconazole	nefazodone	6	6	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  		28031	31565	D017964	C051752
Itraconazole	nefazodone	6	6	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  		28031	31565	D017964	C051752
Itraconazole	nefazodone	7	6	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		28031	31565	D017964	C051752
Itraconazole	nefazodone	7	6	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		28031	31565	D017964	C051752
Itraconazole	erythromycin	6	6	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  		28031	4053	D017964	D004917
Itraconazole	erythromycin	6	6	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  		28031	4053	D017964	D004917
Itraconazole	erythromycin	6	7	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		28031	4053	D017964	D004917
Itraconazole	erythromycin	6	7	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		28031	4053	D017964	D004917
Itraconazole	erythromycin	7	6	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		28031	4053	D017964	D004917
Itraconazole	erythromycin	7	6	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		28031	4053	D017964	D004917
Itraconazole	erythromycin	7	7	false	none	If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		28031	4053	D017964	D004917
Itraconazole	erythromycin	7	7	false	none	If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		28031	4053	D017964	D004917
Simvastatin	niacin	7	8	false	none	If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  		36567	7393	36567	D009525
Simvastatin	niacin	7	8	false	none	If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  		36567	7393	36567	D009525
Simvastatin	niacin	10	8	false	none	7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  [see Warnings and Precautions (5.1)].  7.3 Cyclosporine or Danazol    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of cyclosporine or danazol particularly with higher doses of simvastatin [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].  		36567	7393	36567	D009525
Simvastatin	niacin	10	8	false	none	7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  [see Warnings and Precautions (5.1)].  7.3 Cyclosporine or Danazol    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of cyclosporine or danazol particularly with higher doses of simvastatin [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].  		36567	7393	36567	D009525
Simvastatin	Amiodarone	10	11	false	none	7.3 Cyclosporine or Danazol    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of cyclosporine or danazol particularly with higher doses of simvastatin [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].  7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  		36567	none	36567	none
Simvastatin	Amiodarone	10	11	false	none	7.3 Cyclosporine or Danazol    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of cyclosporine or danazol particularly with higher doses of simvastatin [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].  7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  		36567	none	36567	none
Simvastatin	Amiodarone	11	11	false	none	7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  		36567	none	36567	none
Simvastatin	Amiodarone	11	11	false	none	7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  		36567	none	36567	none
Simvastatin	Amiodarone	12	11	false	none	7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  7.5 Digoxin    In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma.  		36567	none	36567	none
Simvastatin	Amiodarone	12	11	false	none	7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  7.5 Digoxin    In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma.  		36567	none	36567	none
Simvastatin	Amiodarone	13	11	false	none	7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  7.5 Digoxin    In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma.  Patients taking digoxin should be monitored appropriately when simvastatin is initiated [see Clinical Pharmacology (12.3)].  		36567	none	36567	none
Simvastatin	Amiodarone	13	11	false	none	7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  7.5 Digoxin    In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma.  Patients taking digoxin should be monitored appropriately when simvastatin is initiated [see Clinical Pharmacology (12.3)].  		36567	none	36567	none
Simvastatin	Verapamil	10	11	false	none	7.3 Cyclosporine or Danazol    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of cyclosporine or danazol particularly with higher doses of simvastatin [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].  7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  		36567	none	36567	none
Simvastatin	Verapamil	10	11	false	none	7.3 Cyclosporine or Danazol    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of cyclosporine or danazol particularly with higher doses of simvastatin [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].  7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  		36567	none	36567	none
Simvastatin	Verapamil	11	11	false	none	7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  		36567	none	36567	none
Simvastatin	Verapamil	11	11	false	none	7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  		36567	none	36567	none
Simvastatin	Verapamil	12	11	false	none	7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  7.5 Digoxin    In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma.  		36567	none	36567	none
Simvastatin	Verapamil	12	11	false	none	7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  7.5 Digoxin    In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma.  		36567	none	36567	none
Simvastatin	Verapamil	13	11	false	none	7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  7.5 Digoxin    In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma.  Patients taking digoxin should be monitored appropriately when simvastatin is initiated [see Clinical Pharmacology (12.3)].  		36567	none	36567	none
Simvastatin	Verapamil	13	11	false	none	7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  7.5 Digoxin    In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma.  Patients taking digoxin should be monitored appropriately when simvastatin is initiated [see Clinical Pharmacology (12.3)].  		36567	none	36567	none
Simvastatin	nicotinic acid	7	8	false	none	If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  		36567	7393	36567	D009525
Simvastatin	nicotinic acid	7	8	false	none	If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  		36567	7393	36567	D009525
Simvastatin	nicotinic acid	10	8	false	none	7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  [see Warnings and Precautions (5.1)].  7.3 Cyclosporine or Danazol    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of cyclosporine or danazol particularly with higher doses of simvastatin [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].  		36567	7393	36567	D009525
Simvastatin	nicotinic acid	10	8	false	none	7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  [see Warnings and Precautions (5.1)].  7.3 Cyclosporine or Danazol    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of cyclosporine or danazol particularly with higher doses of simvastatin [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].  		36567	7393	36567	D009525
Simvastatin	prothrombin	12	14	false	none	7.5 Digoxin    In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma.  Patients taking digoxin should be monitored appropriately when simvastatin is initiated [see Clinical Pharmacology (12.3)].  7.6 Coumarin Anticoagulants    In two clinical studies, one in normal volunteers and the other in hypercholesterolemic patients, simvastatin 20-40 mg/day modestly potentiated the effect of coumarin anticoagulants: the prothrombin time, reported as International Normalized Ratio (INR), increased from a baseline of 1.7 to 1.8 and from 2.6 to 3.4 in the volunteer and patient studies, respectively.  		36567	none	36567	none
Simvastatin	prothrombin	12	14	false	none	7.5 Digoxin    In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma.  Patients taking digoxin should be monitored appropriately when simvastatin is initiated [see Clinical Pharmacology (12.3)].  7.6 Coumarin Anticoagulants    In two clinical studies, one in normal volunteers and the other in hypercholesterolemic patients, simvastatin 20-40 mg/day modestly potentiated the effect of coumarin anticoagulants: the prothrombin time, reported as International Normalized Ratio (INR), increased from a baseline of 1.7 to 1.8 and from 2.6 to 3.4 in the volunteer and patient studies, respectively.  		36567	none	36567	none
Simvastatin	prothrombin	13	14	false	none	Patients taking digoxin should be monitored appropriately when simvastatin is initiated [see Clinical Pharmacology (12.3)].  7.6 Coumarin Anticoagulants    In two clinical studies, one in normal volunteers and the other in hypercholesterolemic patients, simvastatin 20-40 mg/day modestly potentiated the effect of coumarin anticoagulants: the prothrombin time, reported as International Normalized Ratio (INR), increased from a baseline of 1.7 to 1.8 and from 2.6 to 3.4 in the volunteer and patient studies, respectively.  		36567	none	36567	none
Simvastatin	prothrombin	13	14	false	none	Patients taking digoxin should be monitored appropriately when simvastatin is initiated [see Clinical Pharmacology (12.3)].  7.6 Coumarin Anticoagulants    In two clinical studies, one in normal volunteers and the other in hypercholesterolemic patients, simvastatin 20-40 mg/day modestly potentiated the effect of coumarin anticoagulants: the prothrombin time, reported as International Normalized Ratio (INR), increased from a baseline of 1.7 to 1.8 and from 2.6 to 3.4 in the volunteer and patient studies, respectively.  		36567	none	36567	none
Simvastatin	prothrombin	13	15	false	none	Patients taking digoxin should be monitored appropriately when simvastatin is initiated [see Clinical Pharmacology (12.3)].  7.6 Coumarin Anticoagulants    In two clinical studies, one in normal volunteers and the other in hypercholesterolemic patients, simvastatin 20-40 mg/day modestly potentiated the effect of coumarin anticoagulants: the prothrombin time, reported as International Normalized Ratio (INR), increased from a baseline of 1.7 to 1.8 and from 2.6 to 3.4 in the volunteer and patient studies, respectively.  With other statins, clinically evident bleeding and/or increased prothrombin time has been reported in a few patients taking coumarin anticoagulants concomitantly.  		36567	none	36567	none
Simvastatin	prothrombin	13	15	false	none	Patients taking digoxin should be monitored appropriately when simvastatin is initiated [see Clinical Pharmacology (12.3)].  7.6 Coumarin Anticoagulants    In two clinical studies, one in normal volunteers and the other in hypercholesterolemic patients, simvastatin 20-40 mg/day modestly potentiated the effect of coumarin anticoagulants: the prothrombin time, reported as International Normalized Ratio (INR), increased from a baseline of 1.7 to 1.8 and from 2.6 to 3.4 in the volunteer and patient studies, respectively.  With other statins, clinically evident bleeding and/or increased prothrombin time has been reported in a few patients taking coumarin anticoagulants concomitantly.  		36567	none	36567	none
Simvastatin	prothrombin	14	16	false	none	7.6 Coumarin Anticoagulants    In two clinical studies, one in normal volunteers and the other in hypercholesterolemic patients, simvastatin 20-40 mg/day modestly potentiated the effect of coumarin anticoagulants: the prothrombin time, reported as International Normalized Ratio (INR), increased from a baseline of 1.7 to 1.8 and from 2.6 to 3.4 in the volunteer and patient studies, respectively.  With other statins, clinically evident bleeding and/or increased prothrombin time has been reported in a few patients taking coumarin anticoagulants concomitantly.  In such patients, prothrombin time should be determined before starting simvastatin and frequently enough during early therapy to ensure that no significant alteration of prothrombin time occurs.  		36567	none	36567	none
Simvastatin	prothrombin	14	16	false	none	7.6 Coumarin Anticoagulants    In two clinical studies, one in normal volunteers and the other in hypercholesterolemic patients, simvastatin 20-40 mg/day modestly potentiated the effect of coumarin anticoagulants: the prothrombin time, reported as International Normalized Ratio (INR), increased from a baseline of 1.7 to 1.8 and from 2.6 to 3.4 in the volunteer and patient studies, respectively.  With other statins, clinically evident bleeding and/or increased prothrombin time has been reported in a few patients taking coumarin anticoagulants concomitantly.  In such patients, prothrombin time should be determined before starting simvastatin and frequently enough during early therapy to ensure that no significant alteration of prothrombin time occurs.  		36567	none	36567	none
Simvastatin	prothrombin	14	14	false	none	7.6 Coumarin Anticoagulants    In two clinical studies, one in normal volunteers and the other in hypercholesterolemic patients, simvastatin 20-40 mg/day modestly potentiated the effect of coumarin anticoagulants: the prothrombin time, reported as International Normalized Ratio (INR), increased from a baseline of 1.7 to 1.8 and from 2.6 to 3.4 in the volunteer and patient studies, respectively.  		36567	none	36567	none
Simvastatin	prothrombin	14	14	false	none	7.6 Coumarin Anticoagulants    In two clinical studies, one in normal volunteers and the other in hypercholesterolemic patients, simvastatin 20-40 mg/day modestly potentiated the effect of coumarin anticoagulants: the prothrombin time, reported as International Normalized Ratio (INR), increased from a baseline of 1.7 to 1.8 and from 2.6 to 3.4 in the volunteer and patient studies, respectively.  		36567	none	36567	none
Simvastatin	prothrombin	14	15	false	none	7.6 Coumarin Anticoagulants    In two clinical studies, one in normal volunteers and the other in hypercholesterolemic patients, simvastatin 20-40 mg/day modestly potentiated the effect of coumarin anticoagulants: the prothrombin time, reported as International Normalized Ratio (INR), increased from a baseline of 1.7 to 1.8 and from 2.6 to 3.4 in the volunteer and patient studies, respectively.  With other statins, clinically evident bleeding and/or increased prothrombin time has been reported in a few patients taking coumarin anticoagulants concomitantly.  		36567	none	36567	none
Simvastatin	prothrombin	14	15	false	none	7.6 Coumarin Anticoagulants    In two clinical studies, one in normal volunteers and the other in hypercholesterolemic patients, simvastatin 20-40 mg/day modestly potentiated the effect of coumarin anticoagulants: the prothrombin time, reported as International Normalized Ratio (INR), increased from a baseline of 1.7 to 1.8 and from 2.6 to 3.4 in the volunteer and patient studies, respectively.  With other statins, clinically evident bleeding and/or increased prothrombin time has been reported in a few patients taking coumarin anticoagulants concomitantly.  		36567	none	36567	none
Simvastatin	prothrombin	16	17	false	none	In such patients, prothrombin time should be determined before starting simvastatin and frequently enough during early therapy to ensure that no significant alteration of prothrombin time occurs.  Once a stable prothrombin time has been documented, prothrombin times can be monitored at the intervals usually recommended for patients on coumarin anticoagulants.  		36567	none	36567	none
Simvastatin	prothrombin	16	17	false	none	In such patients, prothrombin time should be determined before starting simvastatin and frequently enough during early therapy to ensure that no significant alteration of prothrombin time occurs.  Once a stable prothrombin time has been documented, prothrombin times can be monitored at the intervals usually recommended for patients on coumarin anticoagulants.  		36567	none	36567	none
Simvastatin	prothrombin	16	16	false	none	In such patients, prothrombin time should be determined before starting simvastatin and frequently enough during early therapy to ensure that no significant alteration of prothrombin time occurs.  		36567	none	36567	none
Simvastatin	prothrombin	16	16	false	none	In such patients, prothrombin time should be determined before starting simvastatin and frequently enough during early therapy to ensure that no significant alteration of prothrombin time occurs.  		36567	none	36567	none
Simvastatin	prothrombin	16	14	false	none	7.6 Coumarin Anticoagulants    In two clinical studies, one in normal volunteers and the other in hypercholesterolemic patients, simvastatin 20-40 mg/day modestly potentiated the effect of coumarin anticoagulants: the prothrombin time, reported as International Normalized Ratio (INR), increased from a baseline of 1.7 to 1.8 and from 2.6 to 3.4 in the volunteer and patient studies, respectively.  With other statins, clinically evident bleeding and/or increased prothrombin time has been reported in a few patients taking coumarin anticoagulants concomitantly.  In such patients, prothrombin time should be determined before starting simvastatin and frequently enough during early therapy to ensure that no significant alteration of prothrombin time occurs.  		36567	none	36567	none
Simvastatin	prothrombin	16	14	false	none	7.6 Coumarin Anticoagulants    In two clinical studies, one in normal volunteers and the other in hypercholesterolemic patients, simvastatin 20-40 mg/day modestly potentiated the effect of coumarin anticoagulants: the prothrombin time, reported as International Normalized Ratio (INR), increased from a baseline of 1.7 to 1.8 and from 2.6 to 3.4 in the volunteer and patient studies, respectively.  With other statins, clinically evident bleeding and/or increased prothrombin time has been reported in a few patients taking coumarin anticoagulants concomitantly.  In such patients, prothrombin time should be determined before starting simvastatin and frequently enough during early therapy to ensure that no significant alteration of prothrombin time occurs.  		36567	none	36567	none
Simvastatin	prothrombin	16	15	false	none	With other statins, clinically evident bleeding and/or increased prothrombin time has been reported in a few patients taking coumarin anticoagulants concomitantly.  In such patients, prothrombin time should be determined before starting simvastatin and frequently enough during early therapy to ensure that no significant alteration of prothrombin time occurs.  		36567	none	36567	none
Simvastatin	prothrombin	16	15	false	none	With other statins, clinically evident bleeding and/or increased prothrombin time has been reported in a few patients taking coumarin anticoagulants concomitantly.  In such patients, prothrombin time should be determined before starting simvastatin and frequently enough during early therapy to ensure that no significant alteration of prothrombin time occurs.  		36567	none	36567	none
Simvastatin	prothrombin	19	17	false	none	Once a stable prothrombin time has been documented, prothrombin times can be monitored at the intervals usually recommended for patients on coumarin anticoagulants.  If the dose of simvastatin is changed or discontinued, the same procedure should be repeated.  Simvastatin therapy has not been associated with bleeding or with changes in prothrombin time in patients not taking anticoagulants.  		36567	none	36567	none
Simvastatin	prothrombin	19	17	false	none	Once a stable prothrombin time has been documented, prothrombin times can be monitored at the intervals usually recommended for patients on coumarin anticoagulants.  If the dose of simvastatin is changed or discontinued, the same procedure should be repeated.  Simvastatin therapy has not been associated with bleeding or with changes in prothrombin time in patients not taking anticoagulants.  		36567	none	36567	none
Simvastatin	prothrombin	19	19	true	positive	Simvastatin therapy has not been associated with bleeding or with changes in prothrombin time in patients not taking anticoagulants.  		36567	none	36567	none
Simvastatin	prothrombin	19	19	true	positive	Simvastatin therapy has not been associated with bleeding or with changes in prothrombin time in patients not taking anticoagulants.  		36567	none	36567	none
Simvastatin	prothrombin	18	17	false	none	Once a stable prothrombin time has been documented, prothrombin times can be monitored at the intervals usually recommended for patients on coumarin anticoagulants.  If the dose of simvastatin is changed or discontinued, the same procedure should be repeated.  		36567	none	36567	none
Simvastatin	prothrombin	18	17	false	none	Once a stable prothrombin time has been documented, prothrombin times can be monitored at the intervals usually recommended for patients on coumarin anticoagulants.  If the dose of simvastatin is changed or discontinued, the same procedure should be repeated.  		36567	none	36567	none
Simvastatin	prothrombin	18	16	false	none	In such patients, prothrombin time should be determined before starting simvastatin and frequently enough during early therapy to ensure that no significant alteration of prothrombin time occurs.  Once a stable prothrombin time has been documented, prothrombin times can be monitored at the intervals usually recommended for patients on coumarin anticoagulants.  If the dose of simvastatin is changed or discontinued, the same procedure should be repeated.  		36567	none	36567	none
Simvastatin	prothrombin	18	16	false	none	In such patients, prothrombin time should be determined before starting simvastatin and frequently enough during early therapy to ensure that no significant alteration of prothrombin time occurs.  Once a stable prothrombin time has been documented, prothrombin times can be monitored at the intervals usually recommended for patients on coumarin anticoagulants.  If the dose of simvastatin is changed or discontinued, the same procedure should be repeated.  		36567	none	36567	none
Simvastatin	prothrombin	18	19	false	none	If the dose of simvastatin is changed or discontinued, the same procedure should be repeated.  Simvastatin therapy has not been associated with bleeding or with changes in prothrombin time in patients not taking anticoagulants.  		36567	none	36567	none
Simvastatin	prothrombin	18	19	false	none	If the dose of simvastatin is changed or discontinued, the same procedure should be repeated.  Simvastatin therapy has not been associated with bleeding or with changes in prothrombin time in patients not taking anticoagulants.  		36567	none	36567	none
Simvastatin	coumarin	12	14	false	none	7.5 Digoxin    In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma.  Patients taking digoxin should be monitored appropriately when simvastatin is initiated [see Clinical Pharmacology (12.3)].  7.6 Coumarin Anticoagulants    In two clinical studies, one in normal volunteers and the other in hypercholesterolemic patients, simvastatin 20-40 mg/day modestly potentiated the effect of coumarin anticoagulants: the prothrombin time, reported as International Normalized Ratio (INR), increased from a baseline of 1.7 to 1.8 and from 2.6 to 3.4 in the volunteer and patient studies, respectively.  		36567	none	36567	none
Simvastatin	coumarin	12	14	false	none	7.5 Digoxin    In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma.  Patients taking digoxin should be monitored appropriately when simvastatin is initiated [see Clinical Pharmacology (12.3)].  7.6 Coumarin Anticoagulants    In two clinical studies, one in normal volunteers and the other in hypercholesterolemic patients, simvastatin 20-40 mg/day modestly potentiated the effect of coumarin anticoagulants: the prothrombin time, reported as International Normalized Ratio (INR), increased from a baseline of 1.7 to 1.8 and from 2.6 to 3.4 in the volunteer and patient studies, respectively.  		36567	none	36567	none
Simvastatin	coumarin	13	14	false	none	Patients taking digoxin should be monitored appropriately when simvastatin is initiated [see Clinical Pharmacology (12.3)].  7.6 Coumarin Anticoagulants    In two clinical studies, one in normal volunteers and the other in hypercholesterolemic patients, simvastatin 20-40 mg/day modestly potentiated the effect of coumarin anticoagulants: the prothrombin time, reported as International Normalized Ratio (INR), increased from a baseline of 1.7 to 1.8 and from 2.6 to 3.4 in the volunteer and patient studies, respectively.  		36567	none	36567	none
Simvastatin	coumarin	13	14	false	none	Patients taking digoxin should be monitored appropriately when simvastatin is initiated [see Clinical Pharmacology (12.3)].  7.6 Coumarin Anticoagulants    In two clinical studies, one in normal volunteers and the other in hypercholesterolemic patients, simvastatin 20-40 mg/day modestly potentiated the effect of coumarin anticoagulants: the prothrombin time, reported as International Normalized Ratio (INR), increased from a baseline of 1.7 to 1.8 and from 2.6 to 3.4 in the volunteer and patient studies, respectively.  		36567	none	36567	none
Simvastatin	coumarin	13	15	false	none	Patients taking digoxin should be monitored appropriately when simvastatin is initiated [see Clinical Pharmacology (12.3)].  7.6 Coumarin Anticoagulants    In two clinical studies, one in normal volunteers and the other in hypercholesterolemic patients, simvastatin 20-40 mg/day modestly potentiated the effect of coumarin anticoagulants: the prothrombin time, reported as International Normalized Ratio (INR), increased from a baseline of 1.7 to 1.8 and from 2.6 to 3.4 in the volunteer and patient studies, respectively.  With other statins, clinically evident bleeding and/or increased prothrombin time has been reported in a few patients taking coumarin anticoagulants concomitantly.  		36567	none	36567	none
Simvastatin	coumarin	13	15	false	none	Patients taking digoxin should be monitored appropriately when simvastatin is initiated [see Clinical Pharmacology (12.3)].  7.6 Coumarin Anticoagulants    In two clinical studies, one in normal volunteers and the other in hypercholesterolemic patients, simvastatin 20-40 mg/day modestly potentiated the effect of coumarin anticoagulants: the prothrombin time, reported as International Normalized Ratio (INR), increased from a baseline of 1.7 to 1.8 and from 2.6 to 3.4 in the volunteer and patient studies, respectively.  With other statins, clinically evident bleeding and/or increased prothrombin time has been reported in a few patients taking coumarin anticoagulants concomitantly.  		36567	none	36567	none
Simvastatin	coumarin	14	14	false	none	7.6 Coumarin Anticoagulants    In two clinical studies, one in normal volunteers and the other in hypercholesterolemic patients, simvastatin 20-40 mg/day modestly potentiated the effect of coumarin anticoagulants: the prothrombin time, reported as International Normalized Ratio (INR), increased from a baseline of 1.7 to 1.8 and from 2.6 to 3.4 in the volunteer and patient studies, respectively.  		36567	none	36567	none
Simvastatin	coumarin	14	14	false	none	7.6 Coumarin Anticoagulants    In two clinical studies, one in normal volunteers and the other in hypercholesterolemic patients, simvastatin 20-40 mg/day modestly potentiated the effect of coumarin anticoagulants: the prothrombin time, reported as International Normalized Ratio (INR), increased from a baseline of 1.7 to 1.8 and from 2.6 to 3.4 in the volunteer and patient studies, respectively.  		36567	none	36567	none
Simvastatin	coumarin	14	15	false	none	7.6 Coumarin Anticoagulants    In two clinical studies, one in normal volunteers and the other in hypercholesterolemic patients, simvastatin 20-40 mg/day modestly potentiated the effect of coumarin anticoagulants: the prothrombin time, reported as International Normalized Ratio (INR), increased from a baseline of 1.7 to 1.8 and from 2.6 to 3.4 in the volunteer and patient studies, respectively.  With other statins, clinically evident bleeding and/or increased prothrombin time has been reported in a few patients taking coumarin anticoagulants concomitantly.  		36567	none	36567	none
Simvastatin	coumarin	14	15	false	none	7.6 Coumarin Anticoagulants    In two clinical studies, one in normal volunteers and the other in hypercholesterolemic patients, simvastatin 20-40 mg/day modestly potentiated the effect of coumarin anticoagulants: the prothrombin time, reported as International Normalized Ratio (INR), increased from a baseline of 1.7 to 1.8 and from 2.6 to 3.4 in the volunteer and patient studies, respectively.  With other statins, clinically evident bleeding and/or increased prothrombin time has been reported in a few patients taking coumarin anticoagulants concomitantly.  		36567	none	36567	none
Simvastatin	coumarin	16	17	false	none	In such patients, prothrombin time should be determined before starting simvastatin and frequently enough during early therapy to ensure that no significant alteration of prothrombin time occurs.  Once a stable prothrombin time has been documented, prothrombin times can be monitored at the intervals usually recommended for patients on coumarin anticoagulants.  		36567	none	36567	none
Simvastatin	coumarin	16	17	false	none	In such patients, prothrombin time should be determined before starting simvastatin and frequently enough during early therapy to ensure that no significant alteration of prothrombin time occurs.  Once a stable prothrombin time has been documented, prothrombin times can be monitored at the intervals usually recommended for patients on coumarin anticoagulants.  		36567	none	36567	none
Simvastatin	coumarin	16	14	false	none	7.6 Coumarin Anticoagulants    In two clinical studies, one in normal volunteers and the other in hypercholesterolemic patients, simvastatin 20-40 mg/day modestly potentiated the effect of coumarin anticoagulants: the prothrombin time, reported as International Normalized Ratio (INR), increased from a baseline of 1.7 to 1.8 and from 2.6 to 3.4 in the volunteer and patient studies, respectively.  With other statins, clinically evident bleeding and/or increased prothrombin time has been reported in a few patients taking coumarin anticoagulants concomitantly.  In such patients, prothrombin time should be determined before starting simvastatin and frequently enough during early therapy to ensure that no significant alteration of prothrombin time occurs.  		36567	none	36567	none
Simvastatin	coumarin	16	14	false	none	7.6 Coumarin Anticoagulants    In two clinical studies, one in normal volunteers and the other in hypercholesterolemic patients, simvastatin 20-40 mg/day modestly potentiated the effect of coumarin anticoagulants: the prothrombin time, reported as International Normalized Ratio (INR), increased from a baseline of 1.7 to 1.8 and from 2.6 to 3.4 in the volunteer and patient studies, respectively.  With other statins, clinically evident bleeding and/or increased prothrombin time has been reported in a few patients taking coumarin anticoagulants concomitantly.  In such patients, prothrombin time should be determined before starting simvastatin and frequently enough during early therapy to ensure that no significant alteration of prothrombin time occurs.  		36567	none	36567	none
Simvastatin	coumarin	16	15	false	none	With other statins, clinically evident bleeding and/or increased prothrombin time has been reported in a few patients taking coumarin anticoagulants concomitantly.  In such patients, prothrombin time should be determined before starting simvastatin and frequently enough during early therapy to ensure that no significant alteration of prothrombin time occurs.  		36567	none	36567	none
Simvastatin	coumarin	16	15	false	none	With other statins, clinically evident bleeding and/or increased prothrombin time has been reported in a few patients taking coumarin anticoagulants concomitantly.  In such patients, prothrombin time should be determined before starting simvastatin and frequently enough during early therapy to ensure that no significant alteration of prothrombin time occurs.  		36567	none	36567	none
Simvastatin	coumarin	19	17	false	none	Once a stable prothrombin time has been documented, prothrombin times can be monitored at the intervals usually recommended for patients on coumarin anticoagulants.  If the dose of simvastatin is changed or discontinued, the same procedure should be repeated.  Simvastatin therapy has not been associated with bleeding or with changes in prothrombin time in patients not taking anticoagulants.  		36567	none	36567	none
Simvastatin	coumarin	19	17	false	none	Once a stable prothrombin time has been documented, prothrombin times can be monitored at the intervals usually recommended for patients on coumarin anticoagulants.  If the dose of simvastatin is changed or discontinued, the same procedure should be repeated.  Simvastatin therapy has not been associated with bleeding or with changes in prothrombin time in patients not taking anticoagulants.  		36567	none	36567	none
Simvastatin	coumarin	18	17	false	none	Once a stable prothrombin time has been documented, prothrombin times can be monitored at the intervals usually recommended for patients on coumarin anticoagulants.  If the dose of simvastatin is changed or discontinued, the same procedure should be repeated.  		36567	none	36567	none
Simvastatin	coumarin	18	17	false	none	Once a stable prothrombin time has been documented, prothrombin times can be monitored at the intervals usually recommended for patients on coumarin anticoagulants.  If the dose of simvastatin is changed or discontinued, the same procedure should be repeated.  		36567	none	36567	none
Simvastatin	grapefruit	4	6	false	none	Hence when simvastatin is used with an inhibitor of CYP3A4 (e.g., as listed below), elevated plasma levels of HMG-CoA reductase inhibitory activity can increase the risk of myopathy and rhabdomyolysis, particularly with higher doses of simvastatin.  [See Warnings and Precautions (5.1) and Clinical Pharmacology (12.3).]  Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  		36567	none	36567	none
Simvastatin	grapefruit	4	6	false	none	Hence when simvastatin is used with an inhibitor of CYP3A4 (e.g., as listed below), elevated plasma levels of HMG-CoA reductase inhibitory activity can increase the risk of myopathy and rhabdomyolysis, particularly with higher doses of simvastatin.  [See Warnings and Precautions (5.1) and Clinical Pharmacology (12.3).]  Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  		36567	none	36567	none
Simvastatin	grapefruit	7	6	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		36567	none	36567	none
Simvastatin	grapefruit	7	6	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		36567	none	36567	none
Simvastatin	Danazol	10	10	false	none	7.3 Cyclosporine or Danazol    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of cyclosporine or danazol particularly with higher doses of simvastatin [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].  		36567	none	36567	none
Simvastatin	Danazol	10	10	false	none	7.3 Cyclosporine or Danazol    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of cyclosporine or danazol particularly with higher doses of simvastatin [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].  		36567	none	36567	none
Simvastatin	Danazol	11	10	false	none	7.3 Cyclosporine or Danazol    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of cyclosporine or danazol particularly with higher doses of simvastatin [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].  7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  		36567	none	36567	none
Simvastatin	Danazol	11	10	false	none	7.3 Cyclosporine or Danazol    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of cyclosporine or danazol particularly with higher doses of simvastatin [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].  7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  		36567	none	36567	none
Simvastatin	Danazol	12	10	false	none	7.3 Cyclosporine or Danazol    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of cyclosporine or danazol particularly with higher doses of simvastatin [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].  7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  7.5 Digoxin    In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma.  		36567	none	36567	none
Simvastatin	Danazol	12	10	false	none	7.3 Cyclosporine or Danazol    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of cyclosporine or danazol particularly with higher doses of simvastatin [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].  7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  7.5 Digoxin    In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma.  		36567	none	36567	none
Simvastatin	digoxin	10	12	false	none	7.3 Cyclosporine or Danazol    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of cyclosporine or danazol particularly with higher doses of simvastatin [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].  7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  7.5 Digoxin    In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma.  		36567	none	36567	none
Simvastatin	digoxin	10	12	false	none	7.3 Cyclosporine or Danazol    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of cyclosporine or danazol particularly with higher doses of simvastatin [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].  7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  7.5 Digoxin    In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma.  		36567	none	36567	none
Simvastatin	digoxin	11	12	false	none	7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  7.5 Digoxin    In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma.  		36567	none	36567	none
Simvastatin	digoxin	11	12	false	none	7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  7.5 Digoxin    In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma.  		36567	none	36567	none
Simvastatin	digoxin	11	13	false	none	7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  7.5 Digoxin    In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma.  Patients taking digoxin should be monitored appropriately when simvastatin is initiated [see Clinical Pharmacology (12.3)].  		36567	none	36567	none
Simvastatin	digoxin	11	13	false	none	7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  7.5 Digoxin    In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma.  Patients taking digoxin should be monitored appropriately when simvastatin is initiated [see Clinical Pharmacology (12.3)].  		36567	none	36567	none
Simvastatin	digoxin	12	12	false	none	7.5 Digoxin    In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma.  		36567	none	36567	none
Simvastatin	digoxin	12	12	false	none	7.5 Digoxin    In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma.  		36567	none	36567	none
Simvastatin	digoxin	12	13	false	none	7.5 Digoxin    In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma.  Patients taking digoxin should be monitored appropriately when simvastatin is initiated [see Clinical Pharmacology (12.3)].  		36567	none	36567	none
Simvastatin	digoxin	12	13	false	none	7.5 Digoxin    In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma.  Patients taking digoxin should be monitored appropriately when simvastatin is initiated [see Clinical Pharmacology (12.3)].  		36567	none	36567	none
Simvastatin	digoxin	13	12	false	none	7.5 Digoxin    In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma.  Patients taking digoxin should be monitored appropriately when simvastatin is initiated [see Clinical Pharmacology (12.3)].  		36567	none	36567	none
Simvastatin	digoxin	13	12	false	none	7.5 Digoxin    In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma.  Patients taking digoxin should be monitored appropriately when simvastatin is initiated [see Clinical Pharmacology (12.3)].  		36567	none	36567	none
Simvastatin	digoxin	13	13	false	none	Patients taking digoxin should be monitored appropriately when simvastatin is initiated [see Clinical Pharmacology (12.3)].  		36567	none	36567	none
Simvastatin	digoxin	13	13	false	none	Patients taking digoxin should be monitored appropriately when simvastatin is initiated [see Clinical Pharmacology (12.3)].  		36567	none	36567	none
Simvastatin	digoxin	14	12	false	none	7.5 Digoxin    In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma.  Patients taking digoxin should be monitored appropriately when simvastatin is initiated [see Clinical Pharmacology (12.3)].  7.6 Coumarin Anticoagulants    In two clinical studies, one in normal volunteers and the other in hypercholesterolemic patients, simvastatin 20-40 mg/day modestly potentiated the effect of coumarin anticoagulants: the prothrombin time, reported as International Normalized Ratio (INR), increased from a baseline of 1.7 to 1.8 and from 2.6 to 3.4 in the volunteer and patient studies, respectively.  		36567	none	36567	none
Simvastatin	digoxin	14	12	false	none	7.5 Digoxin    In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma.  Patients taking digoxin should be monitored appropriately when simvastatin is initiated [see Clinical Pharmacology (12.3)].  7.6 Coumarin Anticoagulants    In two clinical studies, one in normal volunteers and the other in hypercholesterolemic patients, simvastatin 20-40 mg/day modestly potentiated the effect of coumarin anticoagulants: the prothrombin time, reported as International Normalized Ratio (INR), increased from a baseline of 1.7 to 1.8 and from 2.6 to 3.4 in the volunteer and patient studies, respectively.  		36567	none	36567	none
Simvastatin	digoxin	14	13	false	none	Patients taking digoxin should be monitored appropriately when simvastatin is initiated [see Clinical Pharmacology (12.3)].  7.6 Coumarin Anticoagulants    In two clinical studies, one in normal volunteers and the other in hypercholesterolemic patients, simvastatin 20-40 mg/day modestly potentiated the effect of coumarin anticoagulants: the prothrombin time, reported as International Normalized Ratio (INR), increased from a baseline of 1.7 to 1.8 and from 2.6 to 3.4 in the volunteer and patient studies, respectively.  		36567	none	36567	none
Simvastatin	digoxin	14	13	false	none	Patients taking digoxin should be monitored appropriately when simvastatin is initiated [see Clinical Pharmacology (12.3)].  7.6 Coumarin Anticoagulants    In two clinical studies, one in normal volunteers and the other in hypercholesterolemic patients, simvastatin 20-40 mg/day modestly potentiated the effect of coumarin anticoagulants: the prothrombin time, reported as International Normalized Ratio (INR), increased from a baseline of 1.7 to 1.8 and from 2.6 to 3.4 in the volunteer and patient studies, respectively.  		36567	none	36567	none
Simvastatin	ketoconazole	4	6	false	none	Hence when simvastatin is used with an inhibitor of CYP3A4 (e.g., as listed below), elevated plasma levels of HMG-CoA reductase inhibitory activity can increase the risk of myopathy and rhabdomyolysis, particularly with higher doses of simvastatin.  [See Warnings and Precautions (5.1) and Clinical Pharmacology (12.3).]  Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  		36567	6135	36567	D007654
Simvastatin	ketoconazole	4	6	false	none	Hence when simvastatin is used with an inhibitor of CYP3A4 (e.g., as listed below), elevated plasma levels of HMG-CoA reductase inhibitory activity can increase the risk of myopathy and rhabdomyolysis, particularly with higher doses of simvastatin.  [See Warnings and Precautions (5.1) and Clinical Pharmacology (12.3).]  Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  		36567	6135	36567	D007654
Simvastatin	ketoconazole	7	6	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		36567	6135	36567	D007654
Simvastatin	ketoconazole	7	6	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		36567	6135	36567	D007654
Simvastatin	ketoconazole	7	7	false	none	If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		36567	6135	36567	D007654
Simvastatin	ketoconazole	7	7	false	none	If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		36567	6135	36567	D007654
Simvastatin	itraconazole	4	6	false	none	Hence when simvastatin is used with an inhibitor of CYP3A4 (e.g., as listed below), elevated plasma levels of HMG-CoA reductase inhibitory activity can increase the risk of myopathy and rhabdomyolysis, particularly with higher doses of simvastatin.  [See Warnings and Precautions (5.1) and Clinical Pharmacology (12.3).]  Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  		36567	28031	36567	D017964
Simvastatin	itraconazole	4	6	false	none	Hence when simvastatin is used with an inhibitor of CYP3A4 (e.g., as listed below), elevated plasma levels of HMG-CoA reductase inhibitory activity can increase the risk of myopathy and rhabdomyolysis, particularly with higher doses of simvastatin.  [See Warnings and Precautions (5.1) and Clinical Pharmacology (12.3).]  Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  		36567	28031	36567	D017964
Simvastatin	itraconazole	7	6	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		36567	28031	36567	D017964
Simvastatin	itraconazole	7	6	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		36567	28031	36567	D017964
Simvastatin	itraconazole	7	7	false	none	If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		36567	28031	36567	D017964
Simvastatin	itraconazole	7	7	false	none	If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		36567	28031	36567	D017964
Simvastatin	simvastatin	1	1	false	none	7 DRUG INTERACTIONS    7.1 CYP3A4 Interactions    Simvastatin, like several other inhibitors of HMG-CoA reductase, is a substrate of CYP3A4.  		36567	36567
Simvastatin	simvastatin	1	2	false	none	7 DRUG INTERACTIONS    7.1 CYP3A4 Interactions    Simvastatin, like several other inhibitors of HMG-CoA reductase, is a substrate of CYP3A4.  Simvastatin is metabolized by CYP3A4 but has no CYP3A4 inhibitory activity; therefore it is not expected to affect the plasma concentrations of other drugs metabolized by CYP3A4.  		36567	36567
Simvastatin	simvastatin	1	3	false	none	7 DRUG INTERACTIONS    7.1 CYP3A4 Interactions    Simvastatin, like several other inhibitors of HMG-CoA reductase, is a substrate of CYP3A4.  Simvastatin is metabolized by CYP3A4 but has no CYP3A4 inhibitory activity; therefore it is not expected to affect the plasma concentrations of other drugs metabolized by CYP3A4.  The risk of myopathy is increased by reducing the elimination of simvastatin.  		36567	36567
Simvastatin	simvastatin	2	1	false	none	7 DRUG INTERACTIONS    7.1 CYP3A4 Interactions    Simvastatin, like several other inhibitors of HMG-CoA reductase, is a substrate of CYP3A4.  Simvastatin is metabolized by CYP3A4 but has no CYP3A4 inhibitory activity; therefore it is not expected to affect the plasma concentrations of other drugs metabolized by CYP3A4.  		36567	36567
Simvastatin	simvastatin	2	2	false	none	Simvastatin is metabolized by CYP3A4 but has no CYP3A4 inhibitory activity; therefore it is not expected to affect the plasma concentrations of other drugs metabolized by CYP3A4.  		36567	36567
Simvastatin	simvastatin	2	3	false	none	Simvastatin is metabolized by CYP3A4 but has no CYP3A4 inhibitory activity; therefore it is not expected to affect the plasma concentrations of other drugs metabolized by CYP3A4.  The risk of myopathy is increased by reducing the elimination of simvastatin.  		36567	36567
Simvastatin	simvastatin	2	4	false	none	Simvastatin is metabolized by CYP3A4 but has no CYP3A4 inhibitory activity; therefore it is not expected to affect the plasma concentrations of other drugs metabolized by CYP3A4.  The risk of myopathy is increased by reducing the elimination of simvastatin.  Hence when simvastatin is used with an inhibitor of CYP3A4 (e.g., as listed below), elevated plasma levels of HMG-CoA reductase inhibitory activity can increase the risk of myopathy and rhabdomyolysis, particularly with higher doses of simvastatin.  		36567	36567
Simvastatin	simvastatin	3	1	false	none	7 DRUG INTERACTIONS    7.1 CYP3A4 Interactions    Simvastatin, like several other inhibitors of HMG-CoA reductase, is a substrate of CYP3A4.  Simvastatin is metabolized by CYP3A4 but has no CYP3A4 inhibitory activity; therefore it is not expected to affect the plasma concentrations of other drugs metabolized by CYP3A4.  The risk of myopathy is increased by reducing the elimination of simvastatin.  		36567	36567
Simvastatin	simvastatin	3	2	false	none	Simvastatin is metabolized by CYP3A4 but has no CYP3A4 inhibitory activity; therefore it is not expected to affect the plasma concentrations of other drugs metabolized by CYP3A4.  The risk of myopathy is increased by reducing the elimination of simvastatin.  		36567	36567
Simvastatin	simvastatin	3	3	false	none	The risk of myopathy is increased by reducing the elimination of simvastatin.  		36567	36567
Simvastatin	simvastatin	3	4	false	none	The risk of myopathy is increased by reducing the elimination of simvastatin.  Hence when simvastatin is used with an inhibitor of CYP3A4 (e.g., as listed below), elevated plasma levels of HMG-CoA reductase inhibitory activity can increase the risk of myopathy and rhabdomyolysis, particularly with higher doses of simvastatin.  		36567	36567
Simvastatin	simvastatin	4	2	false	none	Simvastatin is metabolized by CYP3A4 but has no CYP3A4 inhibitory activity; therefore it is not expected to affect the plasma concentrations of other drugs metabolized by CYP3A4.  The risk of myopathy is increased by reducing the elimination of simvastatin.  Hence when simvastatin is used with an inhibitor of CYP3A4 (e.g., as listed below), elevated plasma levels of HMG-CoA reductase inhibitory activity can increase the risk of myopathy and rhabdomyolysis, particularly with higher doses of simvastatin.  		36567	36567
Simvastatin	simvastatin	4	3	false	none	The risk of myopathy is increased by reducing the elimination of simvastatin.  Hence when simvastatin is used with an inhibitor of CYP3A4 (e.g., as listed below), elevated plasma levels of HMG-CoA reductase inhibitory activity can increase the risk of myopathy and rhabdomyolysis, particularly with higher doses of simvastatin.  		36567	36567
Simvastatin	simvastatin	4	4	false	none	Hence when simvastatin is used with an inhibitor of CYP3A4 (e.g., as listed below), elevated plasma levels of HMG-CoA reductase inhibitory activity can increase the risk of myopathy and rhabdomyolysis, particularly with higher doses of simvastatin.  		36567	36567
Simvastatin	simvastatin	7	7	false	none	If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		36567	36567
Simvastatin	simvastatin	10	10	false	none	7.3 Cyclosporine or Danazol    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of cyclosporine or danazol particularly with higher doses of simvastatin [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].  		36567	36567
Simvastatin	simvastatin	10	11	false	none	7.3 Cyclosporine or Danazol    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of cyclosporine or danazol particularly with higher doses of simvastatin [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].  7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  		36567	36567
Simvastatin	simvastatin	10	12	false	none	7.3 Cyclosporine or Danazol    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of cyclosporine or danazol particularly with higher doses of simvastatin [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].  7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  7.5 Digoxin    In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma.  		36567	36567
Simvastatin	simvastatin	11	10	false	none	7.3 Cyclosporine or Danazol    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of cyclosporine or danazol particularly with higher doses of simvastatin [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].  7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  		36567	36567
Simvastatin	simvastatin	11	11	false	none	7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  		36567	36567
Simvastatin	simvastatin	11	12	false	none	7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  7.5 Digoxin    In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma.  		36567	36567
Simvastatin	simvastatin	11	13	false	none	7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  7.5 Digoxin    In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma.  Patients taking digoxin should be monitored appropriately when simvastatin is initiated [see Clinical Pharmacology (12.3)].  		36567	36567
Simvastatin	simvastatin	12	10	false	none	7.3 Cyclosporine or Danazol    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of cyclosporine or danazol particularly with higher doses of simvastatin [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].  7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  7.5 Digoxin    In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma.  		36567	36567
Simvastatin	simvastatin	12	11	false	none	7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  7.5 Digoxin    In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma.  		36567	36567
Simvastatin	simvastatin	12	12	false	none	7.5 Digoxin    In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma.  		36567	36567
Simvastatin	simvastatin	12	13	false	none	7.5 Digoxin    In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma.  Patients taking digoxin should be monitored appropriately when simvastatin is initiated [see Clinical Pharmacology (12.3)].  		36567	36567
Simvastatin	simvastatin	12	14	false	none	7.5 Digoxin    In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma.  Patients taking digoxin should be monitored appropriately when simvastatin is initiated [see Clinical Pharmacology (12.3)].  7.6 Coumarin Anticoagulants    In two clinical studies, one in normal volunteers and the other in hypercholesterolemic patients, simvastatin 20-40 mg/day modestly potentiated the effect of coumarin anticoagulants: the prothrombin time, reported as International Normalized Ratio (INR), increased from a baseline of 1.7 to 1.8 and from 2.6 to 3.4 in the volunteer and patient studies, respectively.  		36567	36567
Simvastatin	simvastatin	13	11	false	none	7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  7.5 Digoxin    In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma.  Patients taking digoxin should be monitored appropriately when simvastatin is initiated [see Clinical Pharmacology (12.3)].  		36567	36567
Simvastatin	simvastatin	13	12	false	none	7.5 Digoxin    In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma.  Patients taking digoxin should be monitored appropriately when simvastatin is initiated [see Clinical Pharmacology (12.3)].  		36567	36567
Simvastatin	simvastatin	13	13	false	none	Patients taking digoxin should be monitored appropriately when simvastatin is initiated [see Clinical Pharmacology (12.3)].  		36567	36567
Simvastatin	simvastatin	13	14	false	none	Patients taking digoxin should be monitored appropriately when simvastatin is initiated [see Clinical Pharmacology (12.3)].  7.6 Coumarin Anticoagulants    In two clinical studies, one in normal volunteers and the other in hypercholesterolemic patients, simvastatin 20-40 mg/day modestly potentiated the effect of coumarin anticoagulants: the prothrombin time, reported as International Normalized Ratio (INR), increased from a baseline of 1.7 to 1.8 and from 2.6 to 3.4 in the volunteer and patient studies, respectively.  		36567	36567
Simvastatin	simvastatin	14	12	false	none	7.5 Digoxin    In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma.  Patients taking digoxin should be monitored appropriately when simvastatin is initiated [see Clinical Pharmacology (12.3)].  7.6 Coumarin Anticoagulants    In two clinical studies, one in normal volunteers and the other in hypercholesterolemic patients, simvastatin 20-40 mg/day modestly potentiated the effect of coumarin anticoagulants: the prothrombin time, reported as International Normalized Ratio (INR), increased from a baseline of 1.7 to 1.8 and from 2.6 to 3.4 in the volunteer and patient studies, respectively.  		36567	36567
Simvastatin	simvastatin	14	13	false	none	Patients taking digoxin should be monitored appropriately when simvastatin is initiated [see Clinical Pharmacology (12.3)].  7.6 Coumarin Anticoagulants    In two clinical studies, one in normal volunteers and the other in hypercholesterolemic patients, simvastatin 20-40 mg/day modestly potentiated the effect of coumarin anticoagulants: the prothrombin time, reported as International Normalized Ratio (INR), increased from a baseline of 1.7 to 1.8 and from 2.6 to 3.4 in the volunteer and patient studies, respectively.  		36567	36567
Simvastatin	simvastatin	14	14	false	none	7.6 Coumarin Anticoagulants    In two clinical studies, one in normal volunteers and the other in hypercholesterolemic patients, simvastatin 20-40 mg/day modestly potentiated the effect of coumarin anticoagulants: the prothrombin time, reported as International Normalized Ratio (INR), increased from a baseline of 1.7 to 1.8 and from 2.6 to 3.4 in the volunteer and patient studies, respectively.  		36567	36567
Simvastatin	simvastatin	14	16	false	none	7.6 Coumarin Anticoagulants    In two clinical studies, one in normal volunteers and the other in hypercholesterolemic patients, simvastatin 20-40 mg/day modestly potentiated the effect of coumarin anticoagulants: the prothrombin time, reported as International Normalized Ratio (INR), increased from a baseline of 1.7 to 1.8 and from 2.6 to 3.4 in the volunteer and patient studies, respectively.  With other statins, clinically evident bleeding and/or increased prothrombin time has been reported in a few patients taking coumarin anticoagulants concomitantly.  In such patients, prothrombin time should be determined before starting simvastatin and frequently enough during early therapy to ensure that no significant alteration of prothrombin time occurs.  		36567	36567
Simvastatin	simvastatin	16	14	false	none	7.6 Coumarin Anticoagulants    In two clinical studies, one in normal volunteers and the other in hypercholesterolemic patients, simvastatin 20-40 mg/day modestly potentiated the effect of coumarin anticoagulants: the prothrombin time, reported as International Normalized Ratio (INR), increased from a baseline of 1.7 to 1.8 and from 2.6 to 3.4 in the volunteer and patient studies, respectively.  With other statins, clinically evident bleeding and/or increased prothrombin time has been reported in a few patients taking coumarin anticoagulants concomitantly.  In such patients, prothrombin time should be determined before starting simvastatin and frequently enough during early therapy to ensure that no significant alteration of prothrombin time occurs.  		36567	36567
Simvastatin	simvastatin	16	16	false	none	In such patients, prothrombin time should be determined before starting simvastatin and frequently enough during early therapy to ensure that no significant alteration of prothrombin time occurs.  		36567	36567
Simvastatin	simvastatin	16	18	false	none	In such patients, prothrombin time should be determined before starting simvastatin and frequently enough during early therapy to ensure that no significant alteration of prothrombin time occurs.  Once a stable prothrombin time has been documented, prothrombin times can be monitored at the intervals usually recommended for patients on coumarin anticoagulants.  If the dose of simvastatin is changed or discontinued, the same procedure should be repeated.  		36567	36567
Simvastatin	simvastatin	19	19	true	positive	Simvastatin therapy has not been associated with bleeding or with changes in prothrombin time in patients not taking anticoagulants.  		36567	36567
Simvastatin	simvastatin	19	18	false	none	If the dose of simvastatin is changed or discontinued, the same procedure should be repeated.  Simvastatin therapy has not been associated with bleeding or with changes in prothrombin time in patients not taking anticoagulants.  		36567	36567
Simvastatin	simvastatin	18	16	false	none	In such patients, prothrombin time should be determined before starting simvastatin and frequently enough during early therapy to ensure that no significant alteration of prothrombin time occurs.  Once a stable prothrombin time has been documented, prothrombin times can be monitored at the intervals usually recommended for patients on coumarin anticoagulants.  If the dose of simvastatin is changed or discontinued, the same procedure should be repeated.  		36567	36567
Simvastatin	simvastatin	18	19	false	none	If the dose of simvastatin is changed or discontinued, the same procedure should be repeated.  Simvastatin therapy has not been associated with bleeding or with changes in prothrombin time in patients not taking anticoagulants.  		36567	36567
Simvastatin	simvastatin	18	18	false	none	If the dose of simvastatin is changed or discontinued, the same procedure should be repeated.  		36567	36567
Simvastatin	gemfibrozil	7	8	false	none	If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  		36567	4719	36567	D015248
Simvastatin	gemfibrozil	7	8	false	none	If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  		36567	4719	36567	D015248
Simvastatin	gemfibrozil	10	8	false	none	7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  [see Warnings and Precautions (5.1)].  7.3 Cyclosporine or Danazol    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of cyclosporine or danazol particularly with higher doses of simvastatin [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].  		36567	4719	36567	D015248
Simvastatin	gemfibrozil	10	8	false	none	7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  [see Warnings and Precautions (5.1)].  7.3 Cyclosporine or Danazol    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of cyclosporine or danazol particularly with higher doses of simvastatin [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].  		36567	4719	36567	D015248
Simvastatin	verapamil	10	11	false	none	7.3 Cyclosporine or Danazol    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of cyclosporine or danazol particularly with higher doses of simvastatin [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].  7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  		36567	none	36567	none
Simvastatin	verapamil	10	11	false	none	7.3 Cyclosporine or Danazol    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of cyclosporine or danazol particularly with higher doses of simvastatin [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].  7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  		36567	none	36567	none
Simvastatin	verapamil	11	11	false	none	7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  		36567	none	36567	none
Simvastatin	verapamil	11	11	false	none	7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  		36567	none	36567	none
Simvastatin	verapamil	12	11	false	none	7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  7.5 Digoxin    In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma.  		36567	none	36567	none
Simvastatin	verapamil	12	11	false	none	7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  7.5 Digoxin    In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma.  		36567	none	36567	none
Simvastatin	verapamil	13	11	false	none	7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  7.5 Digoxin    In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma.  Patients taking digoxin should be monitored appropriately when simvastatin is initiated [see Clinical Pharmacology (12.3)].  		36567	none	36567	none
Simvastatin	verapamil	13	11	false	none	7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  7.5 Digoxin    In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma.  Patients taking digoxin should be monitored appropriately when simvastatin is initiated [see Clinical Pharmacology (12.3)].  		36567	none	36567	none
Simvastatin	Cyclosporine	10	10	false	none	7.3 Cyclosporine or Danazol    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of cyclosporine or danazol particularly with higher doses of simvastatin [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].  		36567	none	36567	none
Simvastatin	Cyclosporine	10	10	false	none	7.3 Cyclosporine or Danazol    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of cyclosporine or danazol particularly with higher doses of simvastatin [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].  		36567	none	36567	none
Simvastatin	Cyclosporine	11	10	false	none	7.3 Cyclosporine or Danazol    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of cyclosporine or danazol particularly with higher doses of simvastatin [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].  7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  		36567	none	36567	none
Simvastatin	Cyclosporine	11	10	false	none	7.3 Cyclosporine or Danazol    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of cyclosporine or danazol particularly with higher doses of simvastatin [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].  7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  		36567	none	36567	none
Simvastatin	Cyclosporine	12	10	false	none	7.3 Cyclosporine or Danazol    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of cyclosporine or danazol particularly with higher doses of simvastatin [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].  7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  7.5 Digoxin    In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma.  		36567	none	36567	none
Simvastatin	Cyclosporine	12	10	false	none	7.3 Cyclosporine or Danazol    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of cyclosporine or danazol particularly with higher doses of simvastatin [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].  7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  7.5 Digoxin    In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma.  		36567	none	36567	none
Simvastatin	danazol	10	10	false	none	7.3 Cyclosporine or Danazol    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of cyclosporine or danazol particularly with higher doses of simvastatin [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].  		36567	none	36567	none
Simvastatin	danazol	10	10	false	none	7.3 Cyclosporine or Danazol    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of cyclosporine or danazol particularly with higher doses of simvastatin [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].  		36567	none	36567	none
Simvastatin	danazol	11	10	false	none	7.3 Cyclosporine or Danazol    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of cyclosporine or danazol particularly with higher doses of simvastatin [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].  7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  		36567	none	36567	none
Simvastatin	danazol	11	10	false	none	7.3 Cyclosporine or Danazol    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of cyclosporine or danazol particularly with higher doses of simvastatin [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].  7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  		36567	none	36567	none
Simvastatin	danazol	12	10	false	none	7.3 Cyclosporine or Danazol    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of cyclosporine or danazol particularly with higher doses of simvastatin [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].  7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  7.5 Digoxin    In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma.  		36567	none	36567	none
Simvastatin	danazol	12	10	false	none	7.3 Cyclosporine or Danazol    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of cyclosporine or danazol particularly with higher doses of simvastatin [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].  7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  7.5 Digoxin    In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma.  		36567	none	36567	none
Simvastatin	amiodarone	10	11	false	none	7.3 Cyclosporine or Danazol    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of cyclosporine or danazol particularly with higher doses of simvastatin [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].  7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  		36567	none	36567	none
Simvastatin	amiodarone	10	11	false	none	7.3 Cyclosporine or Danazol    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of cyclosporine or danazol particularly with higher doses of simvastatin [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].  7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  		36567	none	36567	none
Simvastatin	amiodarone	11	11	false	none	7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  		36567	none	36567	none
Simvastatin	amiodarone	11	11	false	none	7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  		36567	none	36567	none
Simvastatin	amiodarone	12	11	false	none	7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  7.5 Digoxin    In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma.  		36567	none	36567	none
Simvastatin	amiodarone	12	11	false	none	7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  7.5 Digoxin    In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma.  		36567	none	36567	none
Simvastatin	amiodarone	13	11	false	none	7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  7.5 Digoxin    In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma.  Patients taking digoxin should be monitored appropriately when simvastatin is initiated [see Clinical Pharmacology (12.3)].  		36567	none	36567	none
Simvastatin	amiodarone	13	11	false	none	7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  7.5 Digoxin    In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma.  Patients taking digoxin should be monitored appropriately when simvastatin is initiated [see Clinical Pharmacology (12.3)].  		36567	none	36567	none
Simvastatin	clarithromycin	4	6	false	none	Hence when simvastatin is used with an inhibitor of CYP3A4 (e.g., as listed below), elevated plasma levels of HMG-CoA reductase inhibitory activity can increase the risk of myopathy and rhabdomyolysis, particularly with higher doses of simvastatin.  [See Warnings and Precautions (5.1) and Clinical Pharmacology (12.3).]  Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  		36567	21212	36567	21212
Simvastatin	clarithromycin	4	6	false	none	Hence when simvastatin is used with an inhibitor of CYP3A4 (e.g., as listed below), elevated plasma levels of HMG-CoA reductase inhibitory activity can increase the risk of myopathy and rhabdomyolysis, particularly with higher doses of simvastatin.  [See Warnings and Precautions (5.1) and Clinical Pharmacology (12.3).]  Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  		36567	21212	36567	21212
Simvastatin	clarithromycin	7	6	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		36567	21212	36567	21212
Simvastatin	clarithromycin	7	6	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		36567	21212	36567	21212
Simvastatin	clarithromycin	7	7	false	none	If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		36567	21212	36567	21212
Simvastatin	clarithromycin	7	7	false	none	If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		36567	21212	36567	21212
Simvastatin	telithromycin	4	6	false	none	Hence when simvastatin is used with an inhibitor of CYP3A4 (e.g., as listed below), elevated plasma levels of HMG-CoA reductase inhibitory activity can increase the risk of myopathy and rhabdomyolysis, particularly with higher doses of simvastatin.  [See Warnings and Precautions (5.1) and Clinical Pharmacology (12.3).]  Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  		36567	274786	36567	274786
Simvastatin	telithromycin	4	6	false	none	Hence when simvastatin is used with an inhibitor of CYP3A4 (e.g., as listed below), elevated plasma levels of HMG-CoA reductase inhibitory activity can increase the risk of myopathy and rhabdomyolysis, particularly with higher doses of simvastatin.  [See Warnings and Precautions (5.1) and Clinical Pharmacology (12.3).]  Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  		36567	274786	36567	274786
Simvastatin	telithromycin	7	6	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		36567	274786	36567	274786
Simvastatin	telithromycin	7	6	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		36567	274786	36567	274786
Simvastatin	telithromycin	7	7	false	none	If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		36567	274786	36567	274786
Simvastatin	telithromycin	7	7	false	none	If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		36567	274786	36567	274786
Simvastatin	fibrates	7	8	false	none	If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  		36567	none	36567	none
Simvastatin	fibrates	7	8	false	none	If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  		36567	none	36567	none
Simvastatin	fibrates	10	8	false	none	7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  [see Warnings and Precautions (5.1)].  7.3 Cyclosporine or Danazol    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of cyclosporine or danazol particularly with higher doses of simvastatin [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].  		36567	none	36567	none
Simvastatin	fibrates	10	8	false	none	7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  [see Warnings and Precautions (5.1)].  7.3 Cyclosporine or Danazol    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of cyclosporine or danazol particularly with higher doses of simvastatin [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].  		36567	none	36567	none
Simvastatin	cyclosporine	10	10	false	none	7.3 Cyclosporine or Danazol    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of cyclosporine or danazol particularly with higher doses of simvastatin [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].  		36567	none	36567	none
Simvastatin	cyclosporine	10	10	false	none	7.3 Cyclosporine or Danazol    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of cyclosporine or danazol particularly with higher doses of simvastatin [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].  		36567	none	36567	none
Simvastatin	cyclosporine	11	10	false	none	7.3 Cyclosporine or Danazol    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of cyclosporine or danazol particularly with higher doses of simvastatin [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].  7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  		36567	none	36567	none
Simvastatin	cyclosporine	11	10	false	none	7.3 Cyclosporine or Danazol    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of cyclosporine or danazol particularly with higher doses of simvastatin [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].  7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  		36567	none	36567	none
Simvastatin	cyclosporine	12	10	false	none	7.3 Cyclosporine or Danazol    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of cyclosporine or danazol particularly with higher doses of simvastatin [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].  7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  7.5 Digoxin    In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma.  		36567	none	36567	none
Simvastatin	cyclosporine	12	10	false	none	7.3 Cyclosporine or Danazol    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of cyclosporine or danazol particularly with higher doses of simvastatin [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].  7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  7.5 Digoxin    In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma.  		36567	none	36567	none
Simvastatin	nefazodone	4	6	false	none	Hence when simvastatin is used with an inhibitor of CYP3A4 (e.g., as listed below), elevated plasma levels of HMG-CoA reductase inhibitory activity can increase the risk of myopathy and rhabdomyolysis, particularly with higher doses of simvastatin.  [See Warnings and Precautions (5.1) and Clinical Pharmacology (12.3).]  Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  		36567	31565	36567	C051752
Simvastatin	nefazodone	4	6	false	none	Hence when simvastatin is used with an inhibitor of CYP3A4 (e.g., as listed below), elevated plasma levels of HMG-CoA reductase inhibitory activity can increase the risk of myopathy and rhabdomyolysis, particularly with higher doses of simvastatin.  [See Warnings and Precautions (5.1) and Clinical Pharmacology (12.3).]  Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  		36567	31565	36567	C051752
Simvastatin	nefazodone	7	6	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		36567	31565	36567	C051752
Simvastatin	nefazodone	7	6	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		36567	31565	36567	C051752
Simvastatin	erythromycin	4	6	false	none	Hence when simvastatin is used with an inhibitor of CYP3A4 (e.g., as listed below), elevated plasma levels of HMG-CoA reductase inhibitory activity can increase the risk of myopathy and rhabdomyolysis, particularly with higher doses of simvastatin.  [See Warnings and Precautions (5.1) and Clinical Pharmacology (12.3).]  Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  		36567	4053	36567	D004917
Simvastatin	erythromycin	4	6	false	none	Hence when simvastatin is used with an inhibitor of CYP3A4 (e.g., as listed below), elevated plasma levels of HMG-CoA reductase inhibitory activity can increase the risk of myopathy and rhabdomyolysis, particularly with higher doses of simvastatin.  [See Warnings and Precautions (5.1) and Clinical Pharmacology (12.3).]  Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  		36567	4053	36567	D004917
Simvastatin	erythromycin	7	6	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		36567	4053	36567	D004917
Simvastatin	erythromycin	7	6	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		36567	4053	36567	D004917
Simvastatin	erythromycin	7	7	false	none	If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		36567	4053	36567	D004917
Simvastatin	erythromycin	7	7	false	none	If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		36567	4053	36567	D004917
niacin	nicotinic acid	8	8	false	none	7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  		D009525	D009525
niacin	grapefruit	8	6	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  		7393	none	D009525	none
niacin	grapefruit	8	6	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  		7393	none	D009525	none
niacin	Danazol	8	10	false	none	7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  [see Warnings and Precautions (5.1)].  7.3 Cyclosporine or Danazol    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of cyclosporine or danazol particularly with higher doses of simvastatin [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].  		7393	none	D009525	none
niacin	Danazol	8	10	false	none	7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  [see Warnings and Precautions (5.1)].  7.3 Cyclosporine or Danazol    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of cyclosporine or danazol particularly with higher doses of simvastatin [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].  		7393	none	D009525	none
niacin	ketoconazole	8	6	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  		7393	6135	D009525	D007654
niacin	ketoconazole	8	6	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  		7393	6135	D009525	D007654
niacin	ketoconazole	8	7	false	none	If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  		7393	6135	D009525	D007654
niacin	ketoconazole	8	7	false	none	If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  		7393	6135	D009525	D007654
niacin	itraconazole	8	6	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  		7393	28031	D009525	D017964
niacin	itraconazole	8	6	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  		7393	28031	D009525	D017964
niacin	itraconazole	8	7	false	none	If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  		7393	28031	D009525	D017964
niacin	itraconazole	8	7	false	none	If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  		7393	28031	D009525	D017964
niacin	simvastatin	8	7	false	none	If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  		7393	36567	D009525	36567
niacin	simvastatin	8	7	false	none	If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  		7393	36567	D009525	36567
niacin	simvastatin	8	10	false	none	7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  [see Warnings and Precautions (5.1)].  7.3 Cyclosporine or Danazol    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of cyclosporine or danazol particularly with higher doses of simvastatin [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].  		7393	36567	D009525	36567
niacin	simvastatin	8	10	false	none	7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  [see Warnings and Precautions (5.1)].  7.3 Cyclosporine or Danazol    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of cyclosporine or danazol particularly with higher doses of simvastatin [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].  		7393	36567	D009525	36567
niacin	gemfibrozil	8	8	false	none	7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  		7393	4719	D009525	D015248
niacin	gemfibrozil	8	8	false	none	7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  		7393	4719	D009525	D015248
niacin	Cyclosporine	8	10	false	none	7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  [see Warnings and Precautions (5.1)].  7.3 Cyclosporine or Danazol    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of cyclosporine or danazol particularly with higher doses of simvastatin [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].  		7393	none	D009525	none
niacin	Cyclosporine	8	10	false	none	7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  [see Warnings and Precautions (5.1)].  7.3 Cyclosporine or Danazol    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of cyclosporine or danazol particularly with higher doses of simvastatin [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].  		7393	none	D009525	none
niacin	danazol	8	10	false	none	7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  [see Warnings and Precautions (5.1)].  7.3 Cyclosporine or Danazol    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of cyclosporine or danazol particularly with higher doses of simvastatin [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].  		7393	none	D009525	none
niacin	danazol	8	10	false	none	7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  [see Warnings and Precautions (5.1)].  7.3 Cyclosporine or Danazol    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of cyclosporine or danazol particularly with higher doses of simvastatin [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].  		7393	none	D009525	none
niacin	clarithromycin	8	6	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  		7393	21212	D009525	21212
niacin	clarithromycin	8	6	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  		7393	21212	D009525	21212
niacin	clarithromycin	8	7	false	none	If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  		7393	21212	D009525	21212
niacin	clarithromycin	8	7	false	none	If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  		7393	21212	D009525	21212
niacin	telithromycin	8	6	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  		7393	274786	D009525	274786
niacin	telithromycin	8	6	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  		7393	274786	D009525	274786
niacin	telithromycin	8	7	false	none	If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  		7393	274786	D009525	274786
niacin	telithromycin	8	7	false	none	If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  		7393	274786	D009525	274786
niacin	fibrates	8	8	false	none	7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  		7393	none	D009525	none
niacin	fibrates	8	8	false	none	7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  		7393	none	D009525	none
niacin	cyclosporine	8	10	false	none	7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  [see Warnings and Precautions (5.1)].  7.3 Cyclosporine or Danazol    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of cyclosporine or danazol particularly with higher doses of simvastatin [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].  		7393	none	D009525	none
niacin	cyclosporine	8	10	false	none	7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  [see Warnings and Precautions (5.1)].  7.3 Cyclosporine or Danazol    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of cyclosporine or danazol particularly with higher doses of simvastatin [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].  		7393	none	D009525	none
niacin	nefazodone	8	6	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  		7393	31565	D009525	C051752
niacin	nefazodone	8	6	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  		7393	31565	D009525	C051752
niacin	erythromycin	8	6	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  		7393	4053	D009525	D004917
niacin	erythromycin	8	6	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  		7393	4053	D009525	D004917
niacin	erythromycin	8	7	false	none	If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  		7393	4053	D009525	D004917
niacin	erythromycin	8	7	false	none	If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  		7393	4053	D009525	D004917
Amiodarone	Verapamil	11	11	false	none	7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  		none	none	none	none
Amiodarone	Danazol	11	10	false	none	7.3 Cyclosporine or Danazol    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of cyclosporine or danazol particularly with higher doses of simvastatin [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].  7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  		none	none	none	none
Amiodarone	digoxin	11	12	false	none	7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  7.5 Digoxin    In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma.  		none	none	none	none
Amiodarone	digoxin	11	13	false	none	7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  7.5 Digoxin    In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma.  Patients taking digoxin should be monitored appropriately when simvastatin is initiated [see Clinical Pharmacology (12.3)].  		none	none	none	none
Amiodarone	simvastatin	11	10	false	none	7.3 Cyclosporine or Danazol    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of cyclosporine or danazol particularly with higher doses of simvastatin [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].  7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  		none	36567	none	36567
Amiodarone	simvastatin	11	10	false	none	7.3 Cyclosporine or Danazol    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of cyclosporine or danazol particularly with higher doses of simvastatin [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].  7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  		none	36567	none	36567
Amiodarone	simvastatin	11	11	false	none	7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  		none	36567	none	36567
Amiodarone	simvastatin	11	11	false	none	7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  		none	36567	none	36567
Amiodarone	simvastatin	11	12	false	none	7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  7.5 Digoxin    In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma.  		none	36567	none	36567
Amiodarone	simvastatin	11	12	false	none	7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  7.5 Digoxin    In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma.  		none	36567	none	36567
Amiodarone	simvastatin	11	13	false	none	7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  7.5 Digoxin    In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma.  Patients taking digoxin should be monitored appropriately when simvastatin is initiated [see Clinical Pharmacology (12.3)].  		none	36567	none	36567
Amiodarone	simvastatin	11	13	false	none	7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  7.5 Digoxin    In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma.  Patients taking digoxin should be monitored appropriately when simvastatin is initiated [see Clinical Pharmacology (12.3)].  		none	36567	none	36567
Amiodarone	verapamil	11	11	false	none	7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  		none	none	none	none
Amiodarone	Cyclosporine	11	10	false	none	7.3 Cyclosporine or Danazol    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of cyclosporine or danazol particularly with higher doses of simvastatin [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].  7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  		none	none	none	none
Amiodarone	danazol	11	10	false	none	7.3 Cyclosporine or Danazol    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of cyclosporine or danazol particularly with higher doses of simvastatin [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].  7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  		none	none	none	none
Amiodarone	amiodarone	11	11	false	none	7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  		none	none	none	none
Amiodarone	cyclosporine	11	10	false	none	7.3 Cyclosporine or Danazol    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of cyclosporine or danazol particularly with higher doses of simvastatin [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].  7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  		none	none	none	none
Verapamil	Danazol	11	10	false	none	7.3 Cyclosporine or Danazol    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of cyclosporine or danazol particularly with higher doses of simvastatin [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].  7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  		none	none	none	none
Verapamil	digoxin	11	12	false	none	7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  7.5 Digoxin    In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma.  		none	none	none	none
Verapamil	digoxin	11	13	false	none	7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  7.5 Digoxin    In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma.  Patients taking digoxin should be monitored appropriately when simvastatin is initiated [see Clinical Pharmacology (12.3)].  		none	none	none	none
Verapamil	simvastatin	11	10	false	none	7.3 Cyclosporine or Danazol    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of cyclosporine or danazol particularly with higher doses of simvastatin [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].  7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  		none	36567	none	36567
Verapamil	simvastatin	11	10	false	none	7.3 Cyclosporine or Danazol    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of cyclosporine or danazol particularly with higher doses of simvastatin [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].  7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  		none	36567	none	36567
Verapamil	simvastatin	11	11	false	none	7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  		none	36567	none	36567
Verapamil	simvastatin	11	11	false	none	7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  		none	36567	none	36567
Verapamil	simvastatin	11	12	false	none	7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  7.5 Digoxin    In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma.  		none	36567	none	36567
Verapamil	simvastatin	11	12	false	none	7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  7.5 Digoxin    In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma.  		none	36567	none	36567
Verapamil	simvastatin	11	13	false	none	7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  7.5 Digoxin    In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma.  Patients taking digoxin should be monitored appropriately when simvastatin is initiated [see Clinical Pharmacology (12.3)].  		none	36567	none	36567
Verapamil	simvastatin	11	13	false	none	7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  7.5 Digoxin    In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma.  Patients taking digoxin should be monitored appropriately when simvastatin is initiated [see Clinical Pharmacology (12.3)].  		none	36567	none	36567
Verapamil	verapamil	11	11	false	none	7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  		none	none	none	none
Verapamil	Cyclosporine	11	10	false	none	7.3 Cyclosporine or Danazol    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of cyclosporine or danazol particularly with higher doses of simvastatin [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].  7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  		none	none	none	none
Verapamil	danazol	11	10	false	none	7.3 Cyclosporine or Danazol    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of cyclosporine or danazol particularly with higher doses of simvastatin [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].  7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  		none	none	none	none
Verapamil	amiodarone	11	11	false	none	7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  		none	none	none	none
Verapamil	cyclosporine	11	10	false	none	7.3 Cyclosporine or Danazol    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of cyclosporine or danazol particularly with higher doses of simvastatin [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].  7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  		none	none	none	none
nicotinic acid	grapefruit	8	6	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  		7393	none	D009525	none
nicotinic acid	grapefruit	8	6	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  		7393	none	D009525	none
nicotinic acid	Danazol	8	10	false	none	7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  [see Warnings and Precautions (5.1)].  7.3 Cyclosporine or Danazol    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of cyclosporine or danazol particularly with higher doses of simvastatin [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].  		7393	none	D009525	none
nicotinic acid	Danazol	8	10	false	none	7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  [see Warnings and Precautions (5.1)].  7.3 Cyclosporine or Danazol    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of cyclosporine or danazol particularly with higher doses of simvastatin [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].  		7393	none	D009525	none
nicotinic acid	ketoconazole	8	6	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  		7393	6135	D009525	D007654
nicotinic acid	ketoconazole	8	6	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  		7393	6135	D009525	D007654
nicotinic acid	ketoconazole	8	7	false	none	If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  		7393	6135	D009525	D007654
nicotinic acid	ketoconazole	8	7	false	none	If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  		7393	6135	D009525	D007654
nicotinic acid	itraconazole	8	6	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  		7393	28031	D009525	D017964
nicotinic acid	itraconazole	8	6	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  		7393	28031	D009525	D017964
nicotinic acid	itraconazole	8	7	false	none	If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  		7393	28031	D009525	D017964
nicotinic acid	itraconazole	8	7	false	none	If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  		7393	28031	D009525	D017964
nicotinic acid	simvastatin	8	7	false	none	If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  		7393	36567	D009525	36567
nicotinic acid	simvastatin	8	7	false	none	If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  		7393	36567	D009525	36567
nicotinic acid	simvastatin	8	10	false	none	7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  [see Warnings and Precautions (5.1)].  7.3 Cyclosporine or Danazol    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of cyclosporine or danazol particularly with higher doses of simvastatin [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].  		7393	36567	D009525	36567
nicotinic acid	simvastatin	8	10	false	none	7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  [see Warnings and Precautions (5.1)].  7.3 Cyclosporine or Danazol    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of cyclosporine or danazol particularly with higher doses of simvastatin [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].  		7393	36567	D009525	36567
nicotinic acid	gemfibrozil	8	8	false	none	7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  		7393	4719	D009525	D015248
nicotinic acid	gemfibrozil	8	8	false	none	7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  		7393	4719	D009525	D015248
nicotinic acid	Cyclosporine	8	10	false	none	7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  [see Warnings and Precautions (5.1)].  7.3 Cyclosporine or Danazol    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of cyclosporine or danazol particularly with higher doses of simvastatin [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].  		7393	none	D009525	none
nicotinic acid	Cyclosporine	8	10	false	none	7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  [see Warnings and Precautions (5.1)].  7.3 Cyclosporine or Danazol    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of cyclosporine or danazol particularly with higher doses of simvastatin [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].  		7393	none	D009525	none
nicotinic acid	danazol	8	10	false	none	7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  [see Warnings and Precautions (5.1)].  7.3 Cyclosporine or Danazol    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of cyclosporine or danazol particularly with higher doses of simvastatin [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].  		7393	none	D009525	none
nicotinic acid	danazol	8	10	false	none	7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  [see Warnings and Precautions (5.1)].  7.3 Cyclosporine or Danazol    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of cyclosporine or danazol particularly with higher doses of simvastatin [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].  		7393	none	D009525	none
nicotinic acid	clarithromycin	8	6	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  		7393	21212	D009525	21212
nicotinic acid	clarithromycin	8	6	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  		7393	21212	D009525	21212
nicotinic acid	clarithromycin	8	7	false	none	If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  		7393	21212	D009525	21212
nicotinic acid	clarithromycin	8	7	false	none	If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  		7393	21212	D009525	21212
nicotinic acid	telithromycin	8	6	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  		7393	274786	D009525	274786
nicotinic acid	telithromycin	8	6	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  		7393	274786	D009525	274786
nicotinic acid	telithromycin	8	7	false	none	If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  		7393	274786	D009525	274786
nicotinic acid	telithromycin	8	7	false	none	If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  		7393	274786	D009525	274786
nicotinic acid	fibrates	8	8	false	none	7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  		7393	none	D009525	none
nicotinic acid	fibrates	8	8	false	none	7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  		7393	none	D009525	none
nicotinic acid	cyclosporine	8	10	false	none	7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  [see Warnings and Precautions (5.1)].  7.3 Cyclosporine or Danazol    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of cyclosporine or danazol particularly with higher doses of simvastatin [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].  		7393	none	D009525	none
nicotinic acid	cyclosporine	8	10	false	none	7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  [see Warnings and Precautions (5.1)].  7.3 Cyclosporine or Danazol    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of cyclosporine or danazol particularly with higher doses of simvastatin [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].  		7393	none	D009525	none
nicotinic acid	nefazodone	8	6	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  		7393	31565	D009525	C051752
nicotinic acid	nefazodone	8	6	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  		7393	31565	D009525	C051752
nicotinic acid	erythromycin	8	6	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  		7393	4053	D009525	D004917
nicotinic acid	erythromycin	8	6	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  		7393	4053	D009525	D004917
nicotinic acid	erythromycin	8	7	false	none	If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  		7393	4053	D009525	D004917
nicotinic acid	erythromycin	8	7	false	none	If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  		7393	4053	D009525	D004917
prothrombin	coumarin	17	17	false	none	Once a stable prothrombin time has been documented, prothrombin times can be monitored at the intervals usually recommended for patients on coumarin anticoagulants.  		none	none	none	none
prothrombin	coumarin	17	15	false	none	With other statins, clinically evident bleeding and/or increased prothrombin time has been reported in a few patients taking coumarin anticoagulants concomitantly.  In such patients, prothrombin time should be determined before starting simvastatin and frequently enough during early therapy to ensure that no significant alteration of prothrombin time occurs.  Once a stable prothrombin time has been documented, prothrombin times can be monitored at the intervals usually recommended for patients on coumarin anticoagulants.  		none	none	none	none
prothrombin	coumarin	16	17	false	none	In such patients, prothrombin time should be determined before starting simvastatin and frequently enough during early therapy to ensure that no significant alteration of prothrombin time occurs.  Once a stable prothrombin time has been documented, prothrombin times can be monitored at the intervals usually recommended for patients on coumarin anticoagulants.  		none	none	none	none
prothrombin	coumarin	16	14	false	none	7.6 Coumarin Anticoagulants    In two clinical studies, one in normal volunteers and the other in hypercholesterolemic patients, simvastatin 20-40 mg/day modestly potentiated the effect of coumarin anticoagulants: the prothrombin time, reported as International Normalized Ratio (INR), increased from a baseline of 1.7 to 1.8 and from 2.6 to 3.4 in the volunteer and patient studies, respectively.  With other statins, clinically evident bleeding and/or increased prothrombin time has been reported in a few patients taking coumarin anticoagulants concomitantly.  In such patients, prothrombin time should be determined before starting simvastatin and frequently enough during early therapy to ensure that no significant alteration of prothrombin time occurs.  		none	none	none	none
prothrombin	coumarin	16	15	false	none	With other statins, clinically evident bleeding and/or increased prothrombin time has been reported in a few patients taking coumarin anticoagulants concomitantly.  In such patients, prothrombin time should be determined before starting simvastatin and frequently enough during early therapy to ensure that no significant alteration of prothrombin time occurs.  		none	none	none	none
prothrombin	coumarin	19	17	false	none	Once a stable prothrombin time has been documented, prothrombin times can be monitored at the intervals usually recommended for patients on coumarin anticoagulants.  If the dose of simvastatin is changed or discontinued, the same procedure should be repeated.  Simvastatin therapy has not been associated with bleeding or with changes in prothrombin time in patients not taking anticoagulants.  		none	none	none	none
prothrombin	coumarin	14	14	false	none	7.6 Coumarin Anticoagulants    In two clinical studies, one in normal volunteers and the other in hypercholesterolemic patients, simvastatin 20-40 mg/day modestly potentiated the effect of coumarin anticoagulants: the prothrombin time, reported as International Normalized Ratio (INR), increased from a baseline of 1.7 to 1.8 and from 2.6 to 3.4 in the volunteer and patient studies, respectively.  		none	none	none	none
prothrombin	coumarin	14	15	false	none	7.6 Coumarin Anticoagulants    In two clinical studies, one in normal volunteers and the other in hypercholesterolemic patients, simvastatin 20-40 mg/day modestly potentiated the effect of coumarin anticoagulants: the prothrombin time, reported as International Normalized Ratio (INR), increased from a baseline of 1.7 to 1.8 and from 2.6 to 3.4 in the volunteer and patient studies, respectively.  With other statins, clinically evident bleeding and/or increased prothrombin time has been reported in a few patients taking coumarin anticoagulants concomitantly.  		none	none	none	none
prothrombin	coumarin	15	17	false	none	With other statins, clinically evident bleeding and/or increased prothrombin time has been reported in a few patients taking coumarin anticoagulants concomitantly.  In such patients, prothrombin time should be determined before starting simvastatin and frequently enough during early therapy to ensure that no significant alteration of prothrombin time occurs.  Once a stable prothrombin time has been documented, prothrombin times can be monitored at the intervals usually recommended for patients on coumarin anticoagulants.  		none	none	none	none
prothrombin	coumarin	15	14	false	none	7.6 Coumarin Anticoagulants    In two clinical studies, one in normal volunteers and the other in hypercholesterolemic patients, simvastatin 20-40 mg/day modestly potentiated the effect of coumarin anticoagulants: the prothrombin time, reported as International Normalized Ratio (INR), increased from a baseline of 1.7 to 1.8 and from 2.6 to 3.4 in the volunteer and patient studies, respectively.  With other statins, clinically evident bleeding and/or increased prothrombin time has been reported in a few patients taking coumarin anticoagulants concomitantly.  		none	none	none	none
prothrombin	coumarin	15	15	false	none	With other statins, clinically evident bleeding and/or increased prothrombin time has been reported in a few patients taking coumarin anticoagulants concomitantly.  		none	none	none	none
prothrombin	digoxin	14	12	false	none	7.5 Digoxin    In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma.  Patients taking digoxin should be monitored appropriately when simvastatin is initiated [see Clinical Pharmacology (12.3)].  7.6 Coumarin Anticoagulants    In two clinical studies, one in normal volunteers and the other in hypercholesterolemic patients, simvastatin 20-40 mg/day modestly potentiated the effect of coumarin anticoagulants: the prothrombin time, reported as International Normalized Ratio (INR), increased from a baseline of 1.7 to 1.8 and from 2.6 to 3.4 in the volunteer and patient studies, respectively.  		none	none	none	none
prothrombin	digoxin	14	13	false	none	Patients taking digoxin should be monitored appropriately when simvastatin is initiated [see Clinical Pharmacology (12.3)].  7.6 Coumarin Anticoagulants    In two clinical studies, one in normal volunteers and the other in hypercholesterolemic patients, simvastatin 20-40 mg/day modestly potentiated the effect of coumarin anticoagulants: the prothrombin time, reported as International Normalized Ratio (INR), increased from a baseline of 1.7 to 1.8 and from 2.6 to 3.4 in the volunteer and patient studies, respectively.  		none	none	none	none
prothrombin	digoxin	15	13	false	none	Patients taking digoxin should be monitored appropriately when simvastatin is initiated [see Clinical Pharmacology (12.3)].  7.6 Coumarin Anticoagulants    In two clinical studies, one in normal volunteers and the other in hypercholesterolemic patients, simvastatin 20-40 mg/day modestly potentiated the effect of coumarin anticoagulants: the prothrombin time, reported as International Normalized Ratio (INR), increased from a baseline of 1.7 to 1.8 and from 2.6 to 3.4 in the volunteer and patient studies, respectively.  With other statins, clinically evident bleeding and/or increased prothrombin time has been reported in a few patients taking coumarin anticoagulants concomitantly.  		none	none	none	none
prothrombin	simvastatin	17	16	false	none	In such patients, prothrombin time should be determined before starting simvastatin and frequently enough during early therapy to ensure that no significant alteration of prothrombin time occurs.  Once a stable prothrombin time has been documented, prothrombin times can be monitored at the intervals usually recommended for patients on coumarin anticoagulants.  		none	36567	none	36567
prothrombin	simvastatin	17	16	false	none	In such patients, prothrombin time should be determined before starting simvastatin and frequently enough during early therapy to ensure that no significant alteration of prothrombin time occurs.  Once a stable prothrombin time has been documented, prothrombin times can be monitored at the intervals usually recommended for patients on coumarin anticoagulants.  		none	36567	none	36567
prothrombin	simvastatin	17	19	false	none	Once a stable prothrombin time has been documented, prothrombin times can be monitored at the intervals usually recommended for patients on coumarin anticoagulants.  If the dose of simvastatin is changed or discontinued, the same procedure should be repeated.  Simvastatin therapy has not been associated with bleeding or with changes in prothrombin time in patients not taking anticoagulants.  		none	36567	none	36567
prothrombin	simvastatin	17	19	false	none	Once a stable prothrombin time has been documented, prothrombin times can be monitored at the intervals usually recommended for patients on coumarin anticoagulants.  If the dose of simvastatin is changed or discontinued, the same procedure should be repeated.  Simvastatin therapy has not been associated with bleeding or with changes in prothrombin time in patients not taking anticoagulants.  		none	36567	none	36567
prothrombin	simvastatin	17	18	false	none	Once a stable prothrombin time has been documented, prothrombin times can be monitored at the intervals usually recommended for patients on coumarin anticoagulants.  If the dose of simvastatin is changed or discontinued, the same procedure should be repeated.  		none	36567	none	36567
prothrombin	simvastatin	17	18	false	none	Once a stable prothrombin time has been documented, prothrombin times can be monitored at the intervals usually recommended for patients on coumarin anticoagulants.  If the dose of simvastatin is changed or discontinued, the same procedure should be repeated.  		none	36567	none	36567
prothrombin	simvastatin	16	14	false	none	7.6 Coumarin Anticoagulants    In two clinical studies, one in normal volunteers and the other in hypercholesterolemic patients, simvastatin 20-40 mg/day modestly potentiated the effect of coumarin anticoagulants: the prothrombin time, reported as International Normalized Ratio (INR), increased from a baseline of 1.7 to 1.8 and from 2.6 to 3.4 in the volunteer and patient studies, respectively.  With other statins, clinically evident bleeding and/or increased prothrombin time has been reported in a few patients taking coumarin anticoagulants concomitantly.  In such patients, prothrombin time should be determined before starting simvastatin and frequently enough during early therapy to ensure that no significant alteration of prothrombin time occurs.  		none	36567	none	36567
prothrombin	simvastatin	16	14	false	none	7.6 Coumarin Anticoagulants    In two clinical studies, one in normal volunteers and the other in hypercholesterolemic patients, simvastatin 20-40 mg/day modestly potentiated the effect of coumarin anticoagulants: the prothrombin time, reported as International Normalized Ratio (INR), increased from a baseline of 1.7 to 1.8 and from 2.6 to 3.4 in the volunteer and patient studies, respectively.  With other statins, clinically evident bleeding and/or increased prothrombin time has been reported in a few patients taking coumarin anticoagulants concomitantly.  In such patients, prothrombin time should be determined before starting simvastatin and frequently enough during early therapy to ensure that no significant alteration of prothrombin time occurs.  		none	36567	none	36567
prothrombin	simvastatin	16	16	false	none	In such patients, prothrombin time should be determined before starting simvastatin and frequently enough during early therapy to ensure that no significant alteration of prothrombin time occurs.  		none	36567	none	36567
prothrombin	simvastatin	16	16	false	none	In such patients, prothrombin time should be determined before starting simvastatin and frequently enough during early therapy to ensure that no significant alteration of prothrombin time occurs.  		none	36567	none	36567
prothrombin	simvastatin	16	18	false	none	In such patients, prothrombin time should be determined before starting simvastatin and frequently enough during early therapy to ensure that no significant alteration of prothrombin time occurs.  Once a stable prothrombin time has been documented, prothrombin times can be monitored at the intervals usually recommended for patients on coumarin anticoagulants.  If the dose of simvastatin is changed or discontinued, the same procedure should be repeated.  		none	36567	none	36567
prothrombin	simvastatin	16	18	false	none	In such patients, prothrombin time should be determined before starting simvastatin and frequently enough during early therapy to ensure that no significant alteration of prothrombin time occurs.  Once a stable prothrombin time has been documented, prothrombin times can be monitored at the intervals usually recommended for patients on coumarin anticoagulants.  If the dose of simvastatin is changed or discontinued, the same procedure should be repeated.  		none	36567	none	36567
prothrombin	simvastatin	19	19	true	positive	Simvastatin therapy has not been associated with bleeding or with changes in prothrombin time in patients not taking anticoagulants.  		none	36567	none	36567
prothrombin	simvastatin	19	19	true	positive	Simvastatin therapy has not been associated with bleeding or with changes in prothrombin time in patients not taking anticoagulants.  		none	36567	none	36567
prothrombin	simvastatin	19	18	false	none	If the dose of simvastatin is changed or discontinued, the same procedure should be repeated.  Simvastatin therapy has not been associated with bleeding or with changes in prothrombin time in patients not taking anticoagulants.  		none	36567	none	36567
prothrombin	simvastatin	19	18	false	none	If the dose of simvastatin is changed or discontinued, the same procedure should be repeated.  Simvastatin therapy has not been associated with bleeding or with changes in prothrombin time in patients not taking anticoagulants.  		none	36567	none	36567
prothrombin	simvastatin	14	12	false	none	7.5 Digoxin    In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma.  Patients taking digoxin should be monitored appropriately when simvastatin is initiated [see Clinical Pharmacology (12.3)].  7.6 Coumarin Anticoagulants    In two clinical studies, one in normal volunteers and the other in hypercholesterolemic patients, simvastatin 20-40 mg/day modestly potentiated the effect of coumarin anticoagulants: the prothrombin time, reported as International Normalized Ratio (INR), increased from a baseline of 1.7 to 1.8 and from 2.6 to 3.4 in the volunteer and patient studies, respectively.  		none	36567	none	36567
prothrombin	simvastatin	14	12	false	none	7.5 Digoxin    In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma.  Patients taking digoxin should be monitored appropriately when simvastatin is initiated [see Clinical Pharmacology (12.3)].  7.6 Coumarin Anticoagulants    In two clinical studies, one in normal volunteers and the other in hypercholesterolemic patients, simvastatin 20-40 mg/day modestly potentiated the effect of coumarin anticoagulants: the prothrombin time, reported as International Normalized Ratio (INR), increased from a baseline of 1.7 to 1.8 and from 2.6 to 3.4 in the volunteer and patient studies, respectively.  		none	36567	none	36567
prothrombin	simvastatin	14	13	false	none	Patients taking digoxin should be monitored appropriately when simvastatin is initiated [see Clinical Pharmacology (12.3)].  7.6 Coumarin Anticoagulants    In two clinical studies, one in normal volunteers and the other in hypercholesterolemic patients, simvastatin 20-40 mg/day modestly potentiated the effect of coumarin anticoagulants: the prothrombin time, reported as International Normalized Ratio (INR), increased from a baseline of 1.7 to 1.8 and from 2.6 to 3.4 in the volunteer and patient studies, respectively.  		none	36567	none	36567
prothrombin	simvastatin	14	13	false	none	Patients taking digoxin should be monitored appropriately when simvastatin is initiated [see Clinical Pharmacology (12.3)].  7.6 Coumarin Anticoagulants    In two clinical studies, one in normal volunteers and the other in hypercholesterolemic patients, simvastatin 20-40 mg/day modestly potentiated the effect of coumarin anticoagulants: the prothrombin time, reported as International Normalized Ratio (INR), increased from a baseline of 1.7 to 1.8 and from 2.6 to 3.4 in the volunteer and patient studies, respectively.  		none	36567	none	36567
prothrombin	simvastatin	14	14	false	none	7.6 Coumarin Anticoagulants    In two clinical studies, one in normal volunteers and the other in hypercholesterolemic patients, simvastatin 20-40 mg/day modestly potentiated the effect of coumarin anticoagulants: the prothrombin time, reported as International Normalized Ratio (INR), increased from a baseline of 1.7 to 1.8 and from 2.6 to 3.4 in the volunteer and patient studies, respectively.  		none	36567	none	36567
prothrombin	simvastatin	14	14	false	none	7.6 Coumarin Anticoagulants    In two clinical studies, one in normal volunteers and the other in hypercholesterolemic patients, simvastatin 20-40 mg/day modestly potentiated the effect of coumarin anticoagulants: the prothrombin time, reported as International Normalized Ratio (INR), increased from a baseline of 1.7 to 1.8 and from 2.6 to 3.4 in the volunteer and patient studies, respectively.  		none	36567	none	36567
prothrombin	simvastatin	14	16	false	none	7.6 Coumarin Anticoagulants    In two clinical studies, one in normal volunteers and the other in hypercholesterolemic patients, simvastatin 20-40 mg/day modestly potentiated the effect of coumarin anticoagulants: the prothrombin time, reported as International Normalized Ratio (INR), increased from a baseline of 1.7 to 1.8 and from 2.6 to 3.4 in the volunteer and patient studies, respectively.  With other statins, clinically evident bleeding and/or increased prothrombin time has been reported in a few patients taking coumarin anticoagulants concomitantly.  In such patients, prothrombin time should be determined before starting simvastatin and frequently enough during early therapy to ensure that no significant alteration of prothrombin time occurs.  		none	36567	none	36567
prothrombin	simvastatin	14	16	false	none	7.6 Coumarin Anticoagulants    In two clinical studies, one in normal volunteers and the other in hypercholesterolemic patients, simvastatin 20-40 mg/day modestly potentiated the effect of coumarin anticoagulants: the prothrombin time, reported as International Normalized Ratio (INR), increased from a baseline of 1.7 to 1.8 and from 2.6 to 3.4 in the volunteer and patient studies, respectively.  With other statins, clinically evident bleeding and/or increased prothrombin time has been reported in a few patients taking coumarin anticoagulants concomitantly.  In such patients, prothrombin time should be determined before starting simvastatin and frequently enough during early therapy to ensure that no significant alteration of prothrombin time occurs.  		none	36567	none	36567
prothrombin	simvastatin	15	13	false	none	Patients taking digoxin should be monitored appropriately when simvastatin is initiated [see Clinical Pharmacology (12.3)].  7.6 Coumarin Anticoagulants    In two clinical studies, one in normal volunteers and the other in hypercholesterolemic patients, simvastatin 20-40 mg/day modestly potentiated the effect of coumarin anticoagulants: the prothrombin time, reported as International Normalized Ratio (INR), increased from a baseline of 1.7 to 1.8 and from 2.6 to 3.4 in the volunteer and patient studies, respectively.  With other statins, clinically evident bleeding and/or increased prothrombin time has been reported in a few patients taking coumarin anticoagulants concomitantly.  		none	36567	none	36567
prothrombin	simvastatin	15	13	false	none	Patients taking digoxin should be monitored appropriately when simvastatin is initiated [see Clinical Pharmacology (12.3)].  7.6 Coumarin Anticoagulants    In two clinical studies, one in normal volunteers and the other in hypercholesterolemic patients, simvastatin 20-40 mg/day modestly potentiated the effect of coumarin anticoagulants: the prothrombin time, reported as International Normalized Ratio (INR), increased from a baseline of 1.7 to 1.8 and from 2.6 to 3.4 in the volunteer and patient studies, respectively.  With other statins, clinically evident bleeding and/or increased prothrombin time has been reported in a few patients taking coumarin anticoagulants concomitantly.  		none	36567	none	36567
prothrombin	simvastatin	15	14	false	none	7.6 Coumarin Anticoagulants    In two clinical studies, one in normal volunteers and the other in hypercholesterolemic patients, simvastatin 20-40 mg/day modestly potentiated the effect of coumarin anticoagulants: the prothrombin time, reported as International Normalized Ratio (INR), increased from a baseline of 1.7 to 1.8 and from 2.6 to 3.4 in the volunteer and patient studies, respectively.  With other statins, clinically evident bleeding and/or increased prothrombin time has been reported in a few patients taking coumarin anticoagulants concomitantly.  		none	36567	none	36567
prothrombin	simvastatin	15	14	false	none	7.6 Coumarin Anticoagulants    In two clinical studies, one in normal volunteers and the other in hypercholesterolemic patients, simvastatin 20-40 mg/day modestly potentiated the effect of coumarin anticoagulants: the prothrombin time, reported as International Normalized Ratio (INR), increased from a baseline of 1.7 to 1.8 and from 2.6 to 3.4 in the volunteer and patient studies, respectively.  With other statins, clinically evident bleeding and/or increased prothrombin time has been reported in a few patients taking coumarin anticoagulants concomitantly.  		none	36567	none	36567
prothrombin	simvastatin	15	16	false	none	With other statins, clinically evident bleeding and/or increased prothrombin time has been reported in a few patients taking coumarin anticoagulants concomitantly.  In such patients, prothrombin time should be determined before starting simvastatin and frequently enough during early therapy to ensure that no significant alteration of prothrombin time occurs.  		none	36567	none	36567
prothrombin	simvastatin	15	16	false	none	With other statins, clinically evident bleeding and/or increased prothrombin time has been reported in a few patients taking coumarin anticoagulants concomitantly.  In such patients, prothrombin time should be determined before starting simvastatin and frequently enough during early therapy to ensure that no significant alteration of prothrombin time occurs.  		none	36567	none	36567
coumarin	digoxin	14	12	false	none	7.5 Digoxin    In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma.  Patients taking digoxin should be monitored appropriately when simvastatin is initiated [see Clinical Pharmacology (12.3)].  7.6 Coumarin Anticoagulants    In two clinical studies, one in normal volunteers and the other in hypercholesterolemic patients, simvastatin 20-40 mg/day modestly potentiated the effect of coumarin anticoagulants: the prothrombin time, reported as International Normalized Ratio (INR), increased from a baseline of 1.7 to 1.8 and from 2.6 to 3.4 in the volunteer and patient studies, respectively.  		none	none	none	none
coumarin	digoxin	14	13	false	none	Patients taking digoxin should be monitored appropriately when simvastatin is initiated [see Clinical Pharmacology (12.3)].  7.6 Coumarin Anticoagulants    In two clinical studies, one in normal volunteers and the other in hypercholesterolemic patients, simvastatin 20-40 mg/day modestly potentiated the effect of coumarin anticoagulants: the prothrombin time, reported as International Normalized Ratio (INR), increased from a baseline of 1.7 to 1.8 and from 2.6 to 3.4 in the volunteer and patient studies, respectively.  		none	none	none	none
coumarin	digoxin	15	13	false	none	Patients taking digoxin should be monitored appropriately when simvastatin is initiated [see Clinical Pharmacology (12.3)].  7.6 Coumarin Anticoagulants    In two clinical studies, one in normal volunteers and the other in hypercholesterolemic patients, simvastatin 20-40 mg/day modestly potentiated the effect of coumarin anticoagulants: the prothrombin time, reported as International Normalized Ratio (INR), increased from a baseline of 1.7 to 1.8 and from 2.6 to 3.4 in the volunteer and patient studies, respectively.  With other statins, clinically evident bleeding and/or increased prothrombin time has been reported in a few patients taking coumarin anticoagulants concomitantly.  		none	none	none	none
coumarin	simvastatin	17	16	false	none	In such patients, prothrombin time should be determined before starting simvastatin and frequently enough during early therapy to ensure that no significant alteration of prothrombin time occurs.  Once a stable prothrombin time has been documented, prothrombin times can be monitored at the intervals usually recommended for patients on coumarin anticoagulants.  		none	36567	none	36567
coumarin	simvastatin	17	16	false	none	In such patients, prothrombin time should be determined before starting simvastatin and frequently enough during early therapy to ensure that no significant alteration of prothrombin time occurs.  Once a stable prothrombin time has been documented, prothrombin times can be monitored at the intervals usually recommended for patients on coumarin anticoagulants.  		none	36567	none	36567
coumarin	simvastatin	17	19	false	none	Once a stable prothrombin time has been documented, prothrombin times can be monitored at the intervals usually recommended for patients on coumarin anticoagulants.  If the dose of simvastatin is changed or discontinued, the same procedure should be repeated.  Simvastatin therapy has not been associated with bleeding or with changes in prothrombin time in patients not taking anticoagulants.  		none	36567	none	36567
coumarin	simvastatin	17	19	false	none	Once a stable prothrombin time has been documented, prothrombin times can be monitored at the intervals usually recommended for patients on coumarin anticoagulants.  If the dose of simvastatin is changed or discontinued, the same procedure should be repeated.  Simvastatin therapy has not been associated with bleeding or with changes in prothrombin time in patients not taking anticoagulants.  		none	36567	none	36567
coumarin	simvastatin	17	18	false	none	Once a stable prothrombin time has been documented, prothrombin times can be monitored at the intervals usually recommended for patients on coumarin anticoagulants.  If the dose of simvastatin is changed or discontinued, the same procedure should be repeated.  		none	36567	none	36567
coumarin	simvastatin	17	18	false	none	Once a stable prothrombin time has been documented, prothrombin times can be monitored at the intervals usually recommended for patients on coumarin anticoagulants.  If the dose of simvastatin is changed or discontinued, the same procedure should be repeated.  		none	36567	none	36567
coumarin	simvastatin	14	12	false	none	7.5 Digoxin    In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma.  Patients taking digoxin should be monitored appropriately when simvastatin is initiated [see Clinical Pharmacology (12.3)].  7.6 Coumarin Anticoagulants    In two clinical studies, one in normal volunteers and the other in hypercholesterolemic patients, simvastatin 20-40 mg/day modestly potentiated the effect of coumarin anticoagulants: the prothrombin time, reported as International Normalized Ratio (INR), increased from a baseline of 1.7 to 1.8 and from 2.6 to 3.4 in the volunteer and patient studies, respectively.  		none	36567	none	36567
coumarin	simvastatin	14	12	false	none	7.5 Digoxin    In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma.  Patients taking digoxin should be monitored appropriately when simvastatin is initiated [see Clinical Pharmacology (12.3)].  7.6 Coumarin Anticoagulants    In two clinical studies, one in normal volunteers and the other in hypercholesterolemic patients, simvastatin 20-40 mg/day modestly potentiated the effect of coumarin anticoagulants: the prothrombin time, reported as International Normalized Ratio (INR), increased from a baseline of 1.7 to 1.8 and from 2.6 to 3.4 in the volunteer and patient studies, respectively.  		none	36567	none	36567
coumarin	simvastatin	14	13	false	none	Patients taking digoxin should be monitored appropriately when simvastatin is initiated [see Clinical Pharmacology (12.3)].  7.6 Coumarin Anticoagulants    In two clinical studies, one in normal volunteers and the other in hypercholesterolemic patients, simvastatin 20-40 mg/day modestly potentiated the effect of coumarin anticoagulants: the prothrombin time, reported as International Normalized Ratio (INR), increased from a baseline of 1.7 to 1.8 and from 2.6 to 3.4 in the volunteer and patient studies, respectively.  		none	36567	none	36567
coumarin	simvastatin	14	13	false	none	Patients taking digoxin should be monitored appropriately when simvastatin is initiated [see Clinical Pharmacology (12.3)].  7.6 Coumarin Anticoagulants    In two clinical studies, one in normal volunteers and the other in hypercholesterolemic patients, simvastatin 20-40 mg/day modestly potentiated the effect of coumarin anticoagulants: the prothrombin time, reported as International Normalized Ratio (INR), increased from a baseline of 1.7 to 1.8 and from 2.6 to 3.4 in the volunteer and patient studies, respectively.  		none	36567	none	36567
coumarin	simvastatin	14	14	false	none	7.6 Coumarin Anticoagulants    In two clinical studies, one in normal volunteers and the other in hypercholesterolemic patients, simvastatin 20-40 mg/day modestly potentiated the effect of coumarin anticoagulants: the prothrombin time, reported as International Normalized Ratio (INR), increased from a baseline of 1.7 to 1.8 and from 2.6 to 3.4 in the volunteer and patient studies, respectively.  		none	36567	none	36567
coumarin	simvastatin	14	14	false	none	7.6 Coumarin Anticoagulants    In two clinical studies, one in normal volunteers and the other in hypercholesterolemic patients, simvastatin 20-40 mg/day modestly potentiated the effect of coumarin anticoagulants: the prothrombin time, reported as International Normalized Ratio (INR), increased from a baseline of 1.7 to 1.8 and from 2.6 to 3.4 in the volunteer and patient studies, respectively.  		none	36567	none	36567
coumarin	simvastatin	14	16	false	none	7.6 Coumarin Anticoagulants    In two clinical studies, one in normal volunteers and the other in hypercholesterolemic patients, simvastatin 20-40 mg/day modestly potentiated the effect of coumarin anticoagulants: the prothrombin time, reported as International Normalized Ratio (INR), increased from a baseline of 1.7 to 1.8 and from 2.6 to 3.4 in the volunteer and patient studies, respectively.  With other statins, clinically evident bleeding and/or increased prothrombin time has been reported in a few patients taking coumarin anticoagulants concomitantly.  In such patients, prothrombin time should be determined before starting simvastatin and frequently enough during early therapy to ensure that no significant alteration of prothrombin time occurs.  		none	36567	none	36567
coumarin	simvastatin	14	16	false	none	7.6 Coumarin Anticoagulants    In two clinical studies, one in normal volunteers and the other in hypercholesterolemic patients, simvastatin 20-40 mg/day modestly potentiated the effect of coumarin anticoagulants: the prothrombin time, reported as International Normalized Ratio (INR), increased from a baseline of 1.7 to 1.8 and from 2.6 to 3.4 in the volunteer and patient studies, respectively.  With other statins, clinically evident bleeding and/or increased prothrombin time has been reported in a few patients taking coumarin anticoagulants concomitantly.  In such patients, prothrombin time should be determined before starting simvastatin and frequently enough during early therapy to ensure that no significant alteration of prothrombin time occurs.  		none	36567	none	36567
coumarin	simvastatin	15	13	false	none	Patients taking digoxin should be monitored appropriately when simvastatin is initiated [see Clinical Pharmacology (12.3)].  7.6 Coumarin Anticoagulants    In two clinical studies, one in normal volunteers and the other in hypercholesterolemic patients, simvastatin 20-40 mg/day modestly potentiated the effect of coumarin anticoagulants: the prothrombin time, reported as International Normalized Ratio (INR), increased from a baseline of 1.7 to 1.8 and from 2.6 to 3.4 in the volunteer and patient studies, respectively.  With other statins, clinically evident bleeding and/or increased prothrombin time has been reported in a few patients taking coumarin anticoagulants concomitantly.  		none	36567	none	36567
coumarin	simvastatin	15	13	false	none	Patients taking digoxin should be monitored appropriately when simvastatin is initiated [see Clinical Pharmacology (12.3)].  7.6 Coumarin Anticoagulants    In two clinical studies, one in normal volunteers and the other in hypercholesterolemic patients, simvastatin 20-40 mg/day modestly potentiated the effect of coumarin anticoagulants: the prothrombin time, reported as International Normalized Ratio (INR), increased from a baseline of 1.7 to 1.8 and from 2.6 to 3.4 in the volunteer and patient studies, respectively.  With other statins, clinically evident bleeding and/or increased prothrombin time has been reported in a few patients taking coumarin anticoagulants concomitantly.  		none	36567	none	36567
coumarin	simvastatin	15	14	false	none	7.6 Coumarin Anticoagulants    In two clinical studies, one in normal volunteers and the other in hypercholesterolemic patients, simvastatin 20-40 mg/day modestly potentiated the effect of coumarin anticoagulants: the prothrombin time, reported as International Normalized Ratio (INR), increased from a baseline of 1.7 to 1.8 and from 2.6 to 3.4 in the volunteer and patient studies, respectively.  With other statins, clinically evident bleeding and/or increased prothrombin time has been reported in a few patients taking coumarin anticoagulants concomitantly.  		none	36567	none	36567
coumarin	simvastatin	15	14	false	none	7.6 Coumarin Anticoagulants    In two clinical studies, one in normal volunteers and the other in hypercholesterolemic patients, simvastatin 20-40 mg/day modestly potentiated the effect of coumarin anticoagulants: the prothrombin time, reported as International Normalized Ratio (INR), increased from a baseline of 1.7 to 1.8 and from 2.6 to 3.4 in the volunteer and patient studies, respectively.  With other statins, clinically evident bleeding and/or increased prothrombin time has been reported in a few patients taking coumarin anticoagulants concomitantly.  		none	36567	none	36567
coumarin	simvastatin	15	16	false	none	With other statins, clinically evident bleeding and/or increased prothrombin time has been reported in a few patients taking coumarin anticoagulants concomitantly.  In such patients, prothrombin time should be determined before starting simvastatin and frequently enough during early therapy to ensure that no significant alteration of prothrombin time occurs.  		none	36567	none	36567
coumarin	simvastatin	15	16	false	none	With other statins, clinically evident bleeding and/or increased prothrombin time has been reported in a few patients taking coumarin anticoagulants concomitantly.  In such patients, prothrombin time should be determined before starting simvastatin and frequently enough during early therapy to ensure that no significant alteration of prothrombin time occurs.  		none	36567	none	36567
grapefruit	ketoconazole	6	6	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  		none	6135	none	D007654
grapefruit	ketoconazole	6	6	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  		none	6135	none	D007654
grapefruit	ketoconazole	6	7	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		none	6135	none	D007654
grapefruit	ketoconazole	6	7	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		none	6135	none	D007654
grapefruit	itraconazole	6	6	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  		none	28031	none	D017964
grapefruit	itraconazole	6	6	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  		none	28031	none	D017964
grapefruit	itraconazole	6	7	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		none	28031	none	D017964
grapefruit	itraconazole	6	7	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		none	28031	none	D017964
grapefruit	simvastatin	6	4	false	none	Hence when simvastatin is used with an inhibitor of CYP3A4 (e.g., as listed below), elevated plasma levels of HMG-CoA reductase inhibitory activity can increase the risk of myopathy and rhabdomyolysis, particularly with higher doses of simvastatin.  [See Warnings and Precautions (5.1) and Clinical Pharmacology (12.3).]  Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  		none	36567	none	36567
grapefruit	simvastatin	6	4	false	none	Hence when simvastatin is used with an inhibitor of CYP3A4 (e.g., as listed below), elevated plasma levels of HMG-CoA reductase inhibitory activity can increase the risk of myopathy and rhabdomyolysis, particularly with higher doses of simvastatin.  [See Warnings and Precautions (5.1) and Clinical Pharmacology (12.3).]  Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  		none	36567	none	36567
grapefruit	simvastatin	6	7	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		none	36567	none	36567
grapefruit	simvastatin	6	7	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		none	36567	none	36567
grapefruit	gemfibrozil	6	8	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  		none	4719	none	D015248
grapefruit	gemfibrozil	6	8	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  		none	4719	none	D015248
grapefruit	clarithromycin	6	6	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  		none	21212	none	21212
grapefruit	clarithromycin	6	6	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  		none	21212	none	21212
grapefruit	clarithromycin	6	7	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		none	21212	none	21212
grapefruit	clarithromycin	6	7	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		none	21212	none	21212
grapefruit	telithromycin	6	6	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  		none	274786	none	274786
grapefruit	telithromycin	6	6	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  		none	274786	none	274786
grapefruit	telithromycin	6	7	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		none	274786	none	274786
grapefruit	telithromycin	6	7	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		none	274786	none	274786
grapefruit	fibrates	6	8	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  		none	none	none	none
grapefruit	nefazodone	6	6	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  		none	31565	none	C051752
grapefruit	nefazodone	6	6	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  		none	31565	none	C051752
grapefruit	erythromycin	6	6	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  		none	4053	none	D004917
grapefruit	erythromycin	6	6	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  		none	4053	none	D004917
grapefruit	erythromycin	6	7	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		none	4053	none	D004917
grapefruit	erythromycin	6	7	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		none	4053	none	D004917
Danazol	digoxin	10	12	false	none	7.3 Cyclosporine or Danazol    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of cyclosporine or danazol particularly with higher doses of simvastatin [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].  7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  7.5 Digoxin    In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma.  		none	none	none	none
Danazol	simvastatin	10	10	false	none	7.3 Cyclosporine or Danazol    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of cyclosporine or danazol particularly with higher doses of simvastatin [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].  		none	36567	none	36567
Danazol	simvastatin	10	10	false	none	7.3 Cyclosporine or Danazol    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of cyclosporine or danazol particularly with higher doses of simvastatin [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].  		none	36567	none	36567
Danazol	simvastatin	10	11	false	none	7.3 Cyclosporine or Danazol    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of cyclosporine or danazol particularly with higher doses of simvastatin [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].  7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  		none	36567	none	36567
Danazol	simvastatin	10	11	false	none	7.3 Cyclosporine or Danazol    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of cyclosporine or danazol particularly with higher doses of simvastatin [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].  7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  		none	36567	none	36567
Danazol	simvastatin	10	12	false	none	7.3 Cyclosporine or Danazol    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of cyclosporine or danazol particularly with higher doses of simvastatin [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].  7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  7.5 Digoxin    In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma.  		none	36567	none	36567
Danazol	simvastatin	10	12	false	none	7.3 Cyclosporine or Danazol    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of cyclosporine or danazol particularly with higher doses of simvastatin [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].  7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  7.5 Digoxin    In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma.  		none	36567	none	36567
Danazol	gemfibrozil	10	8	false	none	7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  [see Warnings and Precautions (5.1)].  7.3 Cyclosporine or Danazol    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of cyclosporine or danazol particularly with higher doses of simvastatin [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].  		none	4719	none	D015248
Danazol	gemfibrozil	10	8	false	none	7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  [see Warnings and Precautions (5.1)].  7.3 Cyclosporine or Danazol    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of cyclosporine or danazol particularly with higher doses of simvastatin [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].  		none	4719	none	D015248
Danazol	verapamil	10	11	false	none	7.3 Cyclosporine or Danazol    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of cyclosporine or danazol particularly with higher doses of simvastatin [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].  7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  		none	none	none	none
Danazol	Cyclosporine	10	10	false	none	7.3 Cyclosporine or Danazol    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of cyclosporine or danazol particularly with higher doses of simvastatin [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].  		none	none	none	none
Danazol	danazol	10	10	false	none	7.3 Cyclosporine or Danazol    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of cyclosporine or danazol particularly with higher doses of simvastatin [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].  		none	none	none	none
Danazol	amiodarone	10	11	false	none	7.3 Cyclosporine or Danazol    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of cyclosporine or danazol particularly with higher doses of simvastatin [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].  7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  		none	none	none	none
Danazol	fibrates	10	8	false	none	7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  [see Warnings and Precautions (5.1)].  7.3 Cyclosporine or Danazol    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of cyclosporine or danazol particularly with higher doses of simvastatin [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].  		none	none	none	none
Danazol	cyclosporine	10	10	false	none	7.3 Cyclosporine or Danazol    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of cyclosporine or danazol particularly with higher doses of simvastatin [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].  		none	none	none	none
digoxin	simvastatin	12	10	false	none	7.3 Cyclosporine or Danazol    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of cyclosporine or danazol particularly with higher doses of simvastatin [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].  7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  7.5 Digoxin    In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma.  		none	36567	none	36567
digoxin	simvastatin	12	10	false	none	7.3 Cyclosporine or Danazol    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of cyclosporine or danazol particularly with higher doses of simvastatin [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].  7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  7.5 Digoxin    In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma.  		none	36567	none	36567
digoxin	simvastatin	12	11	false	none	7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  7.5 Digoxin    In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma.  		none	36567	none	36567
digoxin	simvastatin	12	11	false	none	7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  7.5 Digoxin    In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma.  		none	36567	none	36567
digoxin	simvastatin	12	12	false	none	7.5 Digoxin    In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma.  		none	36567	none	36567
digoxin	simvastatin	12	12	false	none	7.5 Digoxin    In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma.  		none	36567	none	36567
digoxin	simvastatin	12	13	false	none	7.5 Digoxin    In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma.  Patients taking digoxin should be monitored appropriately when simvastatin is initiated [see Clinical Pharmacology (12.3)].  		none	36567	none	36567
digoxin	simvastatin	12	13	false	none	7.5 Digoxin    In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma.  Patients taking digoxin should be monitored appropriately when simvastatin is initiated [see Clinical Pharmacology (12.3)].  		none	36567	none	36567
digoxin	simvastatin	12	14	false	none	7.5 Digoxin    In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma.  Patients taking digoxin should be monitored appropriately when simvastatin is initiated [see Clinical Pharmacology (12.3)].  7.6 Coumarin Anticoagulants    In two clinical studies, one in normal volunteers and the other in hypercholesterolemic patients, simvastatin 20-40 mg/day modestly potentiated the effect of coumarin anticoagulants: the prothrombin time, reported as International Normalized Ratio (INR), increased from a baseline of 1.7 to 1.8 and from 2.6 to 3.4 in the volunteer and patient studies, respectively.  		none	36567	none	36567
digoxin	simvastatin	12	14	false	none	7.5 Digoxin    In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma.  Patients taking digoxin should be monitored appropriately when simvastatin is initiated [see Clinical Pharmacology (12.3)].  7.6 Coumarin Anticoagulants    In two clinical studies, one in normal volunteers and the other in hypercholesterolemic patients, simvastatin 20-40 mg/day modestly potentiated the effect of coumarin anticoagulants: the prothrombin time, reported as International Normalized Ratio (INR), increased from a baseline of 1.7 to 1.8 and from 2.6 to 3.4 in the volunteer and patient studies, respectively.  		none	36567	none	36567
digoxin	simvastatin	13	11	false	none	7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  7.5 Digoxin    In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma.  Patients taking digoxin should be monitored appropriately when simvastatin is initiated [see Clinical Pharmacology (12.3)].  		none	36567	none	36567
digoxin	simvastatin	13	11	false	none	7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  7.5 Digoxin    In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma.  Patients taking digoxin should be monitored appropriately when simvastatin is initiated [see Clinical Pharmacology (12.3)].  		none	36567	none	36567
digoxin	simvastatin	13	12	false	none	7.5 Digoxin    In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma.  Patients taking digoxin should be monitored appropriately when simvastatin is initiated [see Clinical Pharmacology (12.3)].  		none	36567	none	36567
digoxin	simvastatin	13	12	false	none	7.5 Digoxin    In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma.  Patients taking digoxin should be monitored appropriately when simvastatin is initiated [see Clinical Pharmacology (12.3)].  		none	36567	none	36567
digoxin	simvastatin	13	13	false	none	Patients taking digoxin should be monitored appropriately when simvastatin is initiated [see Clinical Pharmacology (12.3)].  		none	36567	none	36567
digoxin	simvastatin	13	13	false	none	Patients taking digoxin should be monitored appropriately when simvastatin is initiated [see Clinical Pharmacology (12.3)].  		none	36567	none	36567
digoxin	simvastatin	13	14	false	none	Patients taking digoxin should be monitored appropriately when simvastatin is initiated [see Clinical Pharmacology (12.3)].  7.6 Coumarin Anticoagulants    In two clinical studies, one in normal volunteers and the other in hypercholesterolemic patients, simvastatin 20-40 mg/day modestly potentiated the effect of coumarin anticoagulants: the prothrombin time, reported as International Normalized Ratio (INR), increased from a baseline of 1.7 to 1.8 and from 2.6 to 3.4 in the volunteer and patient studies, respectively.  		none	36567	none	36567
digoxin	simvastatin	13	14	false	none	Patients taking digoxin should be monitored appropriately when simvastatin is initiated [see Clinical Pharmacology (12.3)].  7.6 Coumarin Anticoagulants    In two clinical studies, one in normal volunteers and the other in hypercholesterolemic patients, simvastatin 20-40 mg/day modestly potentiated the effect of coumarin anticoagulants: the prothrombin time, reported as International Normalized Ratio (INR), increased from a baseline of 1.7 to 1.8 and from 2.6 to 3.4 in the volunteer and patient studies, respectively.  		none	36567	none	36567
digoxin	verapamil	12	11	false	none	7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  7.5 Digoxin    In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma.  		none	none	none	none
digoxin	verapamil	13	11	false	none	7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  7.5 Digoxin    In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma.  Patients taking digoxin should be monitored appropriately when simvastatin is initiated [see Clinical Pharmacology (12.3)].  		none	none	none	none
digoxin	Cyclosporine	12	10	false	none	7.3 Cyclosporine or Danazol    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of cyclosporine or danazol particularly with higher doses of simvastatin [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].  7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  7.5 Digoxin    In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma.  		none	none	none	none
digoxin	danazol	12	10	false	none	7.3 Cyclosporine or Danazol    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of cyclosporine or danazol particularly with higher doses of simvastatin [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].  7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  7.5 Digoxin    In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma.  		none	none	none	none
digoxin	amiodarone	12	11	false	none	7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  7.5 Digoxin    In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma.  		none	none	none	none
digoxin	amiodarone	13	11	false	none	7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  7.5 Digoxin    In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma.  Patients taking digoxin should be monitored appropriately when simvastatin is initiated [see Clinical Pharmacology (12.3)].  		none	none	none	none
digoxin	cyclosporine	12	10	false	none	7.3 Cyclosporine or Danazol    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of cyclosporine or danazol particularly with higher doses of simvastatin [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].  7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  7.5 Digoxin    In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma.  		none	none	none	none
ketoconazole	itraconazole	6	6	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  		6135	28031	D007654	D017964
ketoconazole	itraconazole	6	6	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  		6135	28031	D007654	D017964
ketoconazole	itraconazole	6	7	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		6135	28031	D007654	D017964
ketoconazole	itraconazole	6	7	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		6135	28031	D007654	D017964
ketoconazole	itraconazole	7	6	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		6135	28031	D007654	D017964
ketoconazole	itraconazole	7	6	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		6135	28031	D007654	D017964
ketoconazole	itraconazole	7	7	false	none	If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		6135	28031	D007654	D017964
ketoconazole	itraconazole	7	7	false	none	If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		6135	28031	D007654	D017964
ketoconazole	simvastatin	6	4	false	none	Hence when simvastatin is used with an inhibitor of CYP3A4 (e.g., as listed below), elevated plasma levels of HMG-CoA reductase inhibitory activity can increase the risk of myopathy and rhabdomyolysis, particularly with higher doses of simvastatin.  [See Warnings and Precautions (5.1) and Clinical Pharmacology (12.3).]  Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  		6135	36567	D007654	36567
ketoconazole	simvastatin	6	4	false	none	Hence when simvastatin is used with an inhibitor of CYP3A4 (e.g., as listed below), elevated plasma levels of HMG-CoA reductase inhibitory activity can increase the risk of myopathy and rhabdomyolysis, particularly with higher doses of simvastatin.  [See Warnings and Precautions (5.1) and Clinical Pharmacology (12.3).]  Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  		6135	36567	D007654	36567
ketoconazole	simvastatin	6	7	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		6135	36567	D007654	36567
ketoconazole	simvastatin	6	7	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		6135	36567	D007654	36567
ketoconazole	simvastatin	7	7	false	none	If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		6135	36567	D007654	36567
ketoconazole	simvastatin	7	7	false	none	If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		6135	36567	D007654	36567
ketoconazole	gemfibrozil	6	8	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  		6135	4719	D007654	D015248
ketoconazole	gemfibrozil	6	8	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  		6135	4719	D007654	D015248
ketoconazole	gemfibrozil	7	8	false	none	If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  		6135	4719	D007654	D015248
ketoconazole	gemfibrozil	7	8	false	none	If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  		6135	4719	D007654	D015248
ketoconazole	clarithromycin	6	6	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  		6135	21212	D007654	21212
ketoconazole	clarithromycin	6	6	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  		6135	21212	D007654	21212
ketoconazole	clarithromycin	6	7	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		6135	21212	D007654	21212
ketoconazole	clarithromycin	6	7	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		6135	21212	D007654	21212
ketoconazole	clarithromycin	7	6	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		6135	21212	D007654	21212
ketoconazole	clarithromycin	7	6	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		6135	21212	D007654	21212
ketoconazole	clarithromycin	7	7	false	none	If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		6135	21212	D007654	21212
ketoconazole	clarithromycin	7	7	false	none	If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		6135	21212	D007654	21212
ketoconazole	telithromycin	6	6	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  		6135	274786	D007654	274786
ketoconazole	telithromycin	6	6	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  		6135	274786	D007654	274786
ketoconazole	telithromycin	6	7	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		6135	274786	D007654	274786
ketoconazole	telithromycin	6	7	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		6135	274786	D007654	274786
ketoconazole	telithromycin	7	6	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		6135	274786	D007654	274786
ketoconazole	telithromycin	7	6	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		6135	274786	D007654	274786
ketoconazole	telithromycin	7	7	false	none	If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		6135	274786	D007654	274786
ketoconazole	telithromycin	7	7	false	none	If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		6135	274786	D007654	274786
ketoconazole	fibrates	6	8	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  		6135	none	D007654	none
ketoconazole	fibrates	6	8	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  		6135	none	D007654	none
ketoconazole	fibrates	7	8	false	none	If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  		6135	none	D007654	none
ketoconazole	fibrates	7	8	false	none	If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  		6135	none	D007654	none
ketoconazole	nefazodone	6	6	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  		6135	31565	D007654	C051752
ketoconazole	nefazodone	6	6	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  		6135	31565	D007654	C051752
ketoconazole	nefazodone	7	6	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		6135	31565	D007654	C051752
ketoconazole	nefazodone	7	6	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		6135	31565	D007654	C051752
ketoconazole	erythromycin	6	6	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  		6135	4053	D007654	D004917
ketoconazole	erythromycin	6	6	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  		6135	4053	D007654	D004917
ketoconazole	erythromycin	6	7	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		6135	4053	D007654	D004917
ketoconazole	erythromycin	6	7	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		6135	4053	D007654	D004917
ketoconazole	erythromycin	7	6	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		6135	4053	D007654	D004917
ketoconazole	erythromycin	7	6	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		6135	4053	D007654	D004917
ketoconazole	erythromycin	7	7	false	none	If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		6135	4053	D007654	D004917
ketoconazole	erythromycin	7	7	false	none	If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		6135	4053	D007654	D004917
itraconazole	simvastatin	6	4	false	none	Hence when simvastatin is used with an inhibitor of CYP3A4 (e.g., as listed below), elevated plasma levels of HMG-CoA reductase inhibitory activity can increase the risk of myopathy and rhabdomyolysis, particularly with higher doses of simvastatin.  [See Warnings and Precautions (5.1) and Clinical Pharmacology (12.3).]  Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  		28031	36567	D017964	36567
itraconazole	simvastatin	6	4	false	none	Hence when simvastatin is used with an inhibitor of CYP3A4 (e.g., as listed below), elevated plasma levels of HMG-CoA reductase inhibitory activity can increase the risk of myopathy and rhabdomyolysis, particularly with higher doses of simvastatin.  [See Warnings and Precautions (5.1) and Clinical Pharmacology (12.3).]  Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  		28031	36567	D017964	36567
itraconazole	simvastatin	6	7	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		28031	36567	D017964	36567
itraconazole	simvastatin	6	7	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		28031	36567	D017964	36567
itraconazole	simvastatin	7	7	false	none	If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		28031	36567	D017964	36567
itraconazole	simvastatin	7	7	false	none	If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		28031	36567	D017964	36567
itraconazole	gemfibrozil	6	8	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  		28031	4719	D017964	D015248
itraconazole	gemfibrozil	6	8	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  		28031	4719	D017964	D015248
itraconazole	gemfibrozil	7	8	false	none	If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  		28031	4719	D017964	D015248
itraconazole	gemfibrozil	7	8	false	none	If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  		28031	4719	D017964	D015248
itraconazole	clarithromycin	6	6	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  		28031	21212	D017964	21212
itraconazole	clarithromycin	6	6	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  		28031	21212	D017964	21212
itraconazole	clarithromycin	6	7	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		28031	21212	D017964	21212
itraconazole	clarithromycin	6	7	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		28031	21212	D017964	21212
itraconazole	clarithromycin	7	6	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		28031	21212	D017964	21212
itraconazole	clarithromycin	7	6	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		28031	21212	D017964	21212
itraconazole	clarithromycin	7	7	false	none	If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		28031	21212	D017964	21212
itraconazole	clarithromycin	7	7	false	none	If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		28031	21212	D017964	21212
itraconazole	telithromycin	6	6	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  		28031	274786	D017964	274786
itraconazole	telithromycin	6	6	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  		28031	274786	D017964	274786
itraconazole	telithromycin	6	7	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		28031	274786	D017964	274786
itraconazole	telithromycin	6	7	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		28031	274786	D017964	274786
itraconazole	telithromycin	7	6	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		28031	274786	D017964	274786
itraconazole	telithromycin	7	6	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		28031	274786	D017964	274786
itraconazole	telithromycin	7	7	false	none	If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		28031	274786	D017964	274786
itraconazole	telithromycin	7	7	false	none	If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		28031	274786	D017964	274786
itraconazole	fibrates	6	8	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  		28031	none	D017964	none
itraconazole	fibrates	6	8	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  		28031	none	D017964	none
itraconazole	fibrates	7	8	false	none	If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  		28031	none	D017964	none
itraconazole	fibrates	7	8	false	none	If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  		28031	none	D017964	none
itraconazole	nefazodone	6	6	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  		28031	31565	D017964	C051752
itraconazole	nefazodone	6	6	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  		28031	31565	D017964	C051752
itraconazole	nefazodone	7	6	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		28031	31565	D017964	C051752
itraconazole	nefazodone	7	6	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		28031	31565	D017964	C051752
itraconazole	erythromycin	6	6	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  		28031	4053	D017964	D004917
itraconazole	erythromycin	6	6	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  		28031	4053	D017964	D004917
itraconazole	erythromycin	6	7	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		28031	4053	D017964	D004917
itraconazole	erythromycin	6	7	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		28031	4053	D017964	D004917
itraconazole	erythromycin	7	6	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		28031	4053	D017964	D004917
itraconazole	erythromycin	7	6	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		28031	4053	D017964	D004917
itraconazole	erythromycin	7	7	false	none	If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		28031	4053	D017964	D004917
itraconazole	erythromycin	7	7	false	none	If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		28031	4053	D017964	D004917
simvastatin	gemfibrozil	7	8	false	none	If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  		36567	4719	36567	D015248
simvastatin	gemfibrozil	7	8	false	none	If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  		36567	4719	36567	D015248
simvastatin	gemfibrozil	10	8	false	none	7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  [see Warnings and Precautions (5.1)].  7.3 Cyclosporine or Danazol    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of cyclosporine or danazol particularly with higher doses of simvastatin [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].  		36567	4719	36567	D015248
simvastatin	gemfibrozil	10	8	false	none	7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  [see Warnings and Precautions (5.1)].  7.3 Cyclosporine or Danazol    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of cyclosporine or danazol particularly with higher doses of simvastatin [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].  		36567	4719	36567	D015248
simvastatin	verapamil	10	11	false	none	7.3 Cyclosporine or Danazol    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of cyclosporine or danazol particularly with higher doses of simvastatin [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].  7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  		36567	none	36567	none
simvastatin	verapamil	10	11	false	none	7.3 Cyclosporine or Danazol    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of cyclosporine or danazol particularly with higher doses of simvastatin [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].  7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  		36567	none	36567	none
simvastatin	verapamil	11	11	false	none	7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  		36567	none	36567	none
simvastatin	verapamil	11	11	false	none	7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  		36567	none	36567	none
simvastatin	verapamil	12	11	false	none	7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  7.5 Digoxin    In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma.  		36567	none	36567	none
simvastatin	verapamil	12	11	false	none	7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  7.5 Digoxin    In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma.  		36567	none	36567	none
simvastatin	verapamil	13	11	false	none	7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  7.5 Digoxin    In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma.  Patients taking digoxin should be monitored appropriately when simvastatin is initiated [see Clinical Pharmacology (12.3)].  		36567	none	36567	none
simvastatin	verapamil	13	11	false	none	7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  7.5 Digoxin    In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma.  Patients taking digoxin should be monitored appropriately when simvastatin is initiated [see Clinical Pharmacology (12.3)].  		36567	none	36567	none
simvastatin	Cyclosporine	10	10	false	none	7.3 Cyclosporine or Danazol    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of cyclosporine or danazol particularly with higher doses of simvastatin [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].  		36567	none	36567	none
simvastatin	Cyclosporine	10	10	false	none	7.3 Cyclosporine or Danazol    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of cyclosporine or danazol particularly with higher doses of simvastatin [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].  		36567	none	36567	none
simvastatin	Cyclosporine	11	10	false	none	7.3 Cyclosporine or Danazol    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of cyclosporine or danazol particularly with higher doses of simvastatin [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].  7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  		36567	none	36567	none
simvastatin	Cyclosporine	11	10	false	none	7.3 Cyclosporine or Danazol    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of cyclosporine or danazol particularly with higher doses of simvastatin [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].  7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  		36567	none	36567	none
simvastatin	Cyclosporine	12	10	false	none	7.3 Cyclosporine or Danazol    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of cyclosporine or danazol particularly with higher doses of simvastatin [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].  7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  7.5 Digoxin    In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma.  		36567	none	36567	none
simvastatin	Cyclosporine	12	10	false	none	7.3 Cyclosporine or Danazol    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of cyclosporine or danazol particularly with higher doses of simvastatin [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].  7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  7.5 Digoxin    In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma.  		36567	none	36567	none
simvastatin	danazol	10	10	false	none	7.3 Cyclosporine or Danazol    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of cyclosporine or danazol particularly with higher doses of simvastatin [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].  		36567	none	36567	none
simvastatin	danazol	10	10	false	none	7.3 Cyclosporine or Danazol    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of cyclosporine or danazol particularly with higher doses of simvastatin [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].  		36567	none	36567	none
simvastatin	danazol	11	10	false	none	7.3 Cyclosporine or Danazol    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of cyclosporine or danazol particularly with higher doses of simvastatin [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].  7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  		36567	none	36567	none
simvastatin	danazol	11	10	false	none	7.3 Cyclosporine or Danazol    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of cyclosporine or danazol particularly with higher doses of simvastatin [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].  7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  		36567	none	36567	none
simvastatin	danazol	12	10	false	none	7.3 Cyclosporine or Danazol    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of cyclosporine or danazol particularly with higher doses of simvastatin [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].  7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  7.5 Digoxin    In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma.  		36567	none	36567	none
simvastatin	danazol	12	10	false	none	7.3 Cyclosporine or Danazol    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of cyclosporine or danazol particularly with higher doses of simvastatin [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].  7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  7.5 Digoxin    In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma.  		36567	none	36567	none
simvastatin	amiodarone	10	11	false	none	7.3 Cyclosporine or Danazol    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of cyclosporine or danazol particularly with higher doses of simvastatin [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].  7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  		36567	none	36567	none
simvastatin	amiodarone	10	11	false	none	7.3 Cyclosporine or Danazol    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of cyclosporine or danazol particularly with higher doses of simvastatin [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].  7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  		36567	none	36567	none
simvastatin	amiodarone	11	11	false	none	7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  		36567	none	36567	none
simvastatin	amiodarone	11	11	false	none	7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  		36567	none	36567	none
simvastatin	amiodarone	12	11	false	none	7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  7.5 Digoxin    In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma.  		36567	none	36567	none
simvastatin	amiodarone	12	11	false	none	7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  7.5 Digoxin    In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma.  		36567	none	36567	none
simvastatin	amiodarone	13	11	false	none	7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  7.5 Digoxin    In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma.  Patients taking digoxin should be monitored appropriately when simvastatin is initiated [see Clinical Pharmacology (12.3)].  		36567	none	36567	none
simvastatin	amiodarone	13	11	false	none	7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  7.5 Digoxin    In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma.  Patients taking digoxin should be monitored appropriately when simvastatin is initiated [see Clinical Pharmacology (12.3)].  		36567	none	36567	none
simvastatin	clarithromycin	4	6	false	none	Hence when simvastatin is used with an inhibitor of CYP3A4 (e.g., as listed below), elevated plasma levels of HMG-CoA reductase inhibitory activity can increase the risk of myopathy and rhabdomyolysis, particularly with higher doses of simvastatin.  [See Warnings and Precautions (5.1) and Clinical Pharmacology (12.3).]  Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  		36567	21212	36567	21212
simvastatin	clarithromycin	4	6	false	none	Hence when simvastatin is used with an inhibitor of CYP3A4 (e.g., as listed below), elevated plasma levels of HMG-CoA reductase inhibitory activity can increase the risk of myopathy and rhabdomyolysis, particularly with higher doses of simvastatin.  [See Warnings and Precautions (5.1) and Clinical Pharmacology (12.3).]  Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  		36567	21212	36567	21212
simvastatin	clarithromycin	7	6	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		36567	21212	36567	21212
simvastatin	clarithromycin	7	6	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		36567	21212	36567	21212
simvastatin	clarithromycin	7	7	false	none	If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		36567	21212	36567	21212
simvastatin	clarithromycin	7	7	false	none	If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		36567	21212	36567	21212
simvastatin	telithromycin	4	6	false	none	Hence when simvastatin is used with an inhibitor of CYP3A4 (e.g., as listed below), elevated plasma levels of HMG-CoA reductase inhibitory activity can increase the risk of myopathy and rhabdomyolysis, particularly with higher doses of simvastatin.  [See Warnings and Precautions (5.1) and Clinical Pharmacology (12.3).]  Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  		36567	274786	36567	274786
simvastatin	telithromycin	4	6	false	none	Hence when simvastatin is used with an inhibitor of CYP3A4 (e.g., as listed below), elevated plasma levels of HMG-CoA reductase inhibitory activity can increase the risk of myopathy and rhabdomyolysis, particularly with higher doses of simvastatin.  [See Warnings and Precautions (5.1) and Clinical Pharmacology (12.3).]  Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  		36567	274786	36567	274786
simvastatin	telithromycin	7	6	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		36567	274786	36567	274786
simvastatin	telithromycin	7	6	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		36567	274786	36567	274786
simvastatin	telithromycin	7	7	false	none	If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		36567	274786	36567	274786
simvastatin	telithromycin	7	7	false	none	If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		36567	274786	36567	274786
simvastatin	fibrates	7	8	false	none	If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  		36567	none	36567	none
simvastatin	fibrates	7	8	false	none	If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  		36567	none	36567	none
simvastatin	fibrates	10	8	false	none	7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  [see Warnings and Precautions (5.1)].  7.3 Cyclosporine or Danazol    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of cyclosporine or danazol particularly with higher doses of simvastatin [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].  		36567	none	36567	none
simvastatin	fibrates	10	8	false	none	7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  [see Warnings and Precautions (5.1)].  7.3 Cyclosporine or Danazol    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of cyclosporine or danazol particularly with higher doses of simvastatin [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].  		36567	none	36567	none
simvastatin	cyclosporine	10	10	false	none	7.3 Cyclosporine or Danazol    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of cyclosporine or danazol particularly with higher doses of simvastatin [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].  		36567	none	36567	none
simvastatin	cyclosporine	10	10	false	none	7.3 Cyclosporine or Danazol    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of cyclosporine or danazol particularly with higher doses of simvastatin [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].  		36567	none	36567	none
simvastatin	cyclosporine	11	10	false	none	7.3 Cyclosporine or Danazol    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of cyclosporine or danazol particularly with higher doses of simvastatin [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].  7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  		36567	none	36567	none
simvastatin	cyclosporine	11	10	false	none	7.3 Cyclosporine or Danazol    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of cyclosporine or danazol particularly with higher doses of simvastatin [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].  7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  		36567	none	36567	none
simvastatin	cyclosporine	12	10	false	none	7.3 Cyclosporine or Danazol    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of cyclosporine or danazol particularly with higher doses of simvastatin [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].  7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  7.5 Digoxin    In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma.  		36567	none	36567	none
simvastatin	cyclosporine	12	10	false	none	7.3 Cyclosporine or Danazol    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of cyclosporine or danazol particularly with higher doses of simvastatin [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].  7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  7.5 Digoxin    In one study, concomitant administration of digoxin with simvastatin resulted in a slight elevation in digoxin concentrations in plasma.  		36567	none	36567	none
simvastatin	nefazodone	4	6	false	none	Hence when simvastatin is used with an inhibitor of CYP3A4 (e.g., as listed below), elevated plasma levels of HMG-CoA reductase inhibitory activity can increase the risk of myopathy and rhabdomyolysis, particularly with higher doses of simvastatin.  [See Warnings and Precautions (5.1) and Clinical Pharmacology (12.3).]  Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  		36567	31565	36567	C051752
simvastatin	nefazodone	4	6	false	none	Hence when simvastatin is used with an inhibitor of CYP3A4 (e.g., as listed below), elevated plasma levels of HMG-CoA reductase inhibitory activity can increase the risk of myopathy and rhabdomyolysis, particularly with higher doses of simvastatin.  [See Warnings and Precautions (5.1) and Clinical Pharmacology (12.3).]  Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  		36567	31565	36567	C051752
simvastatin	nefazodone	7	6	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		36567	31565	36567	C051752
simvastatin	nefazodone	7	6	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		36567	31565	36567	C051752
simvastatin	erythromycin	4	6	false	none	Hence when simvastatin is used with an inhibitor of CYP3A4 (e.g., as listed below), elevated plasma levels of HMG-CoA reductase inhibitory activity can increase the risk of myopathy and rhabdomyolysis, particularly with higher doses of simvastatin.  [See Warnings and Precautions (5.1) and Clinical Pharmacology (12.3).]  Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  		36567	4053	36567	D004917
simvastatin	erythromycin	4	6	false	none	Hence when simvastatin is used with an inhibitor of CYP3A4 (e.g., as listed below), elevated plasma levels of HMG-CoA reductase inhibitory activity can increase the risk of myopathy and rhabdomyolysis, particularly with higher doses of simvastatin.  [See Warnings and Precautions (5.1) and Clinical Pharmacology (12.3).]  Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  		36567	4053	36567	D004917
simvastatin	erythromycin	7	6	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		36567	4053	36567	D004917
simvastatin	erythromycin	7	6	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		36567	4053	36567	D004917
simvastatin	erythromycin	7	7	false	none	If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		36567	4053	36567	D004917
simvastatin	erythromycin	7	7	false	none	If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		36567	4053	36567	D004917
gemfibrozil	Cyclosporine	8	10	false	none	7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  [see Warnings and Precautions (5.1)].  7.3 Cyclosporine or Danazol    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of cyclosporine or danazol particularly with higher doses of simvastatin [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].  		4719	none	D015248	none
gemfibrozil	Cyclosporine	8	10	false	none	7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  [see Warnings and Precautions (5.1)].  7.3 Cyclosporine or Danazol    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of cyclosporine or danazol particularly with higher doses of simvastatin [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].  		4719	none	D015248	none
gemfibrozil	danazol	8	10	false	none	7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  [see Warnings and Precautions (5.1)].  7.3 Cyclosporine or Danazol    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of cyclosporine or danazol particularly with higher doses of simvastatin [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].  		4719	none	D015248	none
gemfibrozil	danazol	8	10	false	none	7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  [see Warnings and Precautions (5.1)].  7.3 Cyclosporine or Danazol    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of cyclosporine or danazol particularly with higher doses of simvastatin [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].  		4719	none	D015248	none
gemfibrozil	clarithromycin	8	6	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  		4719	21212	D015248	21212
gemfibrozil	clarithromycin	8	6	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  		4719	21212	D015248	21212
gemfibrozil	clarithromycin	8	7	false	none	If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  		4719	21212	D015248	21212
gemfibrozil	clarithromycin	8	7	false	none	If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  		4719	21212	D015248	21212
gemfibrozil	telithromycin	8	6	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  		4719	274786	D015248	274786
gemfibrozil	telithromycin	8	6	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  		4719	274786	D015248	274786
gemfibrozil	telithromycin	8	7	false	none	If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  		4719	274786	D015248	274786
gemfibrozil	telithromycin	8	7	false	none	If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  		4719	274786	D015248	274786
gemfibrozil	fibrates	8	8	false	none	7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  		4719	none	D015248	none
gemfibrozil	fibrates	8	8	false	none	7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  		4719	none	D015248	none
gemfibrozil	cyclosporine	8	10	false	none	7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  [see Warnings and Precautions (5.1)].  7.3 Cyclosporine or Danazol    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of cyclosporine or danazol particularly with higher doses of simvastatin [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].  		4719	none	D015248	none
gemfibrozil	cyclosporine	8	10	false	none	7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  [see Warnings and Precautions (5.1)].  7.3 Cyclosporine or Danazol    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of cyclosporine or danazol particularly with higher doses of simvastatin [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].  		4719	none	D015248	none
gemfibrozil	nefazodone	8	6	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  		4719	31565	D015248	C051752
gemfibrozil	nefazodone	8	6	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  		4719	31565	D015248	C051752
gemfibrozil	erythromycin	8	6	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  		4719	4053	D015248	D004917
gemfibrozil	erythromycin	8	6	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  		4719	4053	D015248	D004917
gemfibrozil	erythromycin	8	7	false	none	If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  		4719	4053	D015248	D004917
gemfibrozil	erythromycin	8	7	false	none	If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  		4719	4053	D015248	D004917
verapamil	Cyclosporine	11	10	false	none	7.3 Cyclosporine or Danazol    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of cyclosporine or danazol particularly with higher doses of simvastatin [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].  7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  		none	none	none	none
verapamil	danazol	11	10	false	none	7.3 Cyclosporine or Danazol    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of cyclosporine or danazol particularly with higher doses of simvastatin [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].  7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  		none	none	none	none
verapamil	amiodarone	11	11	false	none	7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  		none	none	none	none
verapamil	cyclosporine	11	10	false	none	7.3 Cyclosporine or Danazol    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of cyclosporine or danazol particularly with higher doses of simvastatin [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].  7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  		none	none	none	none
Cyclosporine	danazol	10	10	false	none	7.3 Cyclosporine or Danazol    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of cyclosporine or danazol particularly with higher doses of simvastatin [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].  		none	none	none	none
Cyclosporine	amiodarone	10	11	false	none	7.3 Cyclosporine or Danazol    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of cyclosporine or danazol particularly with higher doses of simvastatin [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].  7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  		none	none	none	none
Cyclosporine	fibrates	10	8	false	none	7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  [see Warnings and Precautions (5.1)].  7.3 Cyclosporine or Danazol    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of cyclosporine or danazol particularly with higher doses of simvastatin [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].  		none	none	none	none
Cyclosporine	cyclosporine	10	10	false	none	7.3 Cyclosporine or Danazol    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of cyclosporine or danazol particularly with higher doses of simvastatin [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].  		none	none	none	none
danazol	amiodarone	10	11	false	none	7.3 Cyclosporine or Danazol    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of cyclosporine or danazol particularly with higher doses of simvastatin [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].  7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  		none	none	none	none
danazol	fibrates	10	8	false	none	7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  [see Warnings and Precautions (5.1)].  7.3 Cyclosporine or Danazol    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of cyclosporine or danazol particularly with higher doses of simvastatin [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].  		none	none	none	none
danazol	cyclosporine	10	10	false	none	7.3 Cyclosporine or Danazol    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of cyclosporine or danazol particularly with higher doses of simvastatin [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].  		none	none	none	none
amiodarone	cyclosporine	11	10	false	none	7.3 Cyclosporine or Danazol    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of cyclosporine or danazol particularly with higher doses of simvastatin [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].  7.4 Amiodarone or Verapamil    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of amiodarone or verapamil with higher doses of simvastatin [see Warnings and Precautions (5.1)].  		none	none	none	none
clarithromycin	telithromycin	6	6	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  		21212	274786	21212	274786
clarithromycin	telithromycin	6	6	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  		21212	274786	21212	274786
clarithromycin	telithromycin	6	7	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		21212	274786	21212	274786
clarithromycin	telithromycin	6	7	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		21212	274786	21212	274786
clarithromycin	telithromycin	7	6	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		21212	274786	21212	274786
clarithromycin	telithromycin	7	6	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		21212	274786	21212	274786
clarithromycin	telithromycin	7	7	false	none	If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		21212	274786	21212	274786
clarithromycin	telithromycin	7	7	false	none	If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		21212	274786	21212	274786
clarithromycin	fibrates	6	8	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  		21212	none	21212	none
clarithromycin	fibrates	6	8	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  		21212	none	21212	none
clarithromycin	fibrates	7	8	false	none	If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  		21212	none	21212	none
clarithromycin	fibrates	7	8	false	none	If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  		21212	none	21212	none
clarithromycin	nefazodone	6	6	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  		21212	31565	21212	C051752
clarithromycin	nefazodone	6	6	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  		21212	31565	21212	C051752
clarithromycin	nefazodone	7	6	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		21212	31565	21212	C051752
clarithromycin	nefazodone	7	6	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		21212	31565	21212	C051752
clarithromycin	erythromycin	6	6	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  		21212	4053	21212	D004917
clarithromycin	erythromycin	6	6	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  		21212	4053	21212	D004917
clarithromycin	erythromycin	6	7	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		21212	4053	21212	D004917
clarithromycin	erythromycin	6	7	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		21212	4053	21212	D004917
clarithromycin	erythromycin	7	6	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		21212	4053	21212	D004917
clarithromycin	erythromycin	7	6	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		21212	4053	21212	D004917
clarithromycin	erythromycin	7	7	false	none	If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		21212	4053	21212	D004917
clarithromycin	erythromycin	7	7	false	none	If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		21212	4053	21212	D004917
telithromycin	fibrates	6	8	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  		274786	none	274786	none
telithromycin	fibrates	6	8	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  		274786	none	274786	none
telithromycin	fibrates	7	8	false	none	If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  		274786	none	274786	none
telithromycin	fibrates	7	8	false	none	If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  		274786	none	274786	none
telithromycin	nefazodone	6	6	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  		274786	31565	274786	C051752
telithromycin	nefazodone	6	6	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  		274786	31565	274786	C051752
telithromycin	nefazodone	7	6	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		274786	31565	274786	C051752
telithromycin	nefazodone	7	6	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		274786	31565	274786	C051752
telithromycin	erythromycin	6	6	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  		274786	4053	274786	D004917
telithromycin	erythromycin	6	6	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  		274786	4053	274786	D004917
telithromycin	erythromycin	6	7	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		274786	4053	274786	D004917
telithromycin	erythromycin	6	7	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		274786	4053	274786	D004917
telithromycin	erythromycin	7	6	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		274786	4053	274786	D004917
telithromycin	erythromycin	7	6	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		274786	4053	274786	D004917
telithromycin	erythromycin	7	7	false	none	If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		274786	4053	274786	D004917
telithromycin	erythromycin	7	7	false	none	If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		274786	4053	274786	D004917
fibrates	cyclosporine	8	10	false	none	7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  [see Warnings and Precautions (5.1)].  7.3 Cyclosporine or Danazol    The risk of myopathy/rhabdomyolysis is increased by concomitant administration of cyclosporine or danazol particularly with higher doses of simvastatin [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)].  		none	none	none	none
fibrates	nefazodone	8	6	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  		none	31565	none	C051752
fibrates	nefazodone	8	6	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  		none	31565	none	C051752
fibrates	erythromycin	8	6	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  		none	4053	none	D004917
fibrates	erythromycin	8	6	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  		none	4053	none	D004917
fibrates	erythromycin	8	7	false	none	If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  		none	4053	none	D004917
fibrates	erythromycin	8	7	false	none	If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  7.2 Lipid-Lowering Drugs That Can Cause Myopathy When Given Alone    The risk of myopathy is increased by gemfibrozil [see Dosage and Administration (2.5)] and to a lesser extent by other fibrates and niacin (nicotinic acid) (1 g/day).  		none	4053	none	D004917
nefazodone	erythromycin	6	6	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  		31565	4053	C051752	D004917
nefazodone	erythromycin	6	6	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  		31565	4053	C051752	D004917
nefazodone	erythromycin	6	7	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		31565	4053	C051752	D004917
nefazodone	erythromycin	6	7	false	none	Itraconazole, ketoconazole, and other antifungal azoles    Macrolide antibiotics erythromycin, clarithromycin, and the ketolide antibiotic telithromycin    HIV protease inhibitors    Antidepressant nefazodone    Grapefruit juice in large quantities (>1 quart daily)    Concomitant use of these drugs and any medication labeled as having a strong inhibitory effect on CYP3A4 should be avoided unless the benefits of combined therapy outweigh the increased risk.  If treatment with itraconazole, ketoconazole, erythromycin, clarithromycin or telithromycin is unavoidable, therapy with simvastatin should be suspended during the course of treatment.  		31565	4053	C051752	D004917
